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SCIENTIFIC ABSTRACT 
Cancer is a leading cause of death in Australia and approximately 52% of cancer patients will 
require radiotherapy at some stage in their treatment. In recent years, stereotactic radiotherapy has 
emerged as an increasingly common treatment modality for small lesions in various sites of the 
human body. 
 
Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Ablative Body Radiotherapy 
(SABR) techniques deliver a larger dose per fraction then conventional radiotherapy. Therefore, 
the efficacy of the treatment depends on the accurate delivery of radiation to the target whilst 
minimising radiation to healthy tissues. Because of the large doses involved, smaller treatment 
margins are needed and in the context of lung cancer, SBRT faces the challenge of respiratory 
induced target motion. The aim of this work was to assess the impact of motion on both planning 
(imaging) and dose calculation in SBRT for lung cancer.  
 
Motion affects all aspects of the SBRT treatment planning process. It is well known that image 
quality is affected by motion for both PET and CT. In SBRT treatment planning however, the 
target to be imaged may often smaller than that imaged in conventional radiation therapy treatment 
planning. To facilitate the investigation into the effects of imaging small mobile lesions, a see-saw 
4D-CT phantom was developed. This phantom was used to investigate phase-binning artifacts that 
can be present when assigning an insufficient number of phases to 4D-CT data. The interplay 
between a lesion’s size and its amplitude, and the effects this relationship has on 4D-CT data is 
also investigated. An upgrade to a commercially available respiratory motion phantom was also 
pursued in order to replicate patient motion recorded with the Varian RPM system. Monte Carlo 
methods were used to determine the impact of motion on PET data by incorporating a 
computational moving phantom (XCAT) with a full Monte Carlo model of a commercially 
available PET scanner.  
 
To assess the impact of motion on treatment planning and dose calculation, two treatment planning 
scenarios were simulated using Monte Carlo. The traditional method of calculating dose on an 
average intensity projection from 4D-CT was compared to 4D dose calculation, in which tumour 
motion data from 4D-CT is explicitly incorporated into the treatment plan. Monte Carlo methods 
are also employed to evaluate the degree uderdosage at the periphery of lesions arising from 
electronic disequilibrium associated with density changes. 
  
- - 2 - - 
Results presented in this work suggest that small lesions typically seen in SBRT of lung cancer 
require extra care when considering treatment planning, motion mitigation, and treatment delivery. 
The upgraded QUASAR phantom allows for patient specific verification of SBRT/SABR 
treatment plans to be conducted and was found to replicate patient motion accurately. Respiratory 
analysis software presented in this work enables detailed statistics of a patient’s respiratory 
characteristics to be evaluated. These statistics can then be compared with post-biofeedback 
statistics to determine if there is an improvement in reproducibility in the patient’s breathing. This 
software can also inform clinicians if there would be any benefit in using gated radiotherapy, and 
if so, where best to enable the beam ON.  
 
When assessing the impact of motion and small lesion sizes on 4D-CT, the see-saw phantom, 
designed for cheap, fast and accurate 4D-CT QA was found to be useful. Data collected in this 
work indicates that lesion size and amplitude are important factors when assessing the quality of 
projections from 4D-CT. The number of phase-bins required to mitigate banding artifacts is 
quantified in a simple equation for sinusoidal motion. Furthermore, large amplitude motions, 
greater than the diameter of the lesion, result in banding artifacts in maximum and average 
intensity projections and care needs to be taken when using such images for treatment planning. It 
was also found that for lesion with diameters greater than 2.0 cm and amplitudes less than 4.0 cm, 
ten phase-bins are adequate to negate all banding artifacts in projection images. 
 
Experimental and Monte Carlo investigations into the impact of motion on images acquired with 
PET and 4D-PET revealed that the motion of small lesions, subject to both the partial-volume 
effect and motion related effects should be assessed and mitigated carefully. Motion greater than 
1.0 cm resulted in a demonstrable reduction in activity that increased with motion amplitude for 
lesion sizes of 5 – 30 mm in both experimental and Monte Carlo studies. The decrease in apparent 
activity was proportional to an increase in apparent lesion size. 4D-PET was found to partially 
mitigate these effects.  
 
In assessing the impact of motion on treatment planning and dose calculation, Monte Carlo 
simulations using both EGSnrc and Geant4 were used to assess the degree of peripheral 
underdosage that occurs as a result of electronic disequilibrium in lung lesions and determine 
differences between 4D and 3D dose calculation methods. A Dose Reduction Factor (DRF) metric 
was developed which is defined as the ratio of the average of the dose to the periphery of the 
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lesion to the dose in the central portion. The mean of the DRF was found to be 0.97 and 0.92 for 6 
MV and 15 MV photon beams respectively, for lesion sizes ranging from 10 – 50 mm. The DRF 
was found to be dependant on the location of the lesion relative to the chest-wall, lesion size and 
the photon beam energy. The dynamic scenario was simulated with 4D dose calculation methods 
of registering and adding the dose distributions in each phase-bin from 4D-CT. The dose-volume 
distributions compared well with 3D (AIP) methods if multiple beams were used and the 
amplitude of motion was less than 3.0 cm. Motion profiles of varying degrees of symmetry were 
seen to have little effect on the agreement provided multiple beams were used.  
 
In this work, tools have developed and tested phantoms that have been implemented clinically for 
patient specific QA of SABR/SBRT treatment plans. QA devices for 4D imaging modalities have 
also been presented, tested and used for QA purposes. The effects of motion on images acquired 
with 4D-CT and PET have been investigated as well as treatment planning and dose calculation 
strategies determining and incorporating the effects of motion into dose calculation. It is hoped 
that this work will increase the understanding of the impact of motion on all aspects of SBRT and 
enhance the efficacy of motion management strategies and clinical use of SBRT. 
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Chapter 1. Introduction 
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“I was born not knowing  
and have only had a little time to change that 
here and there.” 
 
- Richard Phillips Feynman 
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1.1. PROPOSITUM 
The main aim of this thesis is to address and evaluate the effects of motion on treatment planning 
of small lesions affected by motion as commonly seen in stereotactic radiotherapy of lung cancers. 
The issue of tumour motion affects all three stages of stereotactic radiotherapy; imaging, treatment 
planning and treatment delivery. Much is already known about the impact of motion in 
conventional radiation therapy treatment planning and delivery, however, its impact in the 
bourgeoning field of stereotactic body radiation therapy (SBRT) is less well documented. The fact 
that SBRT employs fewer fractions with higher doses per fraction than conventional radiotherapy 
means that accurate targeting of the lesion itself is critical to the treatment efficacy and patient 
outcome. In the case of SBRT, motion management and understanding of the effects of motion 
throughout the treatment chain is critical. This thesis considers motion effects, such as target size 
determination in anatomical imaging (Computed Tomography), functional imaging (Positron 
Emission Tomography) and SBRT planning on average intensity projections and estimation of 
dosimetric discrepancies in treatment delivery. 
1.2. CANCER 
Cancer is a major cause of death in Australia (AIHW, 2008). In 2010 there were 114,000 new 
cases of cancer diagnosed and 43,000 died from the disease. With the Cancer Council Australia 
stating that one in two Australians will be diagnosed with cancer by the age of 85, it is important 
that research into improving the effectiveness of treatments employing radiotherapy be undertaken.  
1.2.1. Lung cancer 
Lung cancer is the fifth most common cancer in Australia. The majority of lung cancers (four out 
of five) are non-small cell lung carcinomas (NSCLC) and the bulk of discussion here will be 
dedicated to NSCLC. NSCLC’s can be broadly divided by their main cell type into squamous cell, 
adenocarcinoma and large cell. In Australia, there are approximately 9,700 cases of lung cancer 
diagnosed each year. This amounts to 9% of all cancer diagnoses (AIHW, 2008). 
 
For early stage NSCLC diagnoses, the most common form of treatment is surgery with an aim to 
cure. Prior to surgical intervention, all cases have to undergo careful pre-operative assessment to 
assess: 
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 Histological proof of disease 
 Staging of disease 
 Fitness for surgery 
 
The alternative therapy for those individuals not suitable for surgery is radical radiation therapy 
usually combined with chemotherapy. Radical radiation therapy is the use of ionising radiation to 
kill malignant cells and is usually employed for patients with stage II or above NSCLC. According 
to Tyldesley et al (2001), approximately 64% of NSCLC cases require radiation therapy, with 
45.9% requiring radiation therapy in the initial treatment stage and 18.3% later in the course of the 
illness due to the inability to provide surgical intervention. The standard international dose and 
fractionation is 60 Gy in 30 fractions delivered daily over six weeks (Tyldesley, Boyd et al., 2001). 
Higher doses than this generally cannot be given due to the increased risk of pulmonary toxicity. 
Local control of NSCLC using the standard international dose and fractionation protocol is very 
poor and much work is being done to investigate the possibility of dose escalation to improve this.  
1.3. EXTERNAL BEAM RADIOTHERAPY 
Radiation therapy, or radiotherapy, is the treatment of disease by exposure to ionising radiation. 
Modern radiation therapy is usually carried out with high energy (megavoltage range) photons and 
electrons produced via a Linear Accelerator or LINAC. At the megavoltage (MV) energies 
typically used in external beam radiotherapy, the primary process by which a ‘dose’ is delivered to 
biological cells is via high-energy electrons liberated from the atomic orbitals of cell atoms by the 
primary photon flux. Cell damage occurs when electrons interacting within the cells lose their 
kinetic energy in discrete ionisation events within the cell. DNA is recognised as the primary target 
for cell inactivation by ionising radiation. As a result of exposure to ionising radiation, cell death is 
usually attributed to lack of repair or disrepair of single and double strand breaks resulting in 
mitotic cell daughters. External beam radiotherapy is usually carried out with multiple radiation 
beams, optimised to achieve a uniform dose distribution inside the target volume whilst 
minimising dose to healthy tissues surrounding the target. Modern radiotherapy treatment can be 
carried out with a variety of beam energies and field sizes to achieve this goal. 
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1.4. THE RADIOTHERAPY PROCESS 
The steps in a typical radiotherapy process are outlined in Figure 1.1 
Figure 1.1. An outline of the radiotherapy process, from imaging to treatment verification and delivery. 
1.5. IMAGING AND DIAGNOSIS 
Medical imaging is a tool used to examine and diagnose disease or injury. In recent decades, 
medical imaging techniques have evolved rapidly with numerous techniques now available. In the 
context of cancer diagnoses, examination and radiotherapy treatment planning an accurate three-
dimensional (3D) representation of the patient’s anatomy is required. The standard approach to 
gathering information about the patient for the purposes of treatment planning usually involves 
Computed Tomography (CT), Positron Emission Tomography (PET) and or Magnetic Resonance 
Imaging (MRI). Depending on the disease site, combinations of these three main imaging 
modalities may be used. Recent developments have steered hybrid merging of existing 
technologies so that functional, as well as anatomical data can be acquired in a single scan. For 
lung cancer, PET and CT are the most important modalities and therefore all work presented in 
this thesis is dedicated to these modalities.  
1.5.1. Computed Tomography (CT) 
Tomography literally means, ‘slice imaging’. Computed tomography uses the attenuation of X-
rays to produce cross-sectional images of the human body. It differs from conventional projection 
radiography whereby images of full three dimensional structure of the body are collapsed into a 
two dimensional representation. CT images are formed by scanning a single plane from multiple 
directions and reconstructing an image from a number of projections. Computed tomography has 
evolved in a number of technological generations since the first conception by Hounsfield in 1973 
(Hounsfield, 1973). Although the evolution of CT has progressed rapidly with each technological 
Imaging and 
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generation, the same physics lies behind the modern CT as previous generations. Essentially, the 
linear attenuation of X-rays depicts an object’s ability to attenuate X-rays of a characteristic 
energy. Attenuation coefficients are used for medical imaging since different anatomical structures 
have different attenuation coefficients. Bone, for example, has a much higher absorption 
coefficient than soft tissue, and, generally, soft tissues themselves will have variable absorption 
coefficients. Since CT’s inception, the clinical use of CT has increased with technological 
advances in detector and X-ray technology, as well as computational processing power. As modern 
detector array technology improved in the 1990s, so too did the generation of CT scanners. Today, 
CT allows imaging of whole organs or the whole body in 5 – 20 s with sub-millimeter isotropic 
resolution (Kalender, 2006). Table 1.1 gives the absorption coefficients of various human tissues 
in Hounsfield units. This is a dimensionless quantity defined by Equation 1.1 and is the 
comparison of the absorption coefficient of a particular tissue / bone to the absorption coefficient 
of water. Table 1.2 shows a list of modern CT scanners post 1998, when multi-detector array 
technology became prevalent. Wider detector arrays allow for faster scanning and a more effective 
use of the available X-ray tube flux due to an increased solid angle. 
 
In diagnostic imaging, the success of CT critically depends on the fact that normal and cancerous 
tissues have slightly different attenuation coefficients due to differing effective atomic numbers.  
 
 
 
 
 
Table 1.1. Approximate attenuation coefficients (μabs) of various human tissues for 100 kVp X-rays. 
Material μabs in Hounsfield units 
Water 0 
Air -1000 
Bone 1086 
Blood 53 
Fat -61 
Brain white/gray -4 
Breast tissue 9 
Muscle 41 
Soft tissue 51 
 
 
 
1000
water
watertissue
tissue 
H (1.1) 
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Numerous methods exist to determine the pixelised linear attenuation coefficient matrix. These 
methods are broadly grouped into convolution and back projection methods. The interested reader 
is directed to the classic textbook by Webb for further information on these methods (Webb, 
1988). 
 
The modern evolution of CT and detector array technology is shown in Figure 1.2 and a schematic 
of a modern 3rd generation CT scanner is shown in Figure 1.3. In this schematic, the CT source 
rotates around the patient in coincidence with the detector bank. In contrast, a 4th generation CT 
scanner has a stationary detection ring surrounding the patient with a rotating X-ray source. 
Although 4th generation scanners became available, the introduction of multi-row detection 
systems marked the end of the 4th generation scanner and a return to the 3rd generation. The latest 
and most powerful CT scanners offered commercially are all 3rd generation scanners. The routine 
use of CT is commonplace in clinics today and is the basis for most radiotherapy treatment plans. 
Modern CT scanners allow detailed, reproducible and accurate examinations of anatomy. With 64-
slice CT and scan time of less than 10 s, (Kalender, 2006) modern CT scans can be completed 
quickly and non-invasively. Table 1.2 lists a number of modern CT scanners with multi-row 
detector systems. 
 
Table 1.2. Modern CT scanners with multi-row detector systems showing the number of detector rows and 
the number of slices, along with the year. Adapted from (Kalender, 2006). The GE LightSpeed 16 and 
Phillips Brilliance 64 scanners (†) were used in the present study. 
Manufacturer Scanner type Number of detector 
rows  
Number of Slices Year 
GE LightSpeed 16 † 16 16 2001 
Phillips IDT 16 24 16 2001 
Siemens SOMATOM Sensation 
16 
24 16 2001 
Toshiba Aquilion 40 16 2001 
GE VCT 64 64 64 2004 
Phillips Brilliance 64 † 64 64 2004 
Siemens  SOMATOM Sensation 
64 
40 64 2004 
Toshiba Aquilion 64 64 64 2004 
Toshiba Prototype 256 256 2004 
Siemens SOMATOM Definition 2 x 40 2 x 64 2005 
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Figure 1.2. The evolution of fan-beam to cone-beam CT in the early 2000s. Where M is the number of slices, 
trot is the scanner’s rotational period and S is the slice width. 
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Figure 1.3. Schematic of a 3rd generation CT scanner showing the X-ray source and detection system moving 
continuously around the patient. 
 
CT images have become the standard treatment planning tool as CT images provide excellent soft 
tissue contrast allowing for greater tumour localisation and definition. Furthermore, electron 
density information from CT is useful in the calculation of dose inhomogeneities due to differing 
tissue densities. 
1.5.2. Positron Emission Tomography (PET) 
Positron Emission Tomography (PET) is a nuclear imaging technique that allows clinicians to 
detect and quantify various physiological processes and depict metabolic activity. To begin, an 
amount of radioactive tracer, commonly FDG (flouro-deoxy-glucose 18F-FDG) is added to the 
body usually via injection into the blood stream. As the isotope undergoes β+ decay, it emits a 
positron. The positron encounters many electrons undergoing coulomb scattering until the 
positron’s energy is low enough at which point annihilation occurs between the matter-antimatter 
pair. Upon annihilation, two 511 keV gamma-rays are emitted in opposite directions to preserve 
conservation of momentum. These annihilation quanta can be detected via a ring of scintillation 
detectors. From those coincidence events and data from tens of thousands of paths through the 
object a localisation of the source can be achieved. Since uptake of FDG is concentrated within 
X-ray source 
and detector
Couch 
Patient 
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cancerous tissue (FDG signal   Cancer cells in the volume), this effectively means that a tumour 
can be located and imaged within the body.  
 
PET is also clinically used to diagnose and monitor treatment efficacy. The amount of uptake of 
FDG by the tumour is characterised by a semi-quantitative index, which reflects glucose 
metabolism. Clinicians often use this value, known as the Standard Uptake Value (SUV) (Hubner, 
Buonocore et al., 1996), to differentiate between benign and malignant lesions. A standard uptake 
value of > 2.5 measured using a filtered back projection algorithm is generally used as an 
identifying feature for a greater probability of malignancy. The PET defined volume based on 
SUV is dependent on a number of variables including image threshold, size of the lesion, the 
presence of tumour motion and the scanning protocol (Yaremko, Riauka et al., 2005). 
 
Together, PET and CT provide important diagnostic information for treatment planning. CT 
provides anatomical information whilst PET provides information on the metabolic function of 
organs and allows for cancerous cells to be detected. PET images can also be mapped onto CT 
data-sets enabling a radiologist to contrast two imaging modalities which exploit fundamentally 
different physical processes. While both CT and PET can be used to isolate tumour masses, each 
technique has weaknesses that can lead to false negative and positive diagnoses. This usually 
occurs when Δμ or ΔSUV is too small for the respective modality to resolve. PET-CT combined 
on the other hand largely negates these issues as it is very rare for a tumour to have the same SUV 
and attenuation characteristics as surrounding tissues. 
1.6. TREATMENT PLANNING IN EXTERNAL BEAM RADIOTHERAPY 
Treatment planning in conventional external beam radiotherapy refers to the assignment of beam 
directions and dose weightings. Treatment planning is a complex process and requires the 
definition of treatment volumes for meaningful 3D treatment planning and accurate dose 
specification. Modern radiotherapy is carried out with a variety of beam energies and increasingly 
complex treatment fields and beam shaping devices such as multi-leaf collimators (MLCs). A 
discussion about treatment planning would not be complete without a definition of the principle 
volumes which make up the treatment volume, as outlined by ICRU reports 50 and 62 (ICRU, 
1993, ICRU, 1999). The following volumes have been defined in the reports: Gross Tumour 
Volume (GTV), Clinical Target Volume (CTV), Internal Target Volume (ITV), Planning Target 
Volume (PTV) and Organ At Risk (OAR). 
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Figure 1.4. Schematic of the ICRU Report 50 and 62 definition of treatment volumes (Podgoršak and 
Agency, 2005). The ‘Gross Tumour Volume’ (GTV) is described as the gross demonstrable extent and 
location of the malignant growth. The ‘Clinical Target Volume’ (CTV) is a tissue volume that contains a 
demonstrable GTV and/or subclinical malignant disease undetectable by imaging that must be eliminated. 
The Internal Target Volume (ITV) is a margin which is added to the CTV to account for all movements of 
the CTV during treatment and the ‘Planning Target Volume’ (PTV) is an added margin to the ITV to 
account for variations in patient position and beam position both intrafractionally and interfractionally. 
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The following definitions are outlined by ICRU Report 50 and 62: 
 
 Gross Tumour Volume (GTV)         
 
 “The Gross Tumour Volume is the gross palpable or visible/demonstrable extent and location of 
malignant growth” (ICRU, 1993) 
 
 Clinical Target Volume (CTV) 
 
 “The clinical target volume is the tissue volume that contains the demonstrable GTV and/or 
sub-clinical microscopic malignant disease, which has to be eliminated. This volume thus has to 
be treated adequately in order to achieve the aim of therapy, cure or palliation” (ICRU, 1993) 
 
 Internal Target Volume (ITV) 
 
 Of particular relevance to this work is the internal target volume. This internal margin is 
designed to take into account the variations in the size, shape and position of the CTV relative 
to the patient’s reference frame. The ITV takes into account movement of the target volume due 
to respiration, and deformation due to other bodily functions. 
 
 Planning Target Volume (PTV) 
 
 “The planning target volume is a geometrical concept, and it is defined to select appropriate 
beam arrangements, taking into consideration the net effect of all possible geometric variations, 
in order to ensure that the prescribed dose is actually absorbed in the CTV”  
1.6.1. Organs at Risk (OAR) 
An organ at risk is an organ whose sensitivity and location relative to the treatment volume means 
that it may receive a significant dose. Beam arrangements are generally arranged to minimise dose 
to these organs. An OAR does not only have to be an organ that is relatively close to the CTV, but 
can be an organ whose radiation sensitivity is such that it has a very low tolerance dose. During 
respiration, some OARs may move into the ITV and this must be taken into account. 
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1.6.2. Dose specification 
In the context of external beam radiotherapy, the specification of the dose reporting point, along 
with detailed information regarding the total dose is important. ICRU report number 23 and report 
number 50 provide several dosimetric endpoints for specifying the dose. The key values are; the 
minimum dose, obtained from either, a distribution or dose-volume histogram, the maximum 
target dose, again, from a distribution or dose-volume histogram and the mean target dose. 
1.6.3. Treatment plan evaluation 
After dose has been prescribed, the plan is evaluated by a radiation oncologist. Dose distributions 
are often evaluated by analysing key points, contour plots and 3D dose distributions. Dose volume 
histograms also provide a useful way to summarise the information contained in a 3D dose 
distribution. Examples of cumulative Dose Volume Histograms (DVH) are shown in Figure 1.5. 
An ideal plan would be one in which 100% of the target volume receives 100% of the prescribed 
dose and an organ at risk receives 0% of the prescribed dose. However, in reality, this is not the 
case due to the expanding of treatment margins to compensate for uncertainties in patient 
positioning, target motion, patient motion, and delineation errors / uncertainties. 
Figure 1.5. Cumulative dose volume histogram, showing ideal target volume DVH, with 100% of the target 
receiving 100% of the prescribed dose, typical DVH shown by the solid black line and a typical organ at risk 
DVH (red line). 
 
 
Target Volume Ideal
Organ an Risk
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Plan optimisation based on the analysis of contours, specific dose points and DVHs is then carried 
out by determining the best arrangement of beams and their energies, which enables the treatment 
maxmimise the dose to the PTV whilst minimising dose to OARs. 
1.7. TREATMENT DELIVERY IN EXTERNAL BEAM RADIOTHERAPY 
Treatment delivery for external beam radiotherapy is usually carried out with multiple beams from 
differing angles. Modern radiotherapy is characterised by highly conformal radiation such as 
Intensity Modulated Radiation Therapy (IMRT) (Van Houtte, 2003). IMRT uses a multi leaf 
collimator (MLC) to modulate the intensity and spatial characteristics of the treatment beam. An 
MLC is a set of pairs of 20 to 80 narrow tungsten leaves in a closely abutting arrangement. Each 
leaf provides a projection width of approximately 3 - 10 mm at isocentre and the dynamic nature 
of the leaves means irregular field shapes can be achieved. Modern linacs may come with the 
MLC as an integral part of the machine head or as an attachment. Figure 1.6 shows the layout of 
multi-leaf collimation and Figure 1.7 shows how an MLC can be used to shield organs at risk 
whilst still providing good PTV coverage. 
 
Figure 1.6. Schematic of an MLC showing tungsten leaves and the field projection at isocentre. 
 
Shaped Field at Isocentre 
MLC Leaves in Linac Head 
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Figure 1.7. The potential for normal tissue sparing with MLCs. The MLC can be used to protect organs at 
risk whilst still maintaining adequate target coverage. 
 
1.7.1. Image-Guided Radiation Therapy 
Image-guided radiation therapy (IGRT) involves imaging the patient anatomy shortly before the 
delivery of a fraction of radiation therapy. The benefit of this technique is that intermittent 
verification of the target’s position is afforded. Therefore, the target volume location can be 
actively compared with the reference location obtained from planning. Coupled with the increased 
delivery efficacy from IMRT, IGRT has the potential to be a vital aid in the development of 
reduced treatment margins, dose escalation, normal tissue sparing and avoidance of geographical 
misses.  
1.8. TREATMENT VERIFICATION 
The final step in the radiotherapy process is treatment verification. Treatment verification can be 
divided into simulation and in-vivo. In-vivo treatment verification is usually achieved through 
online portal imaging and in vivo dosimetry. In vivo dose measurements may be used to check the 
dose delivery by making measurements on the patient’s skin surface or intracavity dose 
measurements. Due to the difficulty of in vivo measurements, phantom measurements can also be 
performed to verify a particular treatment procedure as part of quality assurance. 
 
Patient Anatomy 
(OAR=Organ At Risk) 
Automated Alignment: 
Over-Irradiated OAR
Leaves moved manually 
for better OAR avoidance
PTV 
OAR 
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1.9. QUALITY ASSURANCE IN EXTERNAL BEAM RADIOTHERAPY 
Quality assurance (QA) in external beam radiotherapy is an integral part of the radiotherapy 
process. It can be broadly defined in the context of radiotherapy, as all procedures that ensure the 
consistency and accuracy of the medical dose prescription, within the target volume, with minimal 
dose to normal tissue, minimal exposure to personnel and adequate patient monitoring. 
Comprehensive QA of radiotherapy is involved across all stages, from planning to delivery. QA is 
important since it reduces uncertainties in equipment, treatment planning, and treatment delivery 
and therefore improves the geometric accuracy and precision of the dose delivery and reduces the 
risk of catastrophic errors. 
1.10. STEREOTACTIC BODY RADIATION THERAPY (SBRT) 
1.10.1. Introduction 
Stereotactic radiotherapy (SRT) emerged as a radiation therapy strategy in 1951 and was first 
implemented by Lars Leksell. Leksell, a Swedish neurosurgeon, developed a machine to deliver 
large doses of radiation to intracranial tumours (Leksell, 1983). Leksell’s machine allowed 
neurosurgeons to administer non-invasive ionising radiation to successfully treat inoperable 
intracranial tumours. Stereotactic radiotherapy requires accurate localisation of the target in three 
dimensions and as such requires the use of stereotactic frames to reduce movement of the patient’s 
head completely.  
1.10.2. SBRT 
Recently, Stereotactic Radiation Therapy/surgery has been extended to treat small tumours in other 
areas of the human body. This development has been termed Stereotactic Body Radiation Therapy 
(SBRT). The most common treatment sites employing SBRT are the lung, liver and spine (Taylor, 
Kron et al., 2011). The rationale for SBRT is that delivering a few fractions of large dose in a short 
overall treatment time results in a more potent biological effect (Timmerman, 2008, Benedict, 
Yenice et al., 2010). SBRT is highly effective in controlling early stage primary and 
oligometastatic cancers throughout the thoracic cavity and abdomen (Benedict, Yenice et al., 
2010). The key differences between SBRT and conventional radiotherapy are the dose delivered 
and the total number of fractions the prescribed dose is delivered in. Typical SBRT doses of up to 
> 54 Gy can be given in less than five fractions, whereas in conventional radiotherapy, lower doses 
per fraction (2 - 3 Gy / fraction) up to the prescribed dose are generally given. Table 1.3 
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summarises the main differences between conventional radiotherapy and SBRT and Figure 1.8 
demonstrates the differences between a conventional radiation therapy plan and an SBRT plan. 
Figure 1.9 gives an indication of present research interest into SBRT giving the sum of PubMed 
based search results as a function of disease site for both intracranial and SBRT treatment. 
 
Table 1.3. Comparison of conventional radiotherapy (3D / IMRT) and SBRT adapted form (Benedict, 
Yenice et al., 2010). 
 
 
SBRT has been shown to increase tumor control probability (Wulf, Haedinger et al., 2004, Wulf, 
Hadinger et al., 2004, Uematsu, Shioda et al., 2001, Timmerman, Papiez et al., 2003, Onishi, 
Kuriyama et al., 2004, Onishi, Araki et al., 2004, Nyman, Johansson et al., 2006, Nagata, 
Takayama et al., 2005, McGarry, Papiez et al., 2005, Lee, Choi et al., 2003, Hof, Herfarth et al., 
2003, Fukumoto, Shirato et al., 2002). Although the large doses have been shown to improve 
treatment outcome, there is also a strong relationship between increasing the dose per fraction and 
the complication rate should normal tissue be irradiated. In the case of stereotactic radiotherapy of 
lung cancer, the increase in mean lung dose has been shown to increase the incidence of radiation 
pneumonitis, pulmonary complications, and other toxicity related concerns (Kwa, Theuws et al., 
1998, Kwa, Lebesque et al., 1998, Nagata, Matsuo et al., 2007). Therefore, the practice of SBRT 
requires conformation of high doses to the target as well as a high degree of confidence throughout 
the entire treatment delivery procedure. These conditions, coupled with the added complexities of 
dose calculation in the lung, as well as potential target motion, mean that if higher doses per 
fraction are to be used, smaller margins, accurate localisation, and understanding / management of 
target motion are required.  
 
 
Feature 3D/IMRT SBRT 
Dose / Fraction 1.5 – 3 Gy 6-30 Gy 
No. of fractions 10- 30 1-5 
Target def. GTV / CTV / ITV / PTV GTV / CTV / ITV / PTV 
Treatment planning imaging CT / MR / PET-CT CT / MR / PET-CT 
Margins Centimeters Millimeters 
Need for respiratory motion management Moderate High 
Radiobiology  mitotic cell death  ablative 
Technology implementation High High 
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Owing to the high degree of accuracy required to ensure treatment efficacy and reduce normal 
tissue exposure, a number of immobilisation devices can be used in SBRT. These immobilisation 
apparatus can range from vacuum bags (Lax, Blomgren et al., 1994) to body frames such as the 
Elekta Body Frame (Elekta Oncology, Stockholm, Sweeden). Typical uncertainties using these 
devices range from 1.8 – 5 mm (Taylor, Kron et al., 2011). 
 
 
Figure 1.8. Comparison of dose distributions between a 4-field conventional lung radiotherapy plan (A) and 
a 7-field stereotactic lung radiotherapy plan (B). (Courtesy of Brent Chesson, Radiation Therapist, Peter 
MacCallum Cancer Centre, Melbourne, Australia). 
  
- - 25 - - 
1
10
100
1000
10000
19
50
 - 1
96
0
19
60
 - 1
97
0
19
70
 - 1
98
0
19
80
 - 1
99
0
19
90
 - 2
00
0
20
00
 - p
res
en
t
Year
N
um
be
r o
f p
ub
lic
at
io
ns
(lo
g 
sc
al
e)
SBRT (Lung)
SBRT (Pancreas)
SBRT (Spine)
SBRT (Liver)
Stereotactic (Intracranial)
 
Figure 1.9. A literature search based on publications relating to stereotactic radiotherapy, both intracranial 
and SBRT. Note the logarithmic scale. 
1.11. RADIATION DELIVERY TO A MOVING TARGET 
The potential for dose escalation in SBRT in the lung is complicated by tumour motion. Tumours 
in the abdominal region often undergo motion due to the patient’s respiratory function and the 
potential for dose escalation is reduced due to the inherent uncertainties involved in the target’s 
position, along with the possibility of excess exposure to healthy tissues surrounding the target.  
1.11.1. Complications due to motion of lung tumours in conventional radiotherapy  
In effect, all tumours move to some extent during treatment. In the past, tumour motion has been 
managed by expanding the field size of conventional radiotherapy beams to ensure that the tumour 
receives exposure at all times along its trajectory. This method is sub-optimal as the volume of 
healthy tissue increases as R3, (where R is the radius of a sphere) it is clear that a small increase in 
the margin around the CTV will result in a large amount of healthy tissue being exposed. 
Numerous motion management methods have been proposed in the literature and will be covered 
in the literature review in Chapter 2. Each motion management method has its associated 
advantages and disadvantages and the choice of a particular method depends on the magnitude of 
displacement and the patient’s ability to tolerate the chosen procedure. 
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1.11.2. Lung cancer SBRT and tumour motion: The current problem 
The problem of radiation delivery to a moving target is compounded in SBRT due to the higher 
doses per fraction as well as the increased need for highly localised delivery. Recent research 
suggests a direct correlation between dose escalation and local control. For example, Machtay et al 
(2012) recently determined that there is an associated 18% decrease in the risk of death from 
primary disease with every 10 Gy increase in biologically equivalent dose. Figure 1.10, taken from 
an excellent review paper by Taylor et al (2011) shows the key findings of several studies on 
SBRT for the treatment of primary lung cancer. 
 
 
Figure 1.10. Overview of several key studies reviewed in the paper by Taylor et al (2011). The number of 
patients, N, dose, local control rate and number of fractions are shown.   
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However, research has also shown that the probabilities of complications from the treatment itself, 
such as radiation pneumonitis, are also directly correlated to the mean lung dose (Seppenwoolde, 
Lebesque et al., 2003, Kwa, Lebesque et al., 1998).  
 
One of the primary concerns in SBRT is the difficulty in choosing a prescription point or volume. 
The standard protocol for prescribing and reporting dose is outlined by the International 
Commission on Radiation Measurements and Units (ICRU) reports 52 and 62 (ICRU, 1999, 
ICRU, 1993). This protocol specifies that the variation in dose within the target should be kept 
between -5% and +7% of the prescribed dose. It is for this reason that the 95% isodose line is 
chosen for target coverage in conventional radiotherapy. In SBRT, a lower isodose line, such as 
the 80% isodose line, is used for prescription. The rationale for this is to improve the dose fall-off 
outside the target volume (Figure 1.11) which therefore helps spare organs at risk (Benedict, 
Yenice et al., 2010) however, the choice of a lower isodose prescription also reduces dose 
homogeneity within the target itself. This is well known and accepted in intracranial stereotactic 
radiotherapy. Heterogeneity within the dose distribution can result in hotspots within the target. 
Hotspots are often deemed acceptable, as the objective in SBRT is ablative, as long as there is no 
overlap into normal tissue regions (Cardinale, Wu et al., 1999, Fowler, Tome et al., 2004).  
Figure 1.11. Graph showing the consequences of prescription to a lower covering isodose. The steepness of 
the dose gradient when prescribing to a lower covering isodose results in greater dose heterogeneity within 
the tumour volume. 
 
 
0
10
20
30
40
50
60
70
80
90
100
110
-25 -5 15 35 55 75 95 115 135
distance (arb.)
pe
rc
en
ta
ge
 d
os
e
Dose gradient at 
the 95% isodose line
Dose gradient at 
the 80% isodose line
pe
rc
en
ta
ge
 d
os
e
 - - 28 - - 
If dose escalation is to be utilised in a safe, accurate and effective manner, then increasingly 
conformal fields and strict quality assurance protocols must be developed across all stages of the 
radiotherapy cycle. Motion management must take into account the size of the lesion and the 
treatment methodology. Tumour motion presents a challenge for SBRT due to the high doses 
involved and the relatively small margin for error. This fact, coupled with the reduced number of 
fractions SBRT is usually delivered in, means that errors in delivery and planning could result in 
far greater detriment to the patient. If methodologies and technologies can be developed to 
understand and account for small lesion motion, then increased localisation and accuracy in 
radiation delivery can be expected. This in turn will allow an increased potential for dose 
escalation and may help to improve the balance between complications and cure. 
1.12. AIM & OBJECTIVES 
The main aim of this thesis is to make an assessment of the impact of motion on the treatment of 
small lesions affected by motion as commonly seen in stereotactic radiotherapy of lung cancers. 
This includes the elements of imaging, treatment planning methods and dose calculation which are 
all affected by motion.  
 
To address this aim the following objectives were set: 
Objective 1: Assess the effect of motion on the identification and delineation of small, moving tumours. 
Objective 2: Quantify the influence of lesion size and motion amplitude on data acquired from 4D-CT 
Objective 3: Determine the degree to which the same relationships affect PET data if and when this 
imaging modality is incorporated into the treatment planning process. 
Objective 4: To assess the mitigation of motion effects in PET that can be achieved by implementing 4D 
phase-binned PET.  
Objective 5: To evaluate dose calculation on lung tumours, in particular quantifying the differences 
between 4D calculations, which explicitly account for dynamic geometry and conventional 3D calculation, 
based on average intensity projection data from 4D-CT. 
1.13. APPROACH 
This thesis is organised as follows: Chapter 2 presents a literature review on the effect of tumour 
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motion during imaging and treatment delivery. This section firstly focuses on the biomechanics of 
respiratory motion and tumour motion, with attention paid to the magnitudes of these motions as 
reported in the literature. The effect of motion on images acquired with conventional CT and PET 
is then discussed with a review of the substantial literature on this topic. Motion effects that 
compromise radiation delivery and dose calculation are then presented. 
 
The latter half of Chapter 2 presents currently available motion management strategies that have 
been both presented in the literature and are available clinically. Firstly, surrogate markers and 
respiratory gating are reviewed with both gating based on external and internal surrogates being 
discussed. Breath-hold techniques are then described with the literature on both voluntary and 
mechanically assisted methods reviewed. Motion management in the context of treatment planning 
is outlined for CT and PET imaging modalities and the literature is reviewed. Literature on the 
methods to combat motion effects, such as slow CT scanning and time-resolved 4D-CT is 
presented and reviewed. For PET, gated (4D) acquisitions are described and the literature 
reviewed. The literature and methods of complex motion management techniques, such as real-
time tumour tracking are then presented. A section on motion phantoms is included in this chapter 
since their design and construction is important in the context of this thesis. Finally, Monte Carlo 
methods are presented, starting with a summary of currently available Monte Carlo codes. The 
limited literature on the use of Monte Carlo and simulation of dose delivery to moving lesions is 
then outlined. Finally, SBRT and the need for a better understanding of the effects of tumour 
motion in both treatment planning and delivery of SBRT is discussed leading into Chapter 3. 
 
Chapter 3 describes the development of two motion phantoms. The development of a see-saw 
phantom used in this work is presented followed by an assessment of its motion capabilities and 
the accuracy of a mathematical model describing its motion. This phantom was specifically 
designed to be compatible with CT imaging and is used to determine the magnitude of errors that 
can occur in 4D-CT imaging of moving lesions. These errors are evaluated as a function of lesion 
size and amplitude and are presented in Chapter 4. The upgrade of a commercially available 
motion phantom, so that realistic patient-like motion can be achieved is then presented. The 
methods and materials involved in the upgrade our outlined and the results are presented 
highlighting the accuracy of the upgrade in reproducing patient-like motion. 
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Chapter 4 examines the impact of motion on images acquired with 4D-CT. The results presented in 
this chapter were obtained experimentally with a small computational component utilising the 
XCAT phantom described in Section 2.10.3.3. The experimental data was acquired using the see-
saw phantom described in Section 3.2. Results pertaining to the effect of motion on images 
acquired with 4D-CT are then presented (Objectives 1 & 2). These results focus on the HU 
consistency of phase-bin data, the quality and accuracy of maximum and average intensity 
projections (MIP & AIP) with respect to the minimum number of phase-bins needed to produce an 
accurate description of the tumour motion. The XCAT phantom is then used to simulate scenarios 
to corroborate the experimental results and verify the finding that the quality of MIP and AIP is a 
function of the lesion size and amplitude. 
 
Chapter 5 presents experimental and computational results for the investigation into the impact of 
motion on images acquired using PET. Specifically, this work pertains to Objective 3, with the 
effect of motion on 3D-PET images assessed for a variety of lesion sizes and motion amplitudes. 
Results of 4D-PET simulations in a Monte Carlo framework are then presented (Objective 4).  
 
Chapter 6, the impact of motion on treatment planning and dose calculation (Objective 5) is then 
presented. In this section, Monte Carlo simulations using static lesions of various sizes and 
distances from the chest wall boundary are performed to establish the peripheral underdosage of 
the lesion that occurs as a result of these conditions. Following this, results comparing 4D dose 
calculation, that is, the explicit incorporation of temporal information into dose calculation, to 
performing dose calculation on an AIP are presented (Objective 5). Chapter 7, the conclusion, 
presents a summary of the results presented in thesis and focuses on clinical outcomes and outlook. 
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Chapter 2. Literature review: Motion management in 
radiotherapy 
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“If I have seen further it is by standing on the shoulders of giants.” 
-Sir Isaac Newton 
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The previous chapter provided the relevant introductory material relating to radiotherapy and 
stereotactic radiotherapy. This chapter serves as a literature review of the current status of motion 
management in radiotherapy.  
2.1. INTRODUCTION 
Meeting the specific goal of radiotherapy is a challenging endeavor, which is further complicated 
by motion of the patient’s anatomy. Traditionally, in dealing with motion, a volume larger than the 
tumour boundary was irradiated to ensure adequate dose coverage of the target over its excursion. 
This method is outlined in ICRU Reports 50 and 62 (ICRU, 1999, ICRU, 1993) and an overview 
of the methodology is shown in Figure 1.4. From Figure 1.4, it can be seen that margins to account 
for clinical spread of disease and patient setup uncertainty increase the amount of healthy tissue 
irradiated. The volume is further increased when another additional margin, the Internal Margin 
(IM) must be added to the standard margins to account for expected physiological movements and 
variations in size, shape and position of the CTV during therapy. Motion management is one of the 
primary research areas in radiotherapy today and progress has been made across all stages of the 
radiotherapy cycle. The rest of this chapter will be devoted to describing the issues and current 
motion management methods available clinically. 
2.2. INTRAFRACTIONAL TUMOUR MOTION 
Intrafractional motion (motion during treatment) can be caused by physiological, cardiac, 
gastrointestinal and muscular motion. However, the main cause of concern, regarding motion 
management in radiotherapy is concerned with target motion caused by patient respiratory 
function. Respiratory induced tumour motion is of greater concern than other physiological 
movements due to the large spatial displacements that can occur.  
2.2.1. Biomechanics of breathing 
The basic function of the human respiratory system is to allow gas exchange between blood and air 
to maintain normal levels of pressure in the arterial blood. Respiratory motion is involuntary, 
however, humans have some control over the frequency and amplitude of respiration. The 
diaphragm controls the inspiration cycle of respiration by contracting inferiorly and anteriorly into 
the abdomen (see Figure 2.1 showing a typical diaphragm profile and the resulting anterior-
posterior (AP) chest-wall profile.). In doing so, the intercostal muscles that connect adjacent ribs 
 - - 34 - - 
contract, the ribs are then pulled superiorly and anteriorly expanding the dimensions of the 
thoracic cavity which draws air in to fill the cavity created. Exhalation is an elastic function 
whereby the chest-wall and lungs return passively to their pre-inhalation state. Respiratory 
function and the subsequent breathing profile varies from subject to subject and can be different 
depending on, but not limited to, posture, breathing type (chest or abdominal) and location and 
extent of disease based respiratory function degradation. In addition to the lungs, the liver, 
pancreas, breast, prostate and kidneys can all move with breathing. Furthermore, during the 
radiotherapy process the patient’s breathing can change in period, amplitude and regularity further 
complicating the procedure (Vedam, Kini et al., 2003, George, Vedam et al., 2005, Seppenwoolde, 
Shirato et al., 2002a). In the coming sections, the effects of respiratory motion in the radiotherapy 
process will be summarised for lung tumours. Current methods to manage motion in radiotherapy 
will also be discussed.  
 
  
Figure 2.1. (a) A typical diaphragm motion profile and (b) the corresponding AP chest-wall motion profile. 
 
2.2.2. Magnitude of lung tumour motion caused by respiratory function 
Table 2.1 is a summary of the reported magnitudes of respiratory induced lung tumour motion 
amplitudes (Keall, Mageras et al., 2006a). The magnitude of tumour motion varies depending on a 
number of factors. The type of breathing (shallow or deep), the patient’s disease site (lung / 
abdomen etc.) and, especially for lung, the disease site with respect to the diaphragm can modify 
the magnitude of the effects of respiratory motion on tumour motion. From the literature, it is clear 
that in most cases tumour motion occurs in all three dimensions, Superior-Inferior (SI), Left-Right 
(LR) and Anterior-Posterior (AP), however, the magnitude of tumour motion seems to be greater 
 - - 35 - - 
in the SI direction with the LR and AP motion components being of a smaller magnitude. The 
average motion of tumours in the lower regions of the lung has also been shown to be of greater 
magnitude than of tumours located in the middle or upper lung (Barnes, Murray et al., 2001, Kubo 
and Hill, 1996). Tumour trajectories also experience hysteresis as was shown by (Seppenwoolde, 
Shirato et al., 2002a). Hysteresis occurs when the tumour’s trajectory during inhale is different 
from that during exhale. Using fluoroscopic imaging of implanted fiducial markers, Seppenwoolde 
et al (2002a), observed hysteresis in tumour motion trajectories in half the patients. Their results 
showed a 1-5 mm separation between inhalation and exhalation. It is also clear from the literature 
that there are no simple models that can be applied to respiration. From patient to patient, it is clear 
that no assumptions can be made about respiratory behavior. If respiratory motion is affecting the 
treatment volume significantly, then it must be monitored and accounted for during planning and 
treatment using radiotherapy. Figure 2.2 shows typical respiration induced tumour motion as 
simulated with the XCAT phantom. The tumour’s motion is divided into 10 distinct phases. Figure 
2.3 and Figure 2.4 demonstrate the variability in respiratory function seen between different 
patients. The significance of this is that motion can be large; and quite variable; therefore strategies 
for assessing the impact on imaging, planning and dose delivery should incorporate studies of a 
variety of motion patterns / amplitudes. As a result, the motion phantoms presented in this thesis 
and the investigations performed include motion patterns which vary in regularity as well as 
amplitude. 
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Table 2.1. The magnitude of respiratory motion as observed in several studies. The disease site, mean range 
of motion in mm in three dimensions (Superior Inferior [SI], Anterior Posterior [AP], Left Right [LR]) is 
reported (if available) as well as the maximum and minimum tumour motion in brackets. Where maximum 
and minimum are not reported the plus/minus standard deviation is shown.  
Direction 
Observer Disease Site 
SI (mm) AP (mm) LR (mm) 
(Weiss, Wijesooriya et al., 2007) Lower Lobe 15.4 (3D-Vector) (11.4 - 24.0) 
 Upper Lobe 4.54 (3D-Vector) (1.3 – 11.6) 
(Seppenwoolde, Shirato et al., 2002a) - 5.8 (0 – 25) 2.5 (0 8) 1.5 (0-3) 
(Shirato, Suzuki et al., 2006) - 10.7 (2.1 – 28.0) 8.9 (2.4 – 28.4) 8.1 (2.2 – 24.6) 
(Gierga, Chen et al., 2004) - 7.4 (0 – 18) 3.8 (0 - 8.7) -- 
(Plathow, Ley et al., 2004) Lower Lobe 9.5 (4.5-16.4) 6.1 (2.5-9.8) 6.0 (2.9-9.8) 
 Middle Lobe 7.2 (4.3-10.2) 4.3 (1.9 -7.5) 4.3 (1.5-7.1) 
 Upper Lobe 4.3 (2.6 -7.1) 2.8 (1.2-5.1) 3.4 (1.3 -5.3) 
(Ekberg, Holmberg et al., 1998) - 3.9 (0-12) 2.4 (0-5) 2.4 (0-5) 
(Erridge, Seppenwoolde et al., 2003) - 12.5 (6-34) 9.4 (5-22) 7.3 (3-12) 
(Britton, Starkschall et al., 2007) - 8.6 ± 1.9 3.9 ± 0.8 1.9  ± 0.5 
(Chen, Weinhous et al., 2001) - (0-50)   
(Hanley, Debois et al., 1999) - 12 (1-20) 5 (0-13) 1 (0-1) 
 
 
Figure 2.2. A computer generated example of a tumour’s SI motion as a function of the respiratory phase. 
These images were generated with the XCAT phantom which is discussed in Section 2.10.3.3. In these 
images, 0% corresponds to the peak-exhale phase and 40% corresponds to peak-inhale phase. The red 
dashed line represents the starting position of the mass’s excursion. The lesion can be seen to move in and 
out of this region over a complete respiratory cycle. 
0% 10% 20% 30% 40% 
50% 60% 80%70% 90% 
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Figure 2.3. Six separate patients’ AP chest-wall motion as a function of time showing the variability between 
patients, and within the breathing profiles of individual patients. Data is taken from six patients involved in 
the CHISEL clinical trial1.  
 
                                                          
1 A randomised phase III trial of highly Conformal Hypofractionated Image guided ("Stereotactic") 
radiotherapy (HypoRT) versus conventionally fractionated radiotherapy (ConRT) for inoperable early stage I 
Non-small cell Lung cancer. 
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Figure 2.4. Six patients’ phase versus chest wall amplitude variability (from Figure 2.3). This data shows 
each respiratory cycle overlaid on top of one another. The grouping of these traces represents the degree of 
respiratory regularity. 
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2.3. THE EFFECT OF INTRAFRACTIONAL TUMOUR MOTION DURING IMAGING  
2.3.1. Introduction 
Imaging is critical to the diagnosis of cancer and subsequent radiotherapy treatment planning. 
Common tumours, such as those occurring in the lung, breast and colon are typically diagnosed via 
imaging using X-ray CT, ultrasound, mammography or Magnetic Resonance Imaging. Further 
imaging of the disease depends on the tumour type and its methods of spread. Imaging is also used 
to monitor treatment, whereby, the primary tumour’s size and metastatic spread in response to 
radiotherapy treatment can be determined. These examinations allow the oncologist to determine if 
further intervention, i.e. chemotherapy, is needed in addition to radiotherapy. Furthermore, 
imaging is also used in screening for cancer. Mammography screening of breast cancer, for 
example, is widely accepted for improving detection rates for women aged between 40 and 70 and 
thus provides an improvement for breast cancer mortality (Ohuchi, Yoshida et al., 1993, Elwood, 
Cox et al., 1992, Fletcher, Black et al., 1993).  
 
Radiotherapy planning requires imaging to define the tumour / target volume. This is often 
achieved with the use of Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and 
Positron Emission Tomography (PET). The importance of 3D / volumetric imaging during 
treatment planning of cancer cannot be overstated. With regard to motion, standard techniques 
generally assume a static geometry, therefore, motion of anatomy due to respiration can cause 
artifacts in the images and needs to be explicitly accounted for. 
2.3.2. The effect of tumour motion on images acquired with Computed Tomography 
Computed tomography is the primary method of imaging for stereotactic lung cancer patients 
undergoing radiotherapy. Since CT images are used to determine the treatment plan and calculate 
dose distributions, the accuracy of the images and information about anatomical / target motion is 
critical. Primarily, respiratory motion causes artifacts in image acquisition since the method of 
image reconstruction assumes a static anatomy. Artifacts in computed tomography can cause 
distortions in the tumour’s apparent location and measured size. The cause of the artifacts in CT is 
generally due to different parts of the anatomy being imaged moving in and out of the CT slice 
window. The CT image reconstruction algorithms assume invariance of anatomy, and thus, when 
the slices are combined to form the image, distortions can be present. The degree and type of 
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artifact is dependent on a number of factors, such as the position of the tumour relative to the 
diaphragm, depth of respiration, patient movement during acquisition and interplay between 
scanner acquisition methodology and motion, for example, helical or cine acquisition.  
2.3.2.1 Artifacts in conventional CT 
An accurate CT relies on a static anatomy at the time of acquisition. This is often impossible to 
achieve as the human body is continually in motion internally. The result of patient motion during 
the acquisition of CT data is artifacts in the resulting images. In CT, the term artifact is defined as 
any systematic discrepancy between the CT numbers in the reconstructed image and the true CT 
number of the object being imaged (Barrett and Keat, 2004). The types of artifacts that may occur 
can generally by classified as physics based, scanner based, reconstruction based and patient 
based. They can generally be grouped as (a) Streaking (Sheridan, Keller et al., 1980), due to an 
inconsistency in a single measurement, (b) shading, due to the gradual deviation of a group of 
channels or views. (c) rings (Tsai, Chen et al., 2011, Sadi, Lee et al., 2010, Abu Anas, Lee et al., 
2010), due to errors in individual detector calibration and (d) distortion (Nishimaru, Utsunomiya et 
al., 2005). Most of the artifacts described here are applicable to filtered back projection methods. 
2.3.2.1.1. Physics based artifacts 
Physics based artifacts result from the physical processes involved in the acquisition of CT data. 
Beam hardening occurs as photons pass through an object. Beam hardening results in an increase 
in the mean energy of the spectrum of photons passing through an object due to the greater 
absorption of lower energy photons in the object. There are two types of artifacts that can result 
from beam hardening: cupping and streaks, or dark bands. Cupping artifacts occur since the rate at 
which the beam is attenuated decreases as the beam passes through the object. At the detectors, the 
beam is more intense than would be expected if hardening had not occurred. Dark bands occur 
between two dense objects on an image. Dark bands occur because the portion of the beam that 
passes through one of the objects at a certain tube position is hardened less than when it passes 
through both objects in other tube positions.  
2.3.2.1.2. Scanner based artifacts 
Scanner based artifacts are those related to the detection system itself. For example, Ring artifacts 
on a third generation CT scanner (both tube and detection system rotating) can arise due to one of 
the detectors being out of calibration. This detector will give a consistently incorrect reading at 
each angular position resulting in a circular ‘ring’ artifact. 
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2.3.2.1.3. Reconstruction based artifacts 
The quality of images from CT is highly dependent on the number of projections used for 
reconstruction. Too large an interval between projections can lead to undersampling, where the 
computer misregisters data relating to sharp edges and small objects. Undersampling generally 
leads to aliasing artifacts where fine stripes are present radiating outwards from the edges of dense 
structures. Aliasing artifacts may not greatly affect the diagnostic quality of an image, however, 
where resolution is important aliasing artifacts need to be avoided since these artifacts may cause 
errors in dose calculation. 
2.3.2.1.4. Patient based artifacts 
Patient based artifacts can generally be grouped into metal implant artifacts and patient motion 
(voluntary, involuntary or anatomical) related artifacts. Patient motion can result in a variety of 
artifacts, with the degree of impact on the diagnostic or planning quality of an image being 
dependent on the magnitude of the motion during image acquisition. Patient motion management 
and the effect of patient motion on images acquired with CT are of the greatest importance for 
SBRT (Zamora, Riegel et al., 2010b, Timmerman, Park et al., 2007, Timmerman, Abdulrahman et 
al., 2007).   
 
Figure 2.5 shows a CT data-set simulated with the XCAT phantom. In Figure 2.5 (a), there is no 
motion present during the acquisition of the scan and the image appears artifact free. Figure 2.5 (b) 
on the other hand has motion enabled and the distortion of the image is clearly evident. Several 
authors have investigated the artifacts formed by moving objects. Chen et al (2004) investigated 
the interplay between helical acquisition and moving objects of a known geometry. A phantom 
was used to simulate motion with amplitude of 1 cm and motion period of 4 seconds. High speed 
scans were acquired at incremental phases of respiration and the image quality was assessed. The 
resulting scans showed that moving spherical objects can be shortened by up to 2 cm (twice the 
motion amplitude). Furthermore, the spherical object’s shape was significantly distorted with the 
geometric centre being displaced by up to 0.8 cm in either direction. An interesting result of their 
study was that even if the amplitude was decreased to 0.5 cm, the effects were still observable. 
Balter et al (1996b) studied patients with abdominal and thoracic tumours and compared free-
breathing CTs to breath-hold CTs. Their results showed that free-breathing CT studies may 
incorrectly estimate volumes and positions of critical structures and therefore may lead to incorrect 
plan evaluation when using DVHs and Normal Tissue Complication Probability (NTCP) criteria.  
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Figure 2.5. (a) Simulated CT using the XCAT phantom for a static anatomy, (b) Simulated CT of a moving 
anatomy showing the distortion due to motion.  
 
2.3.2.2 Artifacts and the effect of motion in 4D-CT 
Respiratory induced tumour motion results in a blurring or distorted image set in conventional CT 
where the tumour’s position can move through multiple slices as well as within individual slices. 
This blurring of anatomy and the target itself can result in misdiagnoses and incorrect planning 
information about target size, structures in connection with the target and the average position of 
the target. Breathing triggered 4D-CT was developed by Vedam (spiral) (Vedam, Keall et al., 
2003b) and Keall (multi-slice helical) (Keall, Starkschall et al., 2004). The goal of 4D-CT is to 
gather information on anatomic variation as well as highly detailed visualisations of patient 
anatomy. The spatiotemporal information provided by 4D-CT mitigates many of the respiratory 
motion artifacts associated with conventional CT by binning the CT data as a function of an 
external surrogate based respiratory signal. However, irregular motion (Rietzel and Chen, 2006a) 
and binning artifacts as a result of irregular motion are still an area of concern (Mutaf, Antolak et 
al., 2007). Furthermore, the finite slice acquisition times in 4D-CT mean that residual motion over 
a typical scanner rotation time will exist within each phase-bin. These issues indicate that 4D-CT 
should be used with some caution and the accuracy and limitations of 4D-CT scanner technology 
(a) (b) 
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evaluated accordingly. 
 
In SBRT of thoracic targets, 4D-CT is critical to inform the clinician of the position of the tumour 
over a complete respiratory cycle, the average position of the target, the size of the target and the 
regularity with which the patient breathes. Moreover, due to the high doses per fraction, errors are 
no longer blurred over a larger number of fractions, and therefore the accuracy, and verification of 
the accuracy of 4D-CT is vital. 
 
While there are other methods to assess a tumour’s range of motion such as fluoroscopy (Chen, 
Weinhous et al., 2001), 4D-CT is the most widely used method clinically (Hugo, Vargas et al., 
2006, Pan, Sun et al., 2008, Wink, Panknin et al., 2006). 4D-CT provides useful projections from 
the phase-bin data which can be used for SBRT treatment planning purposes. Individual 
projections will give a more realistic estimate of the real lesion size and its boundaries aver its 
range of motion. Furthermore, the Average Intensity Projection (AIP) (Figure 2.6) is commonly 
used for dose calculation since it is a representation of the average density over the course of a 
respiratory cycle (Huang, Park et al., 2010a, Vinogradskiy, Balter et al., 2009b). The Maximum 
Intensity Projection (MIP) (Figure 2.6) is used to delineate the ITV showing a ‘motion envelope’ 
encompassing the maximum minimum and inter-maxima phases of the tumour’s trajectory 
(Bradley, Nofal et al., 2006, Admiraal, Schuring et al., 2008b, Rietzel, Chen et al., 2005a, Huang, 
Park et al., 2010a, Underberg, Lagerwaard et al., 2005, Muirhead, McNee et al., 2008). In this 
work, artifacts relating to an object’s size and motion on images and projections obtained from 4D-
CT were investigated. 
 
SBRT requires precise localisation of targets and accurate delineation of patient anatomy to aid in 
treatment planning. Three dimensional data is often obtained from CT or 4D-CT for visualisation 
and dose calculation, with PET images being used to assist in visualisation and target definition 
(Chen, Kung et al., 2004). Motion causes problem in traditional imaging. Free breathing spiral CT 
may not represent the true target position since the target can be imaged at different respiratory 
phases at each slice (Chen, Kung et al., 2004).  
 
Previous studies have shown that motion can lead to an over/under estimation of lesion size in CT 
imaging. However to date this has only been shown for relatively large lesions undergoing quite 
small displacements. It has not been analysed for small mobile lesions typical of SBRT targets. 
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This is addressed in this thesis in Chapter 4. 
2.3.3. The effect of tumour motion on images acquired with Positron Emission Tomography (PET) 
In radiotherapy treatment planning, PET is most commonly used in conjunction with CT to 
provide additional metabolic information and help inform treatment planning decisions. During 
PET imaging, data is usually acquired over 3 - 7 minutes per bed position (Nehmeh and Erdi, 
2008). Since many respiratory cycles occur during the acquisition and the rate remains the same, 
the activity profile of the moving tumour is ‘smeared’ across the tumour’s range of motion. Small 
lesions undergoing motion are particularly troublesome for PET since the resolution is of the order 
of 4 - 6 mm, and as a result moving small lesions may be lost against the background activity.  
2.3.3.1 PET used in conjunction with CT (PET/CT) 
Since PET scanning only supplies functional metabolic information, clinically it requires 
anatomical information to add a localisation along with attenuation correction. For this, computed 
tomography (CT) is used. The fusion of these two technologies has allowed for increased accuracy 
of diagnostic information and therefore the potential for increased treatment accuracy 
(Rajagopalan and Heron, 2010). Lung tumour motion presents a number of challenges for 
conventional PET. Previous authors have generally characterised the effects as the underestimation 
of SUV and the overestimation of the tumour’s size and volume (Senan and De Ruysscher, 2005, 
Allen-Auerbach, Yeom et al., 2006, Mac Manus, Hicks et al., 2006). 
 
In a large patient study conducted by Liu et al (2009), 1295 respiratory traces were acquired 
during whole body static PET/CT imaging. By investigating this large population, a 
characterisation of the dependence on motion profile variables for SUVmax underestimation and 
volume overestimation was achieved. Overall, their population study revealed respiratory motion 
can have a significant impact on PET/CT imaging, depending on; motion amplitude, lesion 
location, size of lesion, choice of attenuation map and respiratory irregularity. On average, the 
study found that motion induced an underestimation in SUVmax of 28% and an average 
overestimation of lesion volume of 130%. The study also found that mismatched attenuation 
correction can be partly compensated by using a respiratory-averaged CT, however, the tumour 
quantification and delineation is further complicated by using this method. To summarise, tumour 
motion causes the following issues for PET and PET-CT imaging: 
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1. Metabolic PET activity images taken of moving tumours represent the average of the different 
positions successively occupied by the tumour. This means that a ’hot’ lung lesion’s activity 
profile is smeared over its range of motion. 
2. Since activity concentration is smeared, the volume of the lesion is overestimated. 
3. SUVs are underestimated since the artifactually large lesion’s activity profile is smeared (Liu, 
Pierce et al., 2009). 
4. In static PET/CT of the thorax, tumour motion can lead to a distortion of the combined PET/CT 
(Liu, Pierce et al., 2009) 
5. Misalignment of PET/CT images can reduce diagnostic accuracy and increase treatment 
margins resulting in excessive dose to normal-tissue, and or, organs at risk or underdosage of 
the lesion’s periphery. 
6. PET and CT have largely different scan times; meaning, accurate co-registration between the 
two image sets with meaningful results can be difficult. 
7. Accurate quantification of tracer activity concentration requires CT provided attenuation 
correction. This is difficult to achieve when registering images that are not breathing-phase 
correlated. (Nehmeh, Erdi et al., 2004a, Ponisch, Richter et al., 2008). An outcome of this is 
that accurate attenuation correction can only be achieved when the position of the lesion is the 
same on 4D-CT and 4D-PET images (Osman, Cohade et al., 2003). 
 
Table 2.2 shows the results of several studies assessing the impact of motion on both the tumour’s 
apparent volume and the underestimation of SUV. 
Table 2.2. Summary of the effects of motion on SUV underestimation and volume overestimation. 
Maximum values found over the entire study are presented except where noted. 
Observer Motion range (mm) SUVMAX underestimation (%) Volume overestimation (%) 
(Liu, Pierce et al., 2009) 6 – 16 28 130 
(Pevsner, Nehmeh et al., 2005) 0 – 20 75 -- 
(Callahan, Binns et al., 2011) 0 – 40 450 (5 mm lesion) , 150 (20 mm lesion) 72 
(Nagel, Bosmans et al., 2006) 2.5 – 4.8 75 370 
2.4. THE EFFECT OF TUMOUR MOTION ON RADIATION DELIVERY 
As outlined in Chapter 1, motion not only affects the imaging portion of the SBRT cycle, but also 
the delivery of radiation to the target during treatment. This section looks at the effects of tumour 
motion on radiation delivery.  
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Radiation delivery to moving targets results in a blurring of the static dose distribution possibly 
leading to mistreatment. If the motion of the target is not explicitly accounted for, a discrepancy 
between the planned and delivered dose distributions can result. Generally, as discussed earlier, a 
static field must be made large enough so that the tumour’s motion does not place the PTV near 
the beam edges. This approach is sub-optimal and where tumour motion is significant, say, greater 
than 5 mm, an unnecessary irradiation of healthy tissue often occurs. The effect of blurring during 
radiation delivery to a moving target may be exacerbated during IMRT delivery due to the 
interplay between target motion and that of the MLC leaves and steep dose gradients. For 
stereotactic treatments, motion of tumours during delivery presents a unique challenge. Targets 
moving in small fields, coupled with the high doses and very steep dose gradients involved mean 
that motion needs to be explicitly managed if the dose escalation afforded in SBRT is to be 
pursued. Although tumour motion is predominately perpendicular to the beam direction, for 
multiple field techniques (SBRT), the motion direction may also be parallel to the beam direction. 
In this scenario, although there is a shallower dose gradient, the dose received by the target is 
subject to influence from variations in electron equilibrium associated with the overlying 
inhomogeneities at varying distances. 
2.5. CONCEPTS OF MOTION MANAGEMENT IN RADIOTHERAPY 
Before an in-depth discussion about motion management methodologies specific to imaging and 
subsequently treatment delivery, methods that are common to both: surrogate markers, gating and 
breath-hold methods, will be discussed in the coming sections. 
2.5.1. Surrogate markers 
The near Z independence of attenuation in the MV range means that it is difficult to directly 
measure the target’s position during therapy. Surrogates are therefore often used on the basis that 
their position has a strong correlation to relevant internal anatomy. There are both internal and 
external surrogate markers. The diaphragm, for example, can be imaged with fluoroscopy during 
treatment to get an indication of the target’s location if the target cannot be directly seen. This is an 
example of an internal surrogate. Conversely, external surrogates are structures like the chest-wall 
which rises and lowers depending on the respiration state, or the volume of air entering and exiting 
the mouth. When using a surrogate, without observing the target directly, there is an inherent 
uncertainty based on the correlation between the surrogate and the target itself. Numerous authors 
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have observed phase-shifts and complex changing relationships between the coupling of the 
external surrogate and target itself (Ahn, Yi et al., 2004, Jiang, Cerviño et al., 2009, Ionascu, Jiang 
et al., 2007, Hunjan, Starkschall et al., 2010, Hoisak, Sixel et al., 2004, Gierga, Brewer et al., 
2005, Beddar, Kainz et al., 2007, Tsunashima, Sakae et al., 2004, Mageras, Pevsner et al., 2004a). 
The results of these studies are summarised in Table 2.3. Several other studies noted that the 
motion of the diaphragm may not be a good surrogate for lung cancer patients due to decreased 
pulmonary function (Stevens, Munden et al., 2001, Giraud, De Rycke et al., 2001).  
 
The Varian Real-time Position Management system (Section 3.1.1.1) and the Phillips bellows 
system (Section 3.1.1.2) are two commercially available surrogate based respiratory monitoring 
systems used in this thesis and are described in 3.1.1. Other commercially available surrogate 
marker monitoring systems are the Anzai belt (Siemens Medical Systems, Concord, CA, USA) 
and the ExacTrac Gating/Novalis Gating system (BrainLAb, Heimstetten, Germany). These 
however will not be discussed here even though the issues are similar. 
Table 2.3. Reported variations in the correlation between internal target motion and external surrogates. 
Observer Surrogate N (patients) Correlation Range 
(Ahn, Yi et al., 2004) Abdominal Displacement 43 0.41 – 0.94 
(Hoisak, Sixel et al., 2004) Spirometry 11 0.39 – 0.99 
(Tsunashima, Sakae et al., 
2004) 
Abdominal Displacement 26 1 
(Gierga, Brewer et al., 2005) Fluoroscopy (ext. / int. clips) 4 0.85 – 7.1 
(Beddar, Kainz et al., 2007) Abdominal Displacement 8 Linear (R2 = 0.9298) 
(Cervino, Chao et al., 2009) Fluoroscopy (Diaphragm) 10 0.94 - 0.98 
(Mageras, Pevsner et al., 
2004a) 
Abdominal Displacement 9 0.74 – 0.98 
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2.5.2. Respiratory gating 
Respiratory gating is the synchronisation of imaging or radiation delivery with respiration, such 
that the radiation delivery / image acquisition occurs during a specific part of the patient’s 
respiratory cycle (Keall, Mageras et al., 2006b). Monitoring the patient’s respiratory cycle 
determines the start and duration of the beaming time on, termed “gate”. Respiratory gating has 
been achieved using both external surrogates (Wu, Zhao et al., 2008) and implanted fiducial 
markers (Gierga, Brewer et al., 2005). Since the beam is only actually on for a smaller duration, 
gated treatments / image acquisition periods are longer than conventional procedures.  
 
Respiration can generally be characterised by two variables, displacement and phase. 
Consequently, gating can also be split into displacement or phase based gating. During 
displacement based gating, the radiation beam is activated whenever the respiration signal is 
within a pre-set window of relative positions. Conversely, during phase-based gating, the radiation 
beam is activated whenever the respiration signal phase is within some pre-defined phase window 
of the total cycle (0 - 2π). Generally, a gate window would be chosen based on observation of the 
location or phase where tumour motion is considered to be minimal. This method ensures that any 
residual motion within the pre-defined window is at a minimum. The ratio of the beam on time 
within the gate to the overall treatment time is referred to as the ‘duty-cycle’. 
2.5.2.1 Gating based on external surrogates 
As discussed previously, gating of the beam can be achieved by monitoring the patient’s 
respiratory motion through an external surrogate. Kubo et al (1996) evaluated a number of 
different methods of acquiring an external respiratory signal and monitoring respiration. 
Thermistors, thermocouples, strain gauges and pneumotachographs were all investigated and it 
was found that temperature and strain-gauge based methods provided the most accurate and 
reproducible results. Newer methods of monitoring patient respiration involve using optical based 
methods that track the rise and fall of the chest wall via a CCD camera and an IR reflective marker 
(see Section 3.1.1.1.) Gating is now a commonly available method of motion management with 
numerous commercial vendors now including the option of gated delivery. The potential benefits / 
pitfalls of gated delivery have been investigated by a number of authors (Kubo, Len et al., 2000, 
Vedam, Keall et al., 2001, Verellen, Depuydt et al., 2010, Smith and Becker, 2009, Ramsey, 
Scaperoth et al., 1999, Saito, Sakamoto et al., 2009, Saito, Sakamoto et al., 2010, Saito, Sakamoto 
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et al., 2011). Investigations into the optimal parameters have been reported (Kuechler, Hoinkis et 
al., 2004) as have the desired beam properties (Ramsey, Cordrey et al., 1999). The overall clinical 
efficacy of gating has also been reported (Ramsey, Scaperoth et al., 1999). 
 
A typical gated radiotherapy treatment would occur as follows. During treatment, the reflective 
marker or other external surrogate is positioned as it is in simulation. The fundamental principle 
behind the external surrogate method is that the external surrogate has a motion profile that is 
strongly correlated to the internal motion of anatomy. The internal / external correlation can be 
verified by comparing digitally reconstructed radiographs (DRRs), from the gated planning CT, to 
gated radiographs or portal images. Once satisfactory pre-determined gating / beam conditions 
have been established, beam delivery is initiated. A beam-on signal will trigger only when the 
external marker is within the predefined conditions and the radiation beam will be on whilst the 
condition remains true. This allows the synchronisation between imaging and treatment, therefore 
allowing for CTV-PTV margin reduction by decreasing the PTV margin (since we are only 
interested in a specific portion of the complete tumour trajectory).  
2.5.2.2 Gating based on internal fiducial markers 
An alternative method of gating uses internal fiducial markers as the basis for locating the target. 
In this scenario, markers usually made of gold are inserted directly into, or near the tumour. The 
marker’s position can then be imaged and tracked via fluoroscopy. When each marker is within a 
desired range the beam is turned on. Although this method is more accurate than the external 
method, it is also more invasive and therefore may not be available for all patients. Furthermore, a 
dual kV fluoroscopic and MV imaging system is preferable to locate the fiducials in coincidence 
(Wiersma, Mao et al., 2008).  
2.5.3. Breath hold techniques 
2.5.3.1 Voluntary breath-hold methods 
A simple way to minimise respiration induced tumour motion is to instruct the patient to hold his 
or her breath during the acquisition of images or delivery of radiation. Breath-hold methods can 
either be voluntary or assisted with the aid of devices such as the Active Breathing Control (ABC) 
system. (Wong, Sharpe et al., 1999, Remouchamps, Letts et al., 2003a). If the ABC system is not 
used, and patient involvement is necessary, the patient is instructed to hold his or her breath at a 
particular point in the respiratory cycle. During the breath-hold period the lesion’s motion is 
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assumed minimal, enabling beam delivery with a semi-static target. Generally, it is preferable to 
involve respiratory monitoring (Wurm, Gum et al., 2006, Wong, Tung et al., 2010, Weckesser, 
Stegger et al., 2006, Peng, Vedam et al., 2011) in this process since the patient’s hold time and 
reproducibility can be irregular owing to the decreased lung function commonly seen in lung 
cancer patients. 
 
In treatment planning, modern CT scanners have fast acquisition times and some early stage and 
therefore reasonably healthy patients are able to perform a breath-hold for the entire scan duration. 
During a breath-hold CT (BHCT) (Nehmeh, Erdi et al., 2007), the patient’s respiration is 
monitored and the patient is asked to hold their breath at some point in the respiratory cycle, 
typically peak-inhale or peak-exhale. Due to the deteriorated lung function of lung cancer sufferers 
this method may only be achievable in patients who are able to produce repeatable breath-holds. A 
benefit of using BHCT is that a tumour-encompassing volume can be created by acquiring both 
inhale and exhale BHCTs. A maximum intensity projection (MIP) of the CT data-set would show 
the tumour’s maximum and minimum positions in space and the encompassing volume can then 
be delineated as the boundary of these extremes. The patient’s ability to produce repeatable breath 
holds can be improved with audio based coaching (Nakamura, Narita et al., 2009a) or biofeedback. 
Biofeedback, involves giving the patient feedback on their performance and enabling them to learn 
to increase their breathing reproducibility through visual / auditory stimuli (Kini, Vedam et al., 
2003). 
 
Breath-hold treatments generally occur at deep inspiration or expiration depending on the nature of 
the respiratory cycle, target location and levels of stability at each extreme. Deep Inspiration 
Breath Hold (DIBH) involves verbally or visually (or both) coaching the patient to a reproducible 
breath hold at deep inhale. The patient’s respiration is monitored via a spirometer or other 
monitoring system that enables the therapist to observe the patient’s breathing whilst coaching. 
The general technique used is known as the slow vital capacity technique and involves the patient 
deeply inhaling, deeply exhaling, second deep inhale followed by the hold. DIBH has been shown 
to be advantageous in reducing internal motion. In conjunction with DIBH, it is common to 
monitor the respiratory profile of the patient during the radiation delivery (Mageras and Yorke, 
2004).  
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The use of external surrogate monitoring can ensure that the patient’s breath-hold is reproducible 
as well as providing a beam-off safeguard should the patient’s respiratory motion deviate from that 
seen during planning CT. Wong et al (2010) evaluated the efficacy of the technique in terms of 
tumour immobility and treatment setup accuracy. In their study of 14 patients with non-small cell 
lung carcinoma, the group found that DIBH in conjunction with external respiratory monitoring 
allowed a substantially reduced PTV margin, as well as good tumour immobility and accurate 
treatment positioning. Their group also found that there was decreased lung toxicity owing to the 
expanded cavity and decreased lung density. Hanley et al (1999) found that the DIBH method 
allowed for reduced margins (due to minimised motion), as well as, decreasing lung density which 
contributed to a reduced lung dose by moving the lung tissue out of the high dose region. 
Rosenzweig et al (2000) also found that out of seven patients (164 treatment sessions), the 
estimated normal tissue complication probabilities decreased in all patients at their prescribed dose 
when compared to free breathing. Furthermore, the authors also showed that the dose to which 
patients could be treated with DIBH increased, on average, from 69.4 Gy to 87.9 Gy, without 
increasing the risk of toxicity. There are currently two commercially available systems that are 
compatible with the DIBH method. These are the VMAX Spectra 20C (VIASYS Healthcare Inc, 
Yorba Linda, CA, USA) and the SpiroDyn’RX (Dyn’R, Muret, France) system. 
2.5.4. Mechanically assisted motion reduction methods 
Forced Shallow Breathing (FSB) was developed by Lax and Blomgren at the Karolinska Hospital 
in Stockholm (Lax, Blomgren et al., 1994, Blomgren, Lax et al., 1995). Originally, the method 
was used for patients undergoing stereotactic radiotherapy of small lesions located in the lung and 
liver. The technique uses a stereotactic body frame with an attached plate that can be pressed onto 
the abdomen. The position of the plate is controlled by a screw and is measured on a scale attached 
to the screw mechanism. This allows reproducibility of the abdominal restriction from simulation 
to delivery. The tumour’s superior inferior motion can be monitored using fluoroscopy and should 
the target’s motion exceed 5 mm, the pressure would be increased. By applying pressure to the 
abdomen, the patient’s diaphragmatic motion is restricted, resulting in shallower breathing 
amplitude. The restriction of the patient’s respiratory motion results in a smaller internal organ 
displacement associated with respiration. The stereotactic body frame and the FSB method have 
been used in a number of stereotactic studies (Timmerman, Papiez et al., 2003, Papiez, 
Timmerman et al., 2003, Wulf, Hadinger et al., 2000). For a detailed report on the accuracy and 
reproducibility of this method, the reader is pointed to the paper by Negoro et al (2001). 
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The Active Breathing Control system (ABC) (Wong, Sharpe et al., 1999, Remouchamps, Letts et 
al., 2003a) is another assisted breath-hold device. ABC was developed at William Beaumont 
Hospital (Royal Oak, MI, USA.) and was subsequently commercialised by Elekta Inc. (Norcross, 
GA). The device aims to initiate a reproducible breath-hold at any stage of the respiratory cycle. It 
consists of a digital spirometer connected to a balloon valve. Once the patient reaches the specified 
lung volume the valve is inflated with air via a compressor for a predetermined period of time, 
thereby holding the patient’s breath. The period of time for which the device can sustain a hold is 
determined by the patient’s ability (typically 15 – 30 seconds). The device has been shown to 
achieve substantial and reproducible internal organ movement in clinical scenarios 
(Remouchamps, Letts et al., 2003b). 
 
Abdominal compression has been shown to reduce overall tumour motion and a number of 
commercially available devices exist. Han et al (2010) found that both the Bodyfix and the 
Abdominal Compression Plate (ACP) significantly reduced the superior-inferior (SI) and overall 
respiratory tumour motion compared to free breathing (4.6 and 4.0 vs. 5.3mm; 5.3 and 4.7 vs. 
6.1mm, respectively, p<0.05). The ACP further reduced the SI and overall respiratory tumour 
motion compared to the Bodyfix (p<0.05). Heinzerling et al (2008) investigated the effectiveness 
of different abdominal compression levels on tumor and organ motion during stereotactic body 
radiotherapy of lower lobe lung and liver tumors using 4D-CT. Their study showed a significant 
difference in the control of both superior-inferior (SI) and overall motion of tumors with the 
application of medium compression (47.6 +/- 16.0 N) and high compression (90.7 +/- 27.1 N) 
when compared with no compression (p < 0.0001 for both).  
2.5.5. Biofeedback  for improving respiratory regularity 
Should the patient demonstrate irregular respiratory function, biofeedback, or respiratory coaching 
can be implemented to increase regularity (Cossmann, Stuessi et al., 2007, Locklin, Yanof et al., 
2007, Park, Kim et al., 2011, George, Chung et al., 2006, Raghu, Amit et al., 2008, Cui, Gopalan 
et al., 2010). Raghu et al (2008) studied the effectiveness of two audio-visual biofeedback systems 
for a total of 90 respiratory waveforms. Their results showed a significant improvement in 
respiratory regularity compared to free breathing. Although most authors cited have found an 
improvement in respiratory regularity following implementation of biofeedback respiratory 
coaching, Neuner et al (2010) found that over 11 patients (88 4D-CTs), the mean ITV (MIP) is 
nearly 20% smaller than the mean ITV10 (ITV formed from addition of ten phases) with all 4D-CT 
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techniques tested. Their results suggested that biofeedback using the two methods described did 
not improve the match between ITV (MIP) and ITV10 in any parameter examined in patients with 
both thoracic and abdominal tumors. Based on this, they recommended using an ITV derived from 
a MIP with caution for treatment planning regardless of 4D-CT technique if the goal is to fully 
account for tumor motion. 
2.6. MOTION MANAGEMENT DURING IMAGING FOR TREATMENT PLANNING 
In the previous sections, motion management methods common to both treatment planning and 
delivery have been described. In this section, motion management methods specific to treatment 
planning only, or treatment delivery only are outlined. 
 
Currently, a number of methods are available for managing motion during image acquisition. The 
AAPM Task Group 76 (Keall, Mageras et al., 2006b) investigated many of the methods available 
for respiratory motion management and provided guidelines for minimising potential errors. The 
methods themselves do not provide a complete solution. Instead, they provide a means to improve 
image quality and reduce motion artifacts. 
2.6.1. Motion management for CT 
2.6.1.1 Slow CT scanning 
A simple solution for motion management during treatment planning using CT is the slow 
scanning method. In this method, a CT scan is acquired very slowly with the intention of including 
multiple respiration cycles in the scan data. By oversampling the anatomical data, a time-averaged 
image of the tumour’s motion over a number of respiratory cycles is acquired. The resulting 
images then show the extent of anatomical motion that occurred during the period of acquisition. 
Slow CT scanning has the advantage of being able to be used for target delineation (Seki, Kunieda 
et al., 2007, Nakamura, Narita et al., 2008, de Koste, Lagerwaard et al., 2003, Chinneck, McJury 
et al., 2010, Smeenk, Gaede et al., 2007), however, respiratory motion can change between 
planning and treatment and therefore additional margins must be added. Another advantage is that 
dose calculation performed on a slow CT is more representative of the average density distribution 
that is present during treatment.  
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2.6.1.2 Time-resolved CT (4D-CT) 
Recently, a solution to the problems caused by motion in the acquisition of CT scans has become 
available. The development of four-dimensional computed tomography (4D-CT) is shown in Table 
2.4 (Vedam, Keall et al., 2003b, Ford, Mageras et al., 2003a, Low, Nystrom et al., 2003, Keall, 
2004a, Keall, Starkschall et al., 2004, Rietzel, Chen et al., 2003, Rietzel, Liu et al., 2004, Mageras, 
Pevsner et al., 2004a, Pan, Lee et al., 2004, Dinkel, Hintze et al., 2009). 4D-CT provides the 
means to image the tumour over a complete respiratory cycle by simultaneously recording a 
respiratory signal and binning the CT data into distinct respiratory phase bins. Essentially, 4D-CT 
provides a snapshot of the tumour in a number of locations. 4D-CT has been used to determine the 
tumour’s mean position and range of motion (Starkschall, Forster et al., 2004) and to provide 
added data for dose calculation (Riegel, Sun et al., 2008, Glide-Hurst, Hugo et al., 2008, Seco, 
Sharp et al., 2008, Bradley, Nofal et al., 2006) and target delineation (Rietzel, Chen et al., 2005a, 
Rietzel, Chen et al., 2003, Rietzel, Liu et al., 2008a, Rietzel, Liu et al., 2008b, Rietzel, Liu et al., 
2006b, Rietzel, Pan et al., 2005).  
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Table 2.4. Chronological development of 4D imaging techniques. 
Author Year Technology Development 
(Vedam, Keall et al., 2003a, Ford, 
Mageras et al., 2003b) 
2003 Single slice helical 
(Pan, Lee et al., 2004) 2003 Multi-slice cine (commercial) 
(Low, Nystrom et al., 2003) 2003 Multi-slice cine 
(Keall, Starkschall et al., 2004) 2004 Multi-slice helical 
(Nehmeh, Erdi et al., 2004a) 2004 Multi-slice PET/CT 
(Sonke, Zijp et al., 2005) 2005 Cone beam 
 
 
A particularly useful feature of 4D-CT is the ability to generate Maximum Intensity Projections 
(MIP) and Average Intensity Projections (AIP). A MIP is formed from taking the maximum voxel-
by-voxel values across all phase-bin data sets and forming a new 3D data-set. MIPs have been 
used for target volume delineation (Rietzel, Chen et al., 2005a, Underberg, Lagerwaard et al., 
2005) since they show a volume which is defined by the tumour’s maximum excursion. 
Correspondingly, an AIP is formed from taking the voxel-by-voxel arithmetic mean across all 
phase-bin data sets and forming a new 3D data set. This process is shown Figure 2.6. 
 
 
 
Figure 2.6. A schematic diagram of the construction of the MIP and AIP data-sets. To form the MIP, the 
maximum voxel value across all ten phase-bins is derived; the voxel with the maximum then becomes the 
corresponding voxel on the MIP. Conversely, for the AIP, the mean value is taken.  
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AIPs can be used for dose calculation since the voxel density values in a 3D AIP data-set are more 
representative of the true density values that would be present during treatment. 4D-CT is 
becoming increasingly popular with multiple vendors now offering surrogate acquisition systems 
to allow time resolved acquisition.  
 
Images in 4D-CT need to be sorted according to their respective place amongst the respiratory 
cycle, depending on whether amplitude or phase based gating was used. To accomplish this, 4D-
CT can be split into two subtypes; prospective and retrospective.  
2.6.1.2.1. Prospective gated CT imaging 
Prospective gated CT imaging involves the acquisition of one projection set acquired at a distinct 
period or phase of the breathing/cardiac cycle. The result is a CT data-set at a specified time-point. 
The acquisition of gated CT scans between the respiratory induced motion extremes is still an 
issue (Vedam, Keall et al., 2003b).  
2.6.1.2.2. Retrospective (image space) sorting 
In retrospective based sorting, the projections are tagged based on the respiratory cycle and the 
phase or amplitude interval they were acquired in. Following this, the images are reconstructed and 
sorted corresponding to their tag. The result is several CT data-sets each at a specified time-point 
(e.g. 0%, 10%, 20%, 30%,...,90%). Figure 2.7 demonstrates this principle and Figure 2.8 shows 
how a 4D-CT is acquired for a cine acquisition. 
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Figure 2.7. To achieve retrospective 4D-CT, CT data is tagged with the time stamp which is then compared 
to the respiratory cycle data. For example, if one wanted to reconstruct a slice corresponding to peak-inhale, 
then that point is tagged in the raw data and the data from ± 90o + the fan angle is then binned into the peak-
inhale data-set. This data corresponds to 180o gantry rotation, which is the minimum rotation needed to 
collect enough data for reconstruction. Adapted from (Wolthaus, 2009). 
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Figure 2.8. Time-resolved CT in a retrospective cine acquisition. The couch stays still during acquisition 
(multiple steps) and there is a continuous acquisition of slices for the time interval equal to the cine length 
plus the slice acquisition time. The beam is then switched off and the couch moves to the next position. After 
the complete volume is imaged, reconstructed slices are then sorted based on either the respiratory phase or 
amplitude. Adapted from (Riegel, Chang et al., 2009). 
 
2.6.2. Motion management for PET 
As discussed in Section 2.3.3, PET images are acquired over several minutes per bed position. As 
a result the images are affected by blurring caused by respiratory motion (Visvikis, Lamare et al., 
2006, Nestle, Kremp et al., 2006, García Vicente, Soriano Castrejón et al., Edet-Sanson, Dubray et 
al., Chuang, Chen et al., 2006, Aristophanous, Berbeco et al., 2012b).  
2.6.2.1 Gated PET 
As with other gating methods discussed in 2.5.2, gated PET involves acquiring a PET scan along 
with the respiratory cycle recorded with surrogate markers. The acquired PET data is then binned 
according to the respiratory cycle in what is termed 4D-PET. Generally, a gated PET scan is 
acquired for a longer length of time than a standard acquisition to increase the number of counts 
per respiratory bin and reduce the noise associated with the reduction in counts. Several authors 
have investigated the benefits of a gated acquisition in terms of both SUV recovery as well as 
increased accuracy in target volume delineation.  
 
Garcia et al (2009) compared 4D-PET to 3D-PET in 12 patients with 18 pulmonary lesions with 
sizes ranging from 0.8 - 4 cm. Their results showed that for 17 out of the 18 lesions, an increased 
SUVmax was found when compared to 3D scanning. Interestingly, 4D-PET scans resulted in the 
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reclassification of three of the lesions from benign to malignant. Their study concluded that 4D-
PET provided a more accurate means to correctly classify malignant lesions. Aristophanous et al 
(2012b) also investigated the ability of 4D-PET to reduce the errors associated with 3D-PET. Their 
group investigated 10 patients with NSCLC (22 distinct lesions) and found that 4D-PET may 
better define the full physiological extent of moving tumours and improve radiation treatment 
planning. In particular, the reduction in distortion compared to 3D acquisition allows for increased 
accuracy when analysing regional disease spread. In a recent study by Callahan et al (Callahan, 
Binns et al., 2011), the upgraded QUASAR phantom developed as part of this thesis (Dunn, Kron 
et al., 2011a) was used to determine the potential for 4D-PET to recover SUV loss and reduce 
errors in volume delineation. The study found that when using 4D-PET, larger lesions showed 
better count recovery, compared with un-gated scans. The study also showed that un-gated 
imaging of small mobile lesions decreases the apparent SUV significantly. 
2.7. MOTION MANAGEMENT DURING TREATMENT DELIVERY 
Aside from gating and breath-hold methods described in 2.5.2 - 2.5.3, a number of advanced 
delivery techniques have been, and are currently being, investigated. These methods generally fall 
under the category of motion adaptive techniques such as real-time tumour tracking. These 
advanced techniques show promise in increasing the accuracy of radiation delivery to moving 
targets. Presently, these techniques offer the potential for the most specific knowledge of tumour 
motion profiles during delivery, therefore tracking methods benefit most from studies of profile-
dependant effects such as those presented in this thesis. 
2.7.1. Real-time tumour tracking 
As the name suggests, Real time tumour tracking (RTTT) involves tracking the tumour’s position 
relative to the beam in real time. The technique is relatively new and usually incorporates Multi 
Leaf Collimators (MLCs) or linacs mounted on a robotic arm. Tumour tracking involves 
repositioning the beam in real-time in response to the tumour’s potion, therefore negating the 
tumour’s motion relative to the beam. If real-time tumour tracking is fully realised, then margins in 
place to account for target motion can be significantly reduced or, eliminated entirely. The 
commercially available SynchronyTM Respiratory Tracking System coupled with the CyberKnife® 
robotic linear accelerator (Accuracy Incorporates, Sunnyvale, CA), allows for real-time tumour 
tracking. In general, there are three things real-time tumour tracking must achieve in order to be 
effective: 
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 Identify the target using imaging. 
 Predict the target’s future position to overcome mechanical latency. 
 Adjust the beam to the location of the target. 
2.7.1.1 Target tracking using imaging (identifying the target) 
In order to effectively track the tumour, the location of the tumour must be explicitly known. For 
the delivery to be effective, a number of methods are available for locating the target in real time. 
Fluoroscopy, tracking using internal fiducials implanted within the target, external surrogate 
methods and determining the location of an electromagnetic radio frequency device implanted 
within the patient have all been reported and are under development for implementation clinically 
(Zhang, Hugo et al., 2008, Wiersma, Mao et al., 2008, Smith, Sawant et al., 2009, Seppenwoolde, 
Shirato et al., 2002b, Santanam, Malinowski et al., 2008). The challenge for imaging the target is 
achieving the temporal resolution needed to provide accurate feedback into the prediction 
algorithms, whilst minimising the additional dose to the patient. Given the irregular nature of 
respiratory function, this is a somewhat difficult task. 
2.7.1.2 Tracking using internal fiducial markers 
The most accurate way to locate the target within an image is to implant high-Z metal markers 
within the target itself. The high densities of the markers enable increased contrast to the 
surrounding anatomy and can readily be seen in X-ray images. Using multiple markers allows the 
rotation and translation of the target to be determined in real time, and is favored instead of using a 
single marker (Chen, Weinhous et al., 2001). The implanted markers that have been used in 
studies are either 2 mm diameter spherical gold balls or 0.8 mm by 4 mm cylindrical gold seeds 
(Shirato, Shimizu et al., 2000). The high frequency imaging needed for real time tumour tracking 
means that the patient will receive extra dose, this can be mitigated using a hybrid imaging 
technique (Schweikard, Shiomi et al., 2004, Sharp, Jiang et al., 2004, Murphy, 2004, Ozhasoglu 
and Murphy, 2002). This imaging technique combines occasional radiographic imaging with 
monitoring of an external respiratory signal. It is based on the assumption that the external 
respiratory signal can “fill in the gaps” for prediction during the time between images being 
acquired.  
2.7.1.3 Predicting the target location using external surrogate markers 
Tracking based on internal fiducials is not always available for a variety of reasons. If this method 
is unavailable, the location of the tumour can be ascertained from an external respiratory signal. In 
order for prediction to be accurate, and therefore real time tracking to be effective, a strong 
correlation between the external respiratory signal and the internal anatomic motion needs to be 
present. Generally however, this method is considered unsafe due to the unpredictable nature of 
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irregular respiratory function, coupled with the fact that drifts in correlation may occur during 
treatment (Tsunashima, Sakae et al., 2004, Hoisak, Sixel et al., 2004, Ahn, Yi et al., 2004). The 
unstable correlation between an external surrogate and the internal 3D position of the target can be 
corrected by updating the model with periodic imaging. The added data can then be used to update 
the adaptive filter algorithm and the external/internal correlation can be reassessed (Schweikard, 
Shiomi et al., 2004). 
2.7.1.4 Forward prediction and latency reduction 
The mechanical response of a linac cannot occur instantaneously. Therefore, forward prediction 
models are required to account for the latency between the input of motion data and the 
mechanical adjustment of the beam delivery system. The delay between the location of the tumour 
and beam delivery is due to a number of factors. Images need to be computationally processed, and 
the location of the fiducial marker needs to be ascertained. This is usually ascertained through a 
computational algorithm and the repositioning of the beam takes additional time. Latencies down 
to 90 ms have been reported (Seppenwoolde, Shirato et al., 2002b) between the recognition of a 
fiducial marker and the subsequent delivery of radiation in a gated beam delivery system. 
Increasingly complex mechanical systems, such as the CyberKnife system have a longer latency 
(200 ms) between the acquisition of the target’s location and the mechanical repositioning of the 
beam.  
 
To overcome this latency, predictive algorithms are used to synchronise the beam delivery with the 
actual target’s position. The prediction of time dependent behavior, such as respiratory induced 
target motion is difficult. The errors in prediction can be compounded due to cycle-to-cycle 
fluctuations in the respiratory regularity, with the general rule being that the greater the system 
latency, the greater the error in prediction (Vedam, Keall et al., 2004, Sharp, Jiang et al., 2004). 
2.7.1.5 Dynamic delivery of the treatment beam 
Dynamic adjustment of the beam is achieved by MLCs or robotic arms. Dynamic MLCs are 
commercially available from a number of vendors and present a viable solution to altering the 
beam properties in real time. Several groups have investigated dynamically moving the MLC to 
track targets (Neicu, Shirato et al., 2003, Papiez, McMahon et al., 2007, Papiez and Abolfath, 
2008). 
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2.8. MOTION MANAGEMENT QUALITY ASSURANCE DEVICES: PHANTOMS  
In the context of medical physics, phantoms are surrogates for human patients. Generally, they are 
made from materials which have the same radiological properties as tissues and structures found in 
the human body. Phantoms are used extensively to provide quality assurance and validation of 
treatment methodologies and are often used in conjunction with radiation detectors. In research, 
phantoms can be used to study the effects of a new technology or treatment methodology before it 
is put into use clinically. Recently, moving phantoms have become commercially available. 
Moving phantoms contain structures which represent parts of the human anatomy that move 
during treatment (usually the tumour itself) and a component of the phantom representing the 
chest-wall. 
 
Moving phantoms have now become essential for commissioning of motion management 
equipment, credentialing of clinical trials involving new protocols involving patient motion, and 
quality assurance (Keall, Mageras et al., 2006a). A number of commercially available motion 
phantoms, and upgrades enabling motion have become available, a list of which is shown in Table 
2.5. An example of a commercially available motion phantom is shown in Figure 2.9. With the 
increasing ability of delivery and imaging technology, phantoms that are capable of 
programmable, complex motion are becoming increasingly necessary to provide QA for the 
implementation. In this thesis, software that can import actual patient and lesion motion profiles 
extracted from devices like the Varian RPM system is presented. These upgrades allow for more 
clinically relevant testing of motion management protocols and patient specific treatment plan 
quality assurance. 
Table 2.5. List of motion phantoms, both commercial and custom made and their motion capabilities. 
Manufacturer Model Motion capabilities Programmable Surrogate motion 
coupling 
Use 
CIRS  Dynamic thorax phantom Model 008a 
Complex 3D tumour 
motion within the lung True Independent 
PET / CT and 
dosimetry 
Modus Medical Devices 
QUASAR™ 
Programmable 
Respiratory Motion 
Phantom 
1D linear sinusoidal 
(standard phantom) / 
upgradeable to 
programmable 3D motion 
True Coupled PET/CT and dosimetry 
(Nakayama, Mizowaki et 
al., 2008) 
3D movable 
phantom system 
Complex 3D whole 
phantom motion (range = 
100 mm) 
True N/A Mount existing phantoms. 
(Nioutsikou, 
Seppenwoolde et al., 
2008) 
PULMONE Sinusoidal accordion -like deformation False N/A Film dosimetry 
Washington University 4D QA system 3D motion of translation stage + surrogate motion True Independent 
Mount existing 
phantoms 
(Kashani, Lam et al., 
2007) N/A 
Deformable sponge insert 
for existing human torso 
phantom 
True N/A 
kV + MV 
imaging and 
dosimetry 
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Figure 2.9. The standard QUASAR respiratory motion phantom. 1D sinusoidal motion with coupled chest-
wall motion is possible with this phantom. Since patient lesion motion is often complex, it would be 
beneficial if complex programmable motion could be simulated, thus providing a more clinically relevant 
simulation platform. The dashed lines represent the directions of movement for the moving parts. 
 
 
2.9. DIFFICULTIES IN DOSE CALCULATION FOR SBRT 
Even without considering tumour motion, dose calculation in SBRT of lung cancer is a 
complicated. It is known that inhomogeneous density distributions within regions like the lung and 
lesion interface can cause an errors in dose calculation due to electronic disequilibrium (Ding, 
Duggan et al., 2007, Disher, Hajdok et al., 2012, Engelsman, Damen et al., 2001, Kavanagh, Ding 
et al., 2006).  The concepts of radiation equilibrium will thus be outlined as the first part of 
Chapter 6 deals with the issue of dose calculation in regions of heterogeneous density distributions 
such as those encountered in SBRT of lung cancer.  
2.9.1. Radiation equilibrium 
The deposition of energy in tissue from a photon beam is fundamentally a two step process. (1) 
Photons interact in the medium to impart kinetic energy to charged particles, (2) charged particles 
the deposit their given energy through ionisation and excitation along a track. Radiation 
equilibrium arises when there is a ‘steady state’ between the radiant energy entering a volume, and 
the radiant energy exiting a volume. Conceptually, one can consider an extended volume 
containing a distribution of a radioactive source with a smaller internal volume. Radioactivity of 
this source is emitted isotropically and for there to be radiation equilibrium, the maximum 
Moving lung 
insert 
Perspex body 
Coupled 
chest-wall 
platform 
Drive system 
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penetration distance of any emitted ray and its progeny (scattered, secondary rays) must be less 
than the minimum separation distance of the boundaries of the outer and inner volumes. Radiation 
equilibrium exists for the inner volume if the following conditions exist throughout the outer 
volume: 
 
 The atomic composition of the medium is homogeneous 
 The density is homogeneous 
 The radioactive source is uniformly distributed 
 There are no external electric or magnetic fields present 
 
For a more rigorous definition of radiation equilibrium, one may consider a plane that is tangent to 
the inner volume at a certain point. In the nonstochastic limit, there will be a perfect reciprocity of 
rays of a certain type and energy crossing both ways across the plane due to the uniform 
distribution of the source. If this is true for all possible orientations of the tangent planes around 
the inner volume, then for each ray of a certain type and energy entering the inner volume, an 
identical ray leaves the volume and radiation equilibrium is achieved. As a direct consequence of 
this, the energy carried in and out of the inner volume are in balance for both directly and 
indirectly ionising radiations. This may be written as the following: 
 
       coutcinuoutuin RRandRR        2.1 
 
Where u and c represent the energy carried by uncharged and charged particles respectively. If 
these conditions are met, then the mean energy  imparted to the matter in the inner volume is 
equal to that emitted by the radioactive material contained in the inner volume or: 
 
 Q           2.2 
 
Where Q  represents the release of rest mass energy (Krane and Halliday, 1987). Since D = dε / 
dm under the conditions of radiation equilibrium, then the absorbed dose is simple equal to the 
expectation value of the energy released by the radioactive material per unit mass at that point. i.e.: 
 
Qdmd           2.3 
 
For almost all practical cases, the condition of radiation equilibrium is not satisfied, however, it 
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may be approximately satisfied if charged particle equilibrium exists. 
2.9.1.1 Charged particle equilibrium 
Like radiation equilibrium, charged particle equilibrium (CPE) refers to a steady state occurring 
between all the charged particles entering and leaving a small region of interest. If pure CPE is 
attained, then the primary dose becomes exactly equal to the collisional kinetic energy released to 
charged particles only per unit mass (KERMA). i.e.: 
 
cKD            2.4 
 
The conditions for CPE are as follows: 
 
 The atomic composition of the medium is homogeneous 
 The density of the medium is homogeneous  
 There exists a uniform field of indirectly ionising radiation. I.e. the attenuation of the indirectly 
ionising radiation is negligible. 
 No inhomogeneous electric or magnetic fields present 
 
Satisfying the condition of uniform charged particle fluence is impossible for photon beams due to 
beam divergence and photon attenuation (Podgoršak, 2010, Podgoršak and Agency, 2005). 
Fortunately a state of transient charged particle equilibrium (TCPE) is easier to achieve than full 
CPE (Johns and Cunningham, 1983). 
2.9.1.2 Transient charged particle equilibrium 
Transient charged particle equilibrium is achievable along a central ray in a uniform absorber at 
depths which are greater than the maximum forward range of the particles created. This state is 
achievable on the condition that the width of the beam is of magnitude greater than the maximum 
lateral motion of particles launched (lateral equilibrium). In this specific case, the absorbed dose 
becomes proportional, but not equal to the collisional KERMA.  
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2.9.2. Current problems associated with dose calculation in SBRT of lung lesions: Dosimetry 
considerations 
SBRT and IMRT can employ small fields and beamlets down to 10 mm in diameter to achieve the 
highly focused and modulated dose distributions conforming to the target. Dosimetry of such small 
fields is complicated by the loss of lateral electronic equilibrium (Bjarngard, Tsai et al., 1989, 
Bjarngard, Tsai et al., 1990). Furthermore, volume averaging effects, collimator effects, detector 
position, and detector interface effects make measurement in small photon beams difficult. 
2.9.2.1 Current problems associated with dose calculation in SBRT of lung lesions: Heterogeneity 
calculations in small-fields 
Lesions residing in the lungs represent a challenging environment for accurate dose calculation 
due to the lack of equilibrium conditions discussed previously. When a target is surrounded by a 
low-density tissue like the lungs, some dose calculation algorithms employed by current treatment 
planning systems fail to account for lateral electron scattering, and therefore, can yield incorrect 
results. In the context of SBRT, most treatment planning systems make use of more advanced 
photon dose calculation methodologies which may be based on pre-calculated data from Monte 
Carlo dose-spread kernels. Unlike conventional treatment planning methods that only consider 
photon transport, and are primarily approximation based, newer algorithms can incorporate recoil 
electron transport. However, although treatment planning dose calculation methodologies for 
SBRT have improved, heterogeneity calculations are still only an approximation. The Radiological 
Physics Centre conducted a study comparing the validity of inhomogeneity corrections in small 
field scenarios (Martens, Reynaert et al., 2002, Woo and Cunningham, 1990) as part of a multi-
institutional trial (RTOG 0236 – protocol for lung tumours). Their results showed that the use of 
convolution / superposition and pencil beam algorithms matched well at the centre of the PTV 
embedded within the phantom. However at the periphery of the ‘lesion’, there were significant 
differences (Lee, Fox et al., 2006).  
 
The AAPM reviewed current methods of heterogeneity corrections for megavoltage photon beams 
and concluded that inhomogeneity corrections should be used when considering patient dose 
calculation (Papanikolaou, Battista et al., 2004). However, the group urged caution when using 
several commercially available heterogeneity correction algorithms. Specifically, the group 
discourages the use of pencil beam algorithms in the situation where the target is surrounded by a 
low density tissue, as these algorithms do not take into account the lateral scattering in the small 
field sizes commonly used in SBRT. In contrast to this, the report also found that while 
heterogeneity corrected dose calculations were not accurate in certain situations, it was better than 
using no correction at all. Timmerman et al (2007) demonstrated the consequence of such dose 
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calculation difficulties where a prescribed fractions 20 Gy per fraction dose (totaling 60 Gy) was 
found to be only 18 Gy per fraction (totaling 54 Gy). The error arose due to a lack of appropriate 
tissue heterogeneity corrections.  
 
Currently, Monte Carlo calculation methods provide the most accurate means of determining the 
dose to lesions surrounded by a low-density tissue. The aim of the work presented in Chapter 6 
was to determine clinically relevant factors that would allow clinicians to accurately determine the 
reduction in dose to the periphery of lesions residing in the lung using Monte Carlo methods. This 
work could be considered the first-order approximation to the moving lesion case, presented in the 
latter half of Chapter 6 as a number of lesion sizes and varying chest-wall to lesion distances are 
investigated. 
2.10. MONTE CARLO SIMULATION AND RESPIRATORY INDUCED TUMOUR MOTION 
In this work, Monte Carlo methods are used to determine the absorbed dose to lung lesions in an 
effort to determine degree of underdosage that can occur at the periphery of a lesion embedded in 
lung equivalent material (See Objective 4).. Monte Carlo methods are also used to evaluate two 
distinct dose calculation methodologies for SBRT based on 4D-CT (See Objective 5). Monte Carlo 
methods are often used to address problems that are not amenable to other calculation methods, or 
are difficult (or impossible) to measure directly. In the context of radiation therapy, Monte Carlo 
methods currently provide the most accurate means to model the dose distributions in complex 
heterogeneous density environments. In general, the Monte Carlo method is a numerical solution 
to any problem where an object interacts with other objects or their environment. It attempts to 
model large scale dynamic problems by breaking the system down to the essential dynamics which 
make up the end result. It is, in essence, a solution to a macroscopic system through simulation of 
its microscopic interactions (Bielajew, 2001). To achieve this, random number generation is the 
critical element in any Monte Carlo simulation. Since computer generated random numbers are 
never truly ‘random’ (they are generated via algorithmic methods), the numbers that are generated 
in Monte Carlo simulation are essentially ‘pseudo’ random numbers. The interactions of radiation 
with matter are a perfect system for simulation with Monte Carlo methods and since Monte Carlo 
methods are a step-by-step approach, it is in principle, straight forward to ‘update the geometry’ 
periodically to represent motion. 
 
2.10.1. Dose calculation using Monte Carlo methods 
Monte Carlo methods currently provide the most accurate means of dose calculation by modeling 
the interactions of primary and secondary radiations. The stochastic nature of Monte Carlo 
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simulation means that the inherent uncertainty in any simulation is dependent on the number of 
primary radiations simulated or ‘histories’. It is for this reason that with a single central processing 
unit (CPU), Monte Carlo simulations take a large amount of time to produce reasonably accurate 
results. In a clinical setting, this is the primary reason why full Monte Carlo simulations are not 
implemented to calculate dose for radiation therapy treatment planning purposes. However, the 
evolution of computing power, Moore’s Law (Moore, 2006) means that the time constraints placed 
on the clinical use of Monte Carlo methods may someday be a thing of the past and full Monte 
Carlo dose calculation may be implemented as the primary means of dose distribution calculation. 
Currently, semi-analytical algorithms are employed as the basis for most treatment planning 
system (TPS) calculated dose distributions. TPS dose calculation algorithms produce acceptably 
accurate results for many treatment scenarios. However, their accuracy is limited in the presence of 
inhomogeneities within the human body (tissues of varying densities / bone / cavities) (Aarup, 
Nahum et al., 2009, Carrasco, Jornet et al., 2004, Fotina, Kragl et al., 2011, Schuring and 
Hurkmans, 2008). Furthermore, presently there is no explicit capability for motion. In stereotactic 
radiotherapy, the trend towards higher doses to smaller volumes in fewer fractionations means the 
accuracy of dose calculation is critical.  
2.10.2. Currently available Monte Carlo codes 
There are presently a large number of Monte Carlo simulation packages available for radiotherapy 
applications including, but not limited to: 
 
 Electron Gamma Shower (EGS) codes including BEAMnrc (Rogers, Faddegon et al., 1995, 
Rogers, 2006, Kawrakow, 2000b). 
  PENetration and Energy LOss of Positrons and Electrons (PENELOPE)  
(Baró, Sempau et al., 1995). 
 Monte Carlo N-Particle (MCNPX) (Briesmeister, 1986). 
 Geometry AN Tracking 4 (GEANT4) (Agostinelli, Allison et al., 2003). 
 FLUktuierende KAskade (FLUKA) (Battistoni, Muraro et al., 2007). 
 Geant4 Application for Tomographic Emission (GATE) (Jan, Benoit et al., 2011, Jan, Santin et 
al., 2004). 
 
The most widely used Monte Carlo code in the context of radiotherapy in particular, stereotactic 
radiotherapy is EGSnrc (Taylor, Kron et al., 2011). However, the extension of the high-energy 
codes such as Geant4, to medical applications (low energy [keV-MeV] compared to particle 
physics [GeV-TeV]) has seen a rise in use of this particular code. In this work, both Geant4 and 
EGSnrc are used.  
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2.10.3. Monte Carlo radiation transport codes employed in this work 
2.10.3.1 Geant4 
Geant4 is an object oriented C++ toolkit for the simulation of particle transportation through 
matter. The toolkit includes full functionality for tracking, geometry, physics and hit detection. 
The physics processes in Geant4 cover a large energy range (250 eV to TeV) and include 
electromagnetic, hadronic, optical, long lived particles, materials and elements. It is versatile in 
that it can accommodate wide variety of physics simulation applications. Originally developed by 
CERN for high-energy nuclear and particle physics, it has recently been used in a wide variety of 
applications from astrophysics to food irradiation. The toolkit is showing increasing popularity in 
the field of medical physics. The key components of a Geant4 simulation as outlined in 
(Agostinelli, Allison et al., 2003) are: 
 
 Geometry and materials. 
 Particle interactions in matter. 
 Tracking. 
 Digitisation and hit management. 
 Event and track management.  
 Visualisation. 
 User interface. 
 
The top level class diagram of the Geant4 toolkit and basic ‘G4’ nomenclature is shown in Figure 
2.10. In this representation, the categories connected by open circles indicate a ‘using’ relationship 
where the category at the circle end uses the adjoined category (Agostinelli, Allison et al., 2003). 
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Figure 2.10. The top level class diagram of the Geant4 toolkit adapted from (Agostinelli, Allison et al., 
2003) 
 
A particularly advantageous functionality present in Geant4 is the ability to generate innumerable 
geometric shapes and unions of shapes as the simulation geometry. In Geant4, geometry 
components are described as logical and physical volumes. A logical volume represents a detector 
element of a certain shape and material that can have other shapes (termed daughters or grand 
daughters) within its boundary. A physical volume then represents a spatial positioning of a 
logical volume within the world or simulation universe. Using logical and physical volumes, a 
hierarchical tree of logical volumes, consisting of daughters / grand daughters can be constructed 
with each larger volume containing smaller volumes. Geometrical functions which can define 
geometries include: constructive Solid Geometry (CGS) which are simple shapes (boxes, spheres, 
cones etc.), solids defined by their bounding surfaces (planes, second order surfaces, or B-splines) 
and geometries imported from Computer Aided Design (CAD) systems. Recently, user specific 
classes have allowed the importation of voxelised patient geometries from the DICOM format 
(Kimura, Yamashita et al., 2010, Kimura, Aso et al., 2004, Jiang and Paganetti, 2004).  
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Materials in Geant4 can be described by assigning the various elements into specific compounds 
and atomic properties or read in from an extensive database. Once the geometry and materials are 
defined, the user can then describe the physics applicable to their simulation. Relevant 
(radiotherapy) radiation interactions for photons and electrons in Geant4 are outlined in Table 2.6 
and Table 2.7. Several pre-built physics lists exist depending on the particular application and can 
be activated by the user. The electromagnetic physics list, for example, manages the 
electromagnetic interactions of leptons, photons, hadrons and ions. Two electromagnetic packages, 
the standard and low energy electromagnetic packages discussed in (Section 2.10.3.2.4), can be 
used in simulations pertaining to radiotherapy. 
 
Tracking in Geant4 is achieved by moving each particle step by step. All physics processes 
associated with the specific particle are associated with the notion of a step. Depending on the 
particle and physics process, the following actions are handled by the tracking classes of Geant4, 
at rest for particles at rest, along step for behavior such as continuous energy loss during a step 
and post step which is called at the end of a step, e.g. secondary particle generation by interaction. 
Another key feature of the Geant4 toolkit is the notion of an event. It is the event class structure 
where the user can keep information that is meaningful to the simulation for processing post 
simulation. An event may be a particle depositing energy in a particular voxel. This event would 
be tallied and all other events of no use to the user are disregarded.  
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Table 2.6. Geant4 photon interaction physics processes and the models governing the interactions. For a 
detailed description of the physics models, the reader is pointed to the Geant4 Physics Manual 
(Collaboration, 1999). 
 
Photon Interaction Description GEANT4 – Summary of physics for SEP and LEP 
Cross-section  data source  Standard: Hubbell, Gimm and Overbo (Hubbell, 1980), 
Storm and Israel. Low energy: The Evaluated Photon Data 
Library (EPDL97), Evaluated Atomic Data Library (EADL) 
(Cullen, October 1991) 
 
Photoelectric effect 
 
Incident photon is absorbed resulting in the ejection 
of an electron with energy equal to that of the initial 
photon less the binding energy of the ejected 
electron. 
 
Standard: Cross-section for photo absorption determined by 
F. Biggs and R. Lighthill (Biggs, 1990) angular sampling 
determined from Sauter – Gavrilla (1959) method. In the 
current method atomic relaxation is not simulated, however 
it is counted as a local energy deposit.  
Low energy: The total photo-electric cross-section is 
calculated using the Stepanek method, the sub-shell from 
which the electron was emitted is determined from 
interpolation of cross-section data obtained from EPDL97. 
De-excitation is simulated from the data obtained in the 
Livermore Evaluation Atomic Data Library (EADL)  
 
Coherent scatter 
 
A.k.a Rayleigh scattering. Elastic scattering of 
photons from atoms. 
 
Standard: N/A 
Low energy: Cross-section data is determined from 
Stepanek, the coherently scattered photon angle is sampled 
according to the product of the Rayleigh formula (1+cos2θ) 
sin θ with the square of Hubbell’s (Hubbell, 1979) atomic 
form factor. 
 
Incoherent scatter 
 
Compton scattering – An atomic electron is ejected 
by an incident photon. The wavelength of the 
recoiling photon is changed by an amount 
depending on the energy transferred to the electron. 
 
Standard: Klein-Nishina method, cross-section data is 
empirically determined from a fit to the Hubbell data (down 
to 10 keV), as well as the Storm and Israel data. Standard 
Compton includes cross section suppression, but samples 
final state according to Klein-Nishina formula. 
Low energy: Cross section determined from Stepanek, 
simulation  of scattering is handled via standard method with 
the addition of  Hubbell’s  form factor (Hubbell, 1980), 
angular distribution is given by the product of the Klein 
Nishina formula and the scattering function given by Cullen 
(Cullen, 1995). Sampling of the final state is based on 
composition and rejection Monte Carlo methods Butcher 
and Messel (Butcher and Messel) and (R. Ford, W. Nelson 
SLAC-265, UC-32 (1985)). Updated to handle Doppler 
broadening via EGS database approach. 
 
Pair production 
 
Photon interaction with the field of a nucleus 
resulting in an electron –positron pair.  
 
Standard: Cross-section determined by Hubbell and Gimm 
(Hubbell, 1980),  also applies corrected Bethe-Heitler 
(Heitler, 1954) cross section along with Born 
Approximation. Triplet not modeled explicitly; however, it 
is taken into account in total cross-section. 
Low energy : N/A 
 
Photonuclear 
effects 
 
Direct interaction between an energetic photon and 
an absorbing nucleus. The nucleus absorbs the 
photon, generally resulting in the emission of a 
single neutron. 
 
Giant Dipole Resonance region extending from 10 MeV to 
30 MeV. The GEANT4 photonuclear database contains 
about 50 nuclei for which photonuclear cross-sections have 
been measured.  
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Table 2.7. Electron / positron interaction physics and the models governing the interactions. 
 
2.10.3.1.1. The accuracy of Geant4 
The accuracy of Geant4 has been verified previously by comparison to experimental data, as well 
as previously established Monte Carlo codes such as EGSnrc. Carrier et al (2004) evaluated 
Geant4 for medical physics applications. Their results were compared to published results using 
MCNP, EGS4 and EGSnrc and where possible, experimental data. Their study found differences 
of up to 5% for monoenergetic electrons in homogeneous mediums. Their study, however, found 
that the difference between Geant4 and experimental data for depth-dose curves yielded similar 
results to EGSnrc when EGSnrc was compared to the same data. Their study concluded that 
Geant4 was a promising toolkit for medical physics applications. 
 
 
Electron / Positron interaction Description GEANT4 
Cross-section  data source Evaluated Electron Data Library (EEDL) (Cullen, 
November 1991), Seltzer and Berger (Seltzer and 
Berger, 1985),  
 
Bremsstrahlung 
 
Electromagnetic radiation produced by the 
deceleration of charged particles. 
 
Standard: Total cross-section obtained from EEDL 
database, In discrete Bremsstrahlung the final state is 
sampled according to the spectrum of Seltzer and 
Berger (Seltzer and Berger, 1985). Above 1 MeV 
Coulomb corrected screened Bethe-Heitler formula 
(Heitler, 1954) 
Low energy: Total cross section is obtained from low 
energy limit of EEDL database. Angular sampling 
handled by three distinct generators. 
 
Scattering  
 
electron-electron scattering (Møller) or 
electron-positron (Bhabha) 
 
Møller scattering for e-, Bhabha scattering for e+. 
 
Positron Annihilation 
 
Positron (electron antiparticle) collides with 
electron resulting in annihilation with the total 
mass before annihilation transformed into one, 
two or three photons. 
 
Cross-section and mean-free-path described by formula 
of Heitler (Heitler, 1954). It is assumed that 
annihilation processes one, or three or more photons 
are ignored. 
 
Multiple scattering 
 
Refers to the simulation of multiple scattering 
of charged particles in matter 
 
Cross-sections from Goudsmit and Saunderson (1940) 
for energies < 1GeV. Default model (any energy) by 
Urban. EPSEPA code developed by Penelope group, 
implemented in its final state using EGSnrc method by 
Kawrakov et al. 1998 (Kawrakow and Bielajew, 1998) 
for precise electron transport. Multiple coulomb 
scattering is treated as a cumulative effect of small 
angle scatterings  
 
Transport 
 
Refers to algorithms which calculate whether a 
particle has crossed a geometric boundary. 
 
Boundary crossing algorithm does not allow ‘big’ last 
steps at the boundary of a volume or ‘big’ first steps in 
the following volume.  
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Faddegon et al (2008) benchmarked Geant4, EGSnrc and PENELOPE against published 
measurements of bremsstrahlung yield from thick targets for beams of energy 10 – 30 MeV. Their 
results showed that Geant4 produced results within three standard deviations of measured data for 
all non-zero angles. Furthermore, their study showed that Geant4 calculated spectra closely 
matched measurements at photon energies over 5 MeV. Photon spectra at and below 5 MeV were 
underestimated by as much as 5%. An important finding of this study was that the discrepancy was 
reduced with the use of the low-energy physics list. Poon et al (2005) validated the photon and 
electron transport of the Geant4 toolkit in the context of radiotherapy. Their study examined both 
cross-section and sampling algorithms of three electromagnetic physics models (standard, low 
energy and PENELOPE). Depth doses in water for monoenergetic beams were compared to 
EGSnrc. Their results showed Geant4 to be accurate to within 2% compared to EGSnrc in all 
regions except the build-up region. Larger differences were found with monoenergetic electron 
beams, however the accuracy could be improved by carefully imposing electron step limitations. 
Faddegon et al (2009) benchmarked EGSnrc, PENELOPE and Geant4 against published 
measurements of the angular distributions of 13 MeV and 20 MeV electrons scattered from foils of 
different atomic numbers and thicknesses. Initially, Geant4 was shown to overestimate the 
characteristic angle for the lower atomic number foils by as much as 10%.  
 
By retuning the electron scatter distribution in Geant4, they were able to increase the agreement 
between the simulation and measured data. In doing so, Geant4 provided comparable accuracy to 
both EGSnrc and PENELOPE codes whose results were within one standard deviation with 
measured data. Lechner et al (2007) validated Geant4’s low energy physics models against 
electron deposition and backscattering data. The low energy models are of particular relevance to 
radiotherapy, since low-energy in this case pertains to the MeV range and below. Lechner’s study 
found that energy deposition by electrons modeled with Geant4 agreed well with no systematic 
deviation from measured and simulated data. For both beam energies (0.3 and 1.0 MeV), Geant4 
reproduced the experimental values to within 2%. Backscattering measurements also agreed well 
with measured data over a large range of materials.  
2.10.3.2 GATE 
GATE is advanced open source software dedicated to numerical simulations in medical imaging. It 
has been in development since 2001 by a group of international institutions / laboratories. GATE 
was released publicly in 2004 under a Lesser General Public License (LGPL). Simulations with 
GATE are based on the Monte Carlo platform Geant4 (an all purpose Monte Carlo code: see 
2.10.3.1) and its libraries (Agostinelli, Allison et al., 2003, Allison, Amako et al., 2006). 
Essentially, GATE provides a scripting interface between the C++ code-base of Geant4 and the 
end-user. It provides a way to model complex emission tomography systems such as SPECT and 
 - - 75 - - 
PET systems by dealing with decay phenomena, moving detectors, time management and complex 
geometries (Jan, Santin et al., 2004, Jan, Benoit et al., 2011).  
 
GATE allows the user to build up a description of the different components that make up a PET 
scanner. This process starts with the definition of the scanner geometry (detectors and geometrical 
arrangement), physics processes and phantom geometries and ends with the detailed description of 
a processing chain for the detected events. The software also lets the user activate various physics 
processes which are based on Geant4 and have therefore been benchmarked thoroughly (Parach 
and Rajabi, 2011, Maigne, Perrot et al., 2011, Chauvie, Guatelli et al., 2004). The physics 
employed by Geant4 allows modeling of radioactive sources as well as particle interactions for 
standard and low-energy cases. The user can also determine which gamma-ray interactions should 
be considered i.e. photoelectric, Compton and Rayleigh scattering and gamma-ray conversion. For 
these processes, energy-cuts in particular regions of the detection architecture are applied that 
dictate the production of secondary gamma-rays and electrons.  
 
A particularly important feature of the GATE simulation framework is the handling of time. Time 
dependence is taken into account at all steps of the simulation. The time-dependence of PET 
simulations in GATE means that realistic simulations of count-rates and source-decay as well as 
dynamic geometry such as a rotating scanner or moving phantoms can be achieved. The GATE 
simulation package is the basis for the PET portion of this thesis and therefore a detailed 
introduction and outline of the software’s functionality is necessary. The following sections are 
dedicated to this.  
2.10.3.2.1. Software architecture. 
GATE is written in C++ and follows a modular structure with three layers: 
 
1. Core layer 
2. Application layer 
3. End user layer 
 
The core layer defines all the basic functionality available in GATE relating to geometry 
definition, source definition, time management, digitisation and output. The application layer is a 
set of classes based on the core classes which model specific objects and processes. The end user 
or scripting layer enables the user to define a simulation through the use of an input file. This layer 
acts as a translator and converts simple user commands for use by the application and core layers. 
A complete nuclear medicine simulation can be defined via this interface (Jan, Benoit et al., 2011, 
Jan, Santin et al., 2004).  The structure of GATE is outlined in Figure 2.11. 
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Figure 2.11. The structure of GATE, adapted from (Jan, Santin et al., 2004) 
 
2.10.3.2.2. Systems available for simulation 
There are a number of predefined geometries in GATE that enable the user to simulate a scanner. 
Each group of templates forms a system. Each system can be described by a specific tree-level 
structure with each component playing a certain role. If the user wanted to create a cylindricalPET 
scanner, the geometrical volumes are arranged into matrices containing the crystal detectors. These 
sub modules are then grouped into larger modules to form a group of detector clusters. The top 
level of the detection system is then grouped into a whole and repeated around the cylindrical 
geometry. Table 2.8 shows the various systems that can be modeled using the GATE platform.  
 
Geant4
Core layer
Application layer
User level
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Table 2.8. Systems available for simulation via the GATE platform. The first column shows the type of 
system. The second column describes the keywords used to define the system, the third column outlines the 
shape of the entire ‘mother’ volume and the fourth column shows the available outputs. This table was 
adapted from (Jan, Santin et al., 2004).  
 
2.10.3.2.3. Geometry 
Geometry is defined in a unique module based manner in GATE. All volumes used in simulation 
must be defined as either daughters or grand daughters of the world volume. The world volume 
constitutes the boundary of the simulation universe. In the case of a PET system, the world volume 
would be a box centered at the origin within which all components making up the system must 
reside. For this reason, the user must ensure that the world volume is made large enough to house 
all the components. The world volume is also important with regards to the tracking of particles. 
For any particle that is generated within the world volume, tracking stops upon the particle 
breaching the boundary of the world. Following the construction of the world volumes, logical 
volumes (daughters and grand daughters) must also be defined. A logical volume is defined by all 
its properties except its position within the world volume. One would define a logical volume by 
assigning it a particular shape, size and composite material. Upon the placement of a logical 
volume, that volume is termed a physical volume in that it now has a place within the world 
System Components Shape Output 
Scanner  Level 1 
 Level2 
 Level3 
 Level4 
 Level5 
No fixed geometry 
- 
- 
- 
- 
Ascii, ROOT 
- 
- 
- 
- 
CTScanner  Block 
 Pixel 
Box 
Box 
Binary CT image, Ascii or 
ROOT 
cylindricalPET  Rsector 
 Module 
 Submodule 
 Crystal 
 Layer 
Box 
Box 
Box 
Box 
Box 
Ascii, ROOT, Raw, specific 
List Mode Format (LMF) 
- 
- 
- 
CPET  Crystal Cylinder Ascii, ROOT and Raw 
SPECTHead  Crystal 
 Pixel 
No fixed geometry 
- 
Ascii, ROOT, Raw, 
PROJECTIONSET or 
INTERFILE 
Ecat  Block 
 Crystal 
Box 
Box 
Ascii, ROOT, Raw, 
SINOGRAM or ECAT7 
ecatAccel  Block 
 Crystal 
Box 
Box 
Ascii, ROOT, Raw, 
SINOGRAM or ECAT7 
OPET  Rsector 
 Module 
 Submodule 
 Crystal 
 layer 
Box 
Box 
Box 
Box 
wedge 
Ascii, ROOT, Raw and specific 
LMF. 
- 
- 
- 
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universe. The user can then use repeater volumes which are multiples of the physical volumes with 
some geometrical transformation / rotation / translation applied in succession.  
 
Using these methods, complex structures can be constructed by combining ring, linear and 
quadrant designations for particular physical volumes. All logical volumes must be assigned a 
material from a material database so that Geant4 can calculate the interaction cross-sections. 
Movement of objects during simulation is forbidden by the GEANT geometry architecture, 
however, between each event generation, the geometry can be updated. Since the duration of a 
single event typically takes place in a much shorter time frame (ms for particle transport) 
compared to say, the motion of a phantom, the elements are considered to be at rest during each 
event.  
2.10.3.2.4. Physics 
All the physics in GATE are handled by Geant4 (See Section 2.10.3.1). Two packages are 
available to handle the electromagnetic processes which are the most relevant to PET. The two 
packages are: The Standard Energy Electromagnetic Processes (SEP) and the Low Energy 
Electromagnetic Processes (LEP). Low energy in the context of Geant4 generally refers to the 
regime below 100 GeV. Both packages can generate and transport positrons, electrons, γ-rays, X-
rays, optical photons, hadrons, muons and ions. The physics processes are outlined in detail in the 
physics reference manual provided with the Geant4 (Manual, 2010). Detailed validations of the 
models are provided in several references (Carrier, Archambault et al., 2004, Lazaro, Buvat et al., 
2004, Paganetti and Gottschalk, 2003, Poon and Verhaegen, 2005, Schmidtlein, Kirov et al., 
2006). A brief overview of the physics specific to GATE is provided here since the core physics is 
handled by Geant4 and described in Table 2.6 and Table 2.7. 
 
The SEP package of Geant4 covers the energy range from 10 keV to several PeV and is generally 
used in high-energy nuclear physics applications. For photons, Compton Scattering, photon 
conversion, pair production and the Photoelectric Effect are simulated. For electrons / positrons, 
ionisation, bremsstrahlung and positron-electron annihilation can all be simulated with this model. 
The ionisation class calculates the continuous energy loss due to ionisation and simulates the 
discrete processes of the ionisation. The discrete interactions simulated are: Møller scattering (e-e-
), Bhabha scattering (e+e-) and delta-ray production. Multiple scattering in the SEP is based on 
Lewis theory (Lewis, 1950).  
 
The LEP package is an extension to the standard physics. The LEP package has been validated 
down to 250 eV and covers the interaction of photons and electrons in materials with atomic 
numbers between 1 and 100. Classes within this package relate to the following interactions: 
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Compton Scattering, Rayleigh Scattering, Photoelectric Effect, Ionisation and Bremsstrahlung. 
The user can also implement atomic relaxation. Processes induced by positrons are treated the 
same as in the SEP package. Models and cross-sections are based on theoretical calculations and 
the exploitation of previously evaluated data. The data used for the determination of cross-sections 
and for sampling of the final state are evaluated from the following data libraries (Manual, 2010): 
 
 EPDL97 (Evaluated Photons Data Library) 
 EEDL (Evaluated Electrons Data Library) 
 EADL (Evaluated Atomic Data Library) 
 Stopping power data 
 Binding energy values based on the data of Scofield. 
 
From these data libraries, the energy dependence of the total cross-section is derived for each 
process. With each of the libraries providing cross sections for a set of discrete incident energies, 
the total cross section for a given energy E needs to be interpolated according to the formula:  
 
    (2.5) 
 
Here, E1 and E2 are the closest lower and higher energies respectively for which data (σ1 and σ2) is 
available (Manual, 2010). The final state is then defined by the four-momenta of the final state 
products which are determined according to distributions derived from the evaluated data. Detailed 
descriptions of the models for: Compton Scattering, Rayleigh Scattering, Photoelectric Effect, 
Bremsstrahlung and Ionisation in Geant4 are provided in Table 2.6 and Table 2.7. 
2.10.3.2.5. Production cuts 
Geant4, and therefore GATE does not use tracking cuts. Instead, all particles are tracked down to 
zero kinetic energy unless they pass the boundary of the world volume. A ‘production cut’ refers 
to the fact that photons and secondary electrons are generated only above a given kinetic energy 
threshold. This method is done to ensure the simulation remains accurate whilst limiting the large 
number of secondary particles which would hinder the performance of the simulation (Agostinelli, 
Allison et al., 2003). GATE allows users to either define the cut in range or energy as well as 
define specific cuts that are applied to electrons, X-rays and delta-rays. 
2.10.3.2.6. Positron emission 
Positron emission in GATE is handled differently than in Geant4. Two specific modules dedicated 
to PET were developed. The first uses the von Neumann algorithm to generate the positron energy 
(randomly) according to the β+ spectra. This method bypasses the decay of radionuclide processes 
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in Geant4 and hence greatly increases the speed of the simulation. The second method deals with 
the acollinearity of the generated annihilation quanta by using a 0.58◦ FWHM Gaussian blur over 
the emission angles. 
2.10.3.2.7. Radioactive sources 
Radioactive sources are modeled via the General Particle Source (GPS) classes provided in 
Geant4. The GPS is used to generate particles of a given type in a given direction with a given 
kinetic energy. A source in Geant4 is defined by the type of emission (radionuclide, gamma, 
electron, etc.), position, energy (spectrum), direction and activity. The lifetime of a radioactive 
source can either be provided by the Geant4 database or set by the user. The decay rate is 
determined by the activity of the source during the simulation time. Sources in GATE can also be 
defined from voxelised phantoms or patient data. These types of sources allow for realistic 
simulation of emission data as well as anatomically accurate voxelised attenuation maps that 
convert the gray scale values into material definitions using a translator table. This methodology is 
described in Section 5.4. 
2.10.3.3 The NURBS based CArdiac and Torso (NCAT) and eXtended CArdiac and Torso (XCAT)  phantoms 
The NCAT phantom is part of a family of computerised phantoms for medical imaging research 
developed by Paul Segars (Segars, Mahesh et al., 2008, Segars, Sturgeon et al., 2010, Segars, Tsui 
et al., 2004). The phantom is obtained through a yearly license agreement with the author and the 
maintaining facility (Duke University). The software is based on the UNIX platform, though 
windows versions have recently become available. The NCAT/XCAT software is essentially used 
to generate CT data-sets based on input parameters that dictate the specifications of the virtual 
human. The male and female anatomies can then serve as standard templates upon which 
anatomical variations may be modeled through user-defined parameters. Anatomical motion is 
achieved through parameterised models for the cardiac and respiratory motions. The motion 
models are based on high-resolution cardiac and respiratory gated multislice CT data.  
 
The NCAT phantom is an extension of the 4-D MCAT phantom and allows for realistic modeling 
of the human anatomy. The phantom’s organs are constructed from nonuniform rational B-splines 
(Piegl and Tiller, 1997) (NURBS) rather than voxelised patient data based models previously used 
in computerised phantoms. NURBS are widely used in computer graphics and animation and the 
design of three-dimensional surfaces. A natural extension of these surfaces is the modeling of 
complex anatomical shapes. The organ shapes within the NCAT phantom are based on the 3D 
Visible Human CT dataset (Ackerman, 1998). NURBS also offer flexibility with regards to 
transformation as their shape is defined by a set of control points which form a convex hull around 
the surface itself.  
 - - 81 - - 
 
With the use of NURBS, the NCAT phantom is able to simulate cardiac and respiratory motion 
and also the resultant organ motion induced by these physiological cycles. The cardiac motion is 
based on 4D tagged MRI data obtained from Johns Hopkins University and the National Institute 
of Health. The respiratory motion is based on a set of respiratory gated CT (Section 2.6.1.2) data 
from the University of Iowa. The motion of organs within the respiratory structures was based on 
tracking landmark points on these organs and formulating a general motion model for each organ.  
 
 
The XCAT phantom (Segars, Mahesh et al., 2008) is an extension of the NCAT phantom beyond 
nuclear medicine. The XCAT phantom includes highly detailed anatomy and is constructed 
entirely of NURBS surfaces. The XCAT phantom includes the whole body and has a greater level 
of detail than that of its basis model, the NCAT phantom. The XCAT phantom allows higher 
resolution imaging applications such as CT or MRI. 3D renderings of the XCAT are shown in 
Figure 2.12 and Figure 2.13. The modeling of respiratory motion is shown in Figure 2.14. Figure 
2.15 shows an example of the image data generated with the XCAT phantom showing respiratory 
induced tumour motion. 
 
 
Figure 2.12. (a) Male and (b) female renderings of the XCAT phantom with different levels of detail shown 
building up to the complete model. The skeletal muscles, circulatory system, organs and glands are shown. 
Adapted from (Segars, Sturgeon et al., 2010). 
 
(a) (b) 
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Figure 2.13. (a) Posterior, (b) anterior and (c) saggittal renderings of the XCAT phantom showing the 
anatomical realism of the organs and their placements. Adapted from (Segars, Mahesh et al., 2008). 
 
 
 
 
Figure 2.14. Modeling of respiratory motion in the XCAT phantom. Adapted from (Segars, Sturgeon et al., 
2010). 
 
 
 
 
Figure 2.15. Series of XCAT CT images showing a tumour in the left lung. Five different phases of 
respiratory motion are shown. The red dashed lines indicate the deviation of the position of the tumour from 
the 0% phase of the respiratory cycle. 
 
 
(a) (b) (c) 
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2.10.3.4 Using the NCAT or XCAT phantom in conjunction with GATE 
Descourt et al (2006) developed a new C++ class to incorporate the NCAT / XCAT phantom into 
the GATE framework. GATE already allowed for voxelised activity distributions, however, prior 
to the work by Descourt it did not enable the incorporation of physiological motion effects on 
these distributions. The ‘GateRTPhantom’ class developed by Descourt et al was introduced to 
simulate physiological motion in real time with voxelised phantoms such as the NCAT / XCAT 
phantom described above in Section 2.10.3.3. Using this class, computational phantom data output 
from the NCAT / XCAT platform as a series of 32-bit binary images can be used as a voxelised 
phantom source within the GATE platform. The NCAT / XCAT phantom can be used to create a 
series of ‘frames’, which are complete 3D datasets for a particular period of time. For example, if 
the NCAT / XCAT phantom’s respiratory motion period was set to 4 s and the number of frames 
was set to 40, 40 complete datasets each showing the phantom at 0.1 s intervals are created. These 
40 datasets, or frames can then be incorporated into GATE, and using a range translator table, the 
activities and attenuation properties of organs, lesions and structures can be assigned by converting 
pixel values to activity in Bq and using the raw attenuation data from the simulated XCAT CT 
data-set respectively.  
 
During the Monte Carlo simulation, annihilation photons are recorded during each time frame. 
Once 0.1 s has passed, the simulation is paused and the phantom geometry is updated to the next 
frame and the simulation recommenced. If a PET acquisition lasts for 600 seconds and the 40 
frames only cover 4 s of respiratory motion, the whole process is repeated so that 150 full 
respiratory cycles are simulated during the Monte Carlo simulation. Using this method, realistic 
activity distributions, incorporating physiological motion, can be simulated.  
2.10.3.5 EGSnrc 
The Electron Gamma Shower (EGS) Monte Carlo code is a general purpose radiation transport 
modeling package for simulating the transport of electrons and photons through user-defined 
geometries. EGSnrc has been validated with energies ranging from the keV range up to hundreds 
of GeV. Although EGSnrc was used in this work, other versions exist. A detailed description of 
the code is given by (Kawrakow, 2000b) and in the EGSnrc user manual.  
2.10.3.5.1. Radiation interactions in EGSnrc.  
The radiation transport of photons and electrons can be simulated in any element, mixture or 
compound. The dynamic range of charged particle kinetic energies ranges from tens of keV to 
hundreds of GeV. Table 2.9 shows the physics processes that are taken into account by EGSnrc for 
photons Table 2.10 describes the electron interactions. 
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Table 2.9. Photon interactions and their modeling in EGSnrc (descriptions of the interactions are provided in 
Table 2.6). 
Photon Interaction Description 
 
Photoelectric effect 
 
Dominant process in the keV energy range. Relaxation of excited atoms after vacancies are 
created  create fluorescent photons (K, L, M shells) and Auger and Coster-Kronig electrons 
may be produced and tracked if requested. 
 
Coherent scatter 
 
Rayleigh scattering: EGSnrc uses total coherent scattering cross-sections from (Storm and 
Israel, 1970). negligible for megavoltage beams, a relatively small contribution for kV 
energies 
 
Incoherent scatter 
 
A.k.a Compton scattering: The Klein-Nishina or bound Compton models can be used. 
 
Pair production 
 
Pair production: total cross sections are based on partial-wave analysis calculations which are 
known to be accurate to much better than 1%. 
 
Photonuclear effects 
 
Not simulated.  
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Table 2.10. Electron interactions and their modeling with EGSnrc (descriptions of the interactions are 
provided in Table 2.7). 
 
2.10.3.5.2. The accuracy of EGSnrc 
Monte Carlo simulations currently provide the most accurate means to model dose distributions. In 
medical physics in particular, EGSnrc has been used extensively for a number of years and been 
benchmarked extensively. As such, EGSnrc is often cited as the “gold standard” Monte Carlo 
code, and indeed newer codes are often benchmarked by comparing results of simulations to 
identical simulations performed with EGSnrc. EGSnrc has been shown to produce sub percentage 
agreement with experimental data for both electrons and photons (Chibani and Li, 2002, Doucet, 
Olivares et al., 2003).  
2.10.4. Monte Carlo simulation and tumour motion 
Most currently available Monte Carlo simulation packages do not explicitly allow temporal 
variation of geometries during simulation. As a result of this, not much has been published 
regarding the explicit incorporation of moving geometries and dose calculation. Geant4 allows for 
semi-temporal variation in that the simulation can be paused and the geometry updated. Using this 
method, Paganetti et al (Paganetti, Jiang et al., 2004) implemented object-oriented programming to 
study the irradiation of tumours undergoing induced respiratory motion. Keall et al (Keall, Siebers 
et al., 2004) simulated 4D Monte Carlo by performing separate dose calculations on phase-bin 
data-sets from 4D-CT. By using deformable image registration the group mapped each phase-bin 
dose matrix back to the deep-exhale dose matrix effectively yielding a 4D Monte Carlo calculation 
Electron / Positron interaction EGSnrc modeling  
Bremsstrahlung Bremsstrahlung production using either Bethe-Heitler cross sections or NIST cross sections.  
 
Scattering (inelastic) 
 
Møller scattering for e-, Bhabha scattering for e+. Interactions with energy transfer large 
compared to the binding energies: Bethe-Bloch stopping power theory 
 
Positron Annihilation 
 
Positron annihilation in flight and at rest (the annihilation quanta are followed to 
completion). 
 
Multiple scattering 
 
Handled using a new multiple scattering theory which overcomes the shortcomings of 
Molière multiple scattering theory. It allows for steps of any size and moves seamlessly 
from a single scattering model for short steps to an accurate multiple scattering model at 
large steps. Rutherford scattering or scattering accounting for relativistic and spin effects can 
be simulated by the user. 
 
Transport 
 
Condensed History (CH) simulation (Kawrakow, 2000b) and Presta II – Electron Transport 
Algorithm 
 
Boundary crossing algorithm  
 
and Exact (Kawrakow, 2000a) 
 - - 86 - - 
of dose.  
2.10.5. Stereotactic radiotherapy and tumour motion 
The bulk of research into motion management in radiotherapy has been directed towards 
conventional radiotherapy. With regards to treatment delivery, stereotactic radiotherapy provides a 
unique challenge when considering motion management. The reason for this is that the margin for 
error is reduced based on the decreased number of treatment fractions and increased dose per 
fraction. The relationship between tumour motion and this fact has yet to be thoroughly 
investigated. Small mobile tumours also present challenges for modern imaging methodologies. 
For example, the current resolution of modern PET machines is approximately 4 mm. The small 
tumours commonly treated with SBRT may not be visible on a PET scan since their uptake may be 
lost against the background. This fact, coupled with target motion, may decrease the chances of 
effective treatment with SBRT, unless 4D imaging can be employed. 
 
As there is a smaller margin for error in SBRT, accurate imaging and planning are essential. As the 
use of SBRT becomes accepted clinically, understanding the effects motion has on dose 
distributions and imaging of small lesions is of increasing importance. Throughout this work the 
goal has been to evaluate the impact of lesion motion on images acquired with CT and PET as well 
as to perform Monte Carlo studies to investigate the complexities of delivering radiation to moving 
targets.  
2.10.6. Key points 
 Motion in SBRT presents a unique challenge. 
 Phantoms are useful tools in credentialing and providing quality assurance of new motion 
management strategies in SBRT. Two improvements are needed: (1) Programmable patient-like 
motion and (2) Simple QA phantoms that can be used to investigate the impact of lesion size on 
images acquired with CT and 4D-CT. 
 The impact of motion on images acquired with CT is well known for larger size lesions typical 
for conventional radiotherapy. The effect of smaller, more mobile lesions typically seen in 
SBRT on images acquired with CT and 4D-CT, is not well known. 
 The use of PET and PET/CT in SBRT is hindered by the resolving power of PET when imaging 
small lesions. The reduction in SUV and overestimation of volume may hinder diagnoses and 
treatment efficacy evaluation. Computational studies with both Monte Carlo and noise-free 
XCAT images presented in this thesis provide insight into the impact of motion on images 
acquired with PET. 
 The impact of motion on dose distributions in SBRT is not well known. Specifically, treatment 
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planning is either done on an average intensity projection from 4D-CT, or, a pseudo-4D 
treatment plan is pursued performing dose calculation on each phase-bin data-set from 4D-CT. 
The equivalence of these approaches has not been rigorously demonstrated. 
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Chapter 3. The development of motion phantoms 
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“When you aim for perfection, you discover it’s a moving target.” 
- George Fisher
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3.1. INTRODUCTION 
The previous chapter described the problems that can arise throughout the radiotherapy process 
due to the respiratory induced motion of lung tumours. The latter half of Chapter 2 dealt with 
reported motion management methodologies / technologies and the introduction of Monte Carlo 
radiation transport modeling and the Monte Carlo packages used in this thesis.  
 
In this chapter, the development of two motion phantoms is presented. Firstly, a see saw motion 
phantom for 4D-CT QA is presented. The development of this phantom and the verification of a 
mathematical motion model are presented. The see-saw motion phantom can be used to provide 
quality assurance of 4D-CT in the context of small lesions typically seen in SBRT of lung cancer. 
Aspects of work presented in this chapter have appeared in a publication in Medical Physics, see 
(Dunn, Kron et al., 2012)).  
 
Secondly, an upgrade to a commercially available motion phantom is presented. This phantom 
provides a complete QA package for motion management in SBRT. Custom made software 
detailed in Section 3.3.2.1 allows for the importation of patient motion data recorded with the 
Varian RPM system, as well as several ‘test’ patterns. The upgraded QUASAR phantom presented 
in this chapter (Section 3.3) allows for patient specific QA of SBRT treatment plans. The upgrade 
of this phantom has been outlined in Australasian Physical & Engineering Science in Medicine 
(Dunn, Kron et al., 2011a), the use of this phantom to provide patient specific quality assurance is 
presented in  Radiation Measurements (Kron, Clements et al., 2011). The use of this phantom to 
evaluate the motion effects on SUV and lesion volume in 3D and 4D PET scanning is presented in 
Australasian Physical & Engineering Science in Medicine (Callahan, Binns et al., 2011).  
 
3.1.1. Surrogate markers 
Surrogate markers have previously been defined in Section 2.5.1. Two surrogate marker systems 
used in this work are the Varian Real-time Position Management system and the Phillips ‘Bellows’ 
system. Both of these systems are used to record the AP chest-wall motion of a patient during 
imaging and / or treatment. 
3.1.1.1 The Varian RPM system 
The Varian Real-time Position Management (RPM) system (Varian Medical Systems, Palo Alto, 
CA, USA) is a video-based infra-red tracking system. This system, shown in Figure 3.1, uses an 
infra-red camera to track a reflective marker on the patient’s chest. A live-feed of the position of 
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the marker allows clinicians to determine the correlation between the respiratory cycle and the 
tumour motion in 4D imaging. The RPM system allows gating, as well as breath-hold and free 
breathing protocols to be established in both imaging and during treatment. Figure 3.2 shows 
patient respiratory motion data output from the RPM system. The Varian RPM system has been 
described and used in a number of publications, including, a paper by the author (Dunn, Kron et 
al., 2011b, Steve B, 2006, Ramsey, Cordrey et al., 1999, Ramsey, Scaperoth et al., 1999, Vedam, 
Keall et al., 2001, Vedam, Kini et al., 2003). 
Figure 3.1. The Varian RPM’s infrared camera system capturing the motion of a reflective marker placed on 
the patient’s abdomen and the resulting waveform showing the position of the marker as a function of time. 
Recorded AP chest-wall motion
 - - 92 - - 
Figure 3.2. Respiratory motion data output from the RPM system. (a) The amplitude of the reflective marker 
as a function of time (arbitrary units). (b) The phase of the patient’s respiratory cycle as a function of time 
(arbitrary units) and (c) the amplitude as a function of phase. 
 
 
 
(c) 
(a) 
(b) 
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3.1.1.2 Phillips Bellows system 
The Phillips Bellows system (Phillips Medical Systems, Cleveland, Ohio, USA) is an elastic belt 
which wraps around the patient’s abdomen. The belt contains a pressure transducer which converts 
the pressure waveform to a respiratory cycle. The output signal from the Bellows system is 
interfaced with the CT scanner and used to provide the respiratory signal in 4D-CT. Figure 3.3 
shows the Bellows system setup with the Quasar respiratory motion phantom (Modus Medical 
Devices, London, Ontario, CA). The Phillips Bellows system has been described and used in a 
number of publications (Huang, Park et al., 2010b, Heinzerling, Bland et al., 2011, Heinzerling, 
Anderson et al., 2008) 
 
Figure 3.3. An illustration of the Phillips Bellows system. The expansion and contraction of the chest-wall 
cause the pressure inside the belt to change, which, in turn is converted to a respiratory signal. 
 
 
3.1.2. MATLAB 
MATLAB® Version R2010a (The MathWorks, Natick, Massachusetts, U.S.A.) is a numerical 
computing environment which can be used to analyse data and interface with other languages such 
as C, C++, Java and FORTRAN. MATLAB can also be used to create executable software outside 
of the MATLAB environment. In this thesis, MATLAB was used extensively for both software 
development and analysis of results. 
3.2. DEVELOPMENT OF MOTION PHANTOMS -  THE SEE-SAW MOTION PHANTOM 
Localisation of the target is of the utmost importance in SBRT where the dose per fraction is large. 
(D’Souza, Nazareth et al., 2007). As a consequence, 4D-CT is now becoming the standard of care 
for planning of SBRT. The technological advancement of CT scanner technology now allows for 
Bellows belt
Anterior posterior 
motion stretches belt 
creating signal 
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the millimeter / sub millimeter degree of accuracy (Kalender, 2006) required by SBRT and with 
the use of 4D-CT becoming more prevalent for planning of SBRT, phantoms are also needed that 
facilitate quality assurance (QA) of such technologies. Quality assurance phantoms assess system 
performance and allow for a routine QA programs to be established. QA phantoms should be 
designed so that the maximum performance information can be gathered with minimal additional 
time at the scanner.  
 
This section focuses on the development of a phantom to provide quality assurance of CT and 4D-
CT. Material in this section has been published by the author in Medical Physics in 2012 see 
(Dunn, Kron et al., 2012)  
 
The objective of this work was to design and test a simple moving phantom for 4D-CT QA 
protocols and investigate binning artifacts and motion effects, with particular emphasis on small 
lesions typical in stereotactic body radiotherapy. The design of the phantom gives particular 
consideration to: 
 
 Large peak-to-peak amplitudes (> 20 mm in both SI and AP directions) enabling fast problem 
identification with minimal additional time required at the CT scanner. 
 Variable-amplitude, variable-frequency motions.  
 Multiple adjustable motions; coupled SI and AP motions, or, only one-dimensional motion in 
either direction. 
 Compatibility with most commercial signal acquisition technologies (e.g. Varian RPM, Philips 
Bellows, Siemens Anzai). 
 Consistency between moving and static CT numbers and geometry.   
 Inclusion of both moving and stationary objects of the same size and composition within the 
field-of-view. 
 
A low cost ‘see-saw’ (cantilever) design was selected to meet the above criteria. Important features 
of the see-saw phantom’s design include the compatibility for use with commercial surrogate 
signal acquisition hardware from multiple vendors, and the ability to simulate motion both axially 
and inter-slice. 
3.2.1. Materials 
A phantom was designed to enable quality assurance and testing of 4D-CT, as well as investigate 
the impact of lesion size and motion on images obtained using 4D-CT. The phantom was designed 
from the ground-up to enable multiple motion profiles, respiratory motion signal acquisition 
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hardware universality, a range of amplitudes and the ability to compare stationary and moving 
targets within the field-of-view. A see-saw design was chosen since it allows for variable 
amplitudes by adjusting the motor’s drive point from the central fulcrum, as well as providing a 
means to mount a platform orthogonally to the main cantilever for an additional SI (inter-slice) 
motion. The phantom was constructed from Perspex and is shown in Figure 3.4 and Figure 3.5. Its 
dimensions are 30 x 15 x 15 cm (l x w x h). The motion platform has a width of 5 cm and a length 
of 30 cm. The SI (inter-slice) platform is adjustable and its height can be set anywhere between 
11.0 cm and 15.5 cm from the cantilever platform. The AP motion profile of the phantom is 
controlled via a rotating disc with offset axis of rotation mounted behind a central pivot. Its 
distance from the central pivot is variable, resulting in a range of peak-to-peak AP amplitudes 
between 0.2 – 7.4 cm. Six discrete AP amplitudes can be chosen via changes in the drive-wheel 
contact point. Further continuous variation can be achieved by placing objects at different 
positions along the cantilever platform. AP motion amplitudes of 7.4 cm represent extreme cases. 
However, small lesions with excursions of up to 6.0 cm have been seen by colleagues of the 
author2. Furthermore, large amplitudes exceeding 3.0 cm are useful in ensuring all likely cases are 
covered and problems arising from such motions can be identified easily. The equations defining 
the motion are similar to those describing rotating cams in internal combustion engines (Heywood, 
1988). Equation 3.1 describes the AP motion. Attached orthogonally to the main platform is the SI 
platform. The SI motion amplitude is controlled via the platform’s height and the drive-wheel to 
pivot distance. Its motion is described by Equation 3.2. The variables which control the SI and AP 
amplitudes (d, do, h) are indicated in Figure 3.5. r and l in Equations 3.1 and 3.2 are the radius of 
the drive wheel (3.0 cm) and the centre-to-offset distance (fixed at 1.0 cm) respectively. θ is the 
angle between r and l as the wheel rotates. 
 
    222 sincos,, lrl
d
dddX ooAP 
    (3.1) 
 
    222 sincos,, lrl
d
hdhYSI 
    (3.2) 
 
A KTA-195 high current DC motor (rated up to 55V (20A)) speed controller (Ocean Controls, 
Seaford, Victoria, Australia) controls the sinusoidal motion period and enables frequencies of up to 
40 revolutions per minute (rpm). This control is operated in either analogue (via potentiometer) or 
digital mode for high precision. The see-saw phantom has a support system which can also 
accommodate the Varian Real-time Position Management (RPM) (Varian Medical Systems, Palo 
                                                          
2 .J. Callahan, Peter MacCallum Cancer Centre, private communication. 
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Alto, CA, USA) system’s infra-red reflective marker, the ‘Anzai’ belt (AZ-733V, Anzai Medical, 
Tokyo, Japan), as used in Siemens 4D-CTs and the Phillips ‘Bellows’ (Philips Medical Systems, 
Cleveland, OH) air-pressure transducer system. 
 
Figure 3.4. (a) An experimental QA setup designed to compare moving and static HUs within the FOV. (b) 
An overlay of the see-saw phantom’s motion profile. In this image, the AP motion platform can be seen. 
This adjustable platform, along with the adjustable anterior-posterior platform, provides coupled motions in 
two dimensions. 
Figure 3.5. Schematics of the see-saw motion phantom (dimensions (l x w x h): 30 x 15 x 15 cm). Variables 
which determine the motion of the phantom are shown in blue with dash-dot lines representing adjustments 
that can be made to change the amplitude of motion in both AP and SI directions. 
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3.2.2. Methods 
3.2.2.1 Validation of a mathematical model defining the AP and SI motion profiles 
The Varian RPM system was used to record both SI and AP motion profiles. Motion profiles for 
all six drive-wheel positions were recorded for the AP direction. For the SI case, only the motion 
profile with the SI platform at maximum extension was recorded. A mathematical model 
describing the motion was derived and the model was then compared to the physical motion 
recorded with the RPM system. 
3.2.2.2 Inter-vendor compatibility tests: GE Discovery STE PET/CT acquisition methodology 
The see-saw phantom was tested for inter-vendor compatibility, by using scanners with different 
respiratory signal acquisition systems, as well as different acquisition protocols (Helical vs. Cine). 
A study was performed on the GE Discovery STE PET/CT (General Electric Medical Systems, 
Milwaukee, WI, USA). The GE Discovery acquires a respiratory signal with an optical based 
system (Varian RPM) in contrast to the Phillips system, which uses the Bellows system discussed 
previously. Imaging data presented in Chapter 4 was all acquired using the Philips Brilliance Big 
Bore CT scanner. 
 
Three imaging studies were carried out on the GE system. The first was a standard CT acquisition 
of the see-saw phantom with no motion. In the second study, the amplitude was set to 2 cm in the 
AP direction with a period of 4 s (15 rpm). No 4D capability was initiated during the second study, 
and as a result, this data represented a ‘free-breathing’ 3D-CT. In the third study, the phantom’s 
AP motion signal was recorded optically using the Varian RPM system during acquisition for 4D 
reconstruction. The amplitude in the AP direction for the 4D study was again set to 2 cm, with the 
correlated SI amplitude being 2.5 cm (peak-to-peak) and the motion period was again set to 4 s.  
 
In the 4D study, data was acquired in ‘cine’ mode with cine duration 5.0 s, a slice thickness of 2.5 
mm, 1.024 pixels per mm resolution, FOV of 500 x 500 x 360 mm3 (512 x 512 x 144 pixels), X-
ray tube current of 30 mA, 140 kVp and rotation time of 0.5 s. For the 3D acquisitions (stationary 
and free-breathing), data was acquired in helical mode with a slice thickness of 2.5 mm, pitch 
factor of 1.35, 0.975 pixels per mm resolution, FOV 525 x 525 x 362.5 mm3 (512 x 512 x 145 
pixels) and rotation time of 0.5 s. 
3.2.3. Results – The see-saw motion phantom 
The specifications of the see-saw phantom are provided in Table 3.1. The see-saw phantom is 
compact (overall dimensions: 30 x 15 x 15 cm), light-weight (total weight 2.6 kg) and is capable of 
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producing large amplitude motions up to 7.4 cm, with variable periods from 1.5 s – 10 s (6 - 40 
rpm). Table 3.2 shows the motion capabilities of the see-saw phantom. The full range of possible 
AP amplitudes is determined by both the drive-cam location relative to the pivot point and the 
location of the sample placed on the AP platform. These options allow a range of amplitudes 
between 0.2 cm (d0 = 1.0 cm, d =10.35 in Equation 3.1) to 7.4 cm (d0 = 15.0 cm, d = 4.05 cm in 
Equation 3.1). The SI amplitudes are also variable and depend on the distance from the SI platform 
mount to the central pivot, the height of the SI platform with respect to the AP platform and the 
drive-cam to pivot distance. Multiple motion amplitudes are available, ranging from a minimum of 
1.5 cm to a maximum of 6.5 cm in the SI (inter-slice) direction. The motor control system was 
found to be accurate and its frequency setting matched the frequencies reported by the Bellows 
system and the RPM system. Since the phantom is mechanically driven by a rotary cam, its motion 
profile and amplitude is consistent and reproducible within the resolution of the RPM system, 0.6 
mm (Mostafavi, H. (2001).U.S. Patent No. 6,937,696. Washington, DC: U.S.). 
 
Due to its cantilever design, the see-saw platform is able to support the Bellows system or RPM 
infrared reflective marker, as well as a number of objects of varying masses and densities. The 
coupled two dimensional motion means that both axial and inter-slice motion can be used for 
quality assurance tests in a highly portable (12 V battery operated), cheap and easy to implement 
system. Furthermore, the adjustable coupling of SI and AP motion makes numerous amplitude 
combinations possible. 
 
Table 3.1. Specifications of the see-saw motion phantom. 
Dimensions 30 x 15 x 15 cm (l x w x h) 
Weight: 
Phantom: 
Battery: 
Controller: 
 
1.4 kg 
0.6 kg 
0.6 kg 
Power 12V Battery 
Battery life 20+ hrs (full charge) 
 
 
Table 3.2. Motion capabilities of the see-saw phantom. Both the AP amplitudes and SI amplitudes are 
continuously variable between these minimum and maximum amplitudes. 
 Min  Max Description 
Period 1.5 s 10.0 s The period is varied via a potentiometer or by digitally setting the motor frequency. 
SI Amplitude 1.5 cm 6.5 cm The SI amplitude is variable and depends on the height of the platform, the distance from the 
SI platform to the central pivot and the drive-wheel cam to pivot distance. 
AP Amplitude 0.2 cm 7.4 cm The AP amplitude is variable and depends on the object’s distance from the central pivot and 
the drive-wheel cam to pivot distance. 
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3.2.3.1 Accuracy of the motion model 
To assess the accuracy of the motion model (Equations 3.1 and 3.2), AP and SI motion profiles 
were recorded with the Varian RPM. The motion model predictions were then compared with the 
Varian RPM recorded data. These results are shown in Figure 3.6 and Figure 3.7. 
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Figure 3.6. The phantom’s AP motion profile. The solid blue line indicates the profile as recorded by the 
Varian RPM system and the red line indicates the motion described by Equation 3.1. (a) Large amplitude 
motion with the drive wheel close to the central pivot point, (b-f) the five other drive wheel locations in 
order of increasing distance from the central pivot (decreasing amplitude). 
 
 
  
(a)    
d = 4.05 
cm   
(b) d = 5.6 cm
(c) d = 7.45 cm   (d) d = 8.7 cm
(e) d = 9.6 cm   (f) d = 10.35 cm
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Figure 3.7. A phantom SI platform motion profile. The blue line shows the motion profile as measured with 
the RPM and the red line shows the profile as modelled by Equation 3.2. 
 
3.2.3.2 Compatibility of the see-saw phantom with different acquisition protocols 
Stationary, ‘free-breathing’ 3D-CT and 4D sagittal images are shown in Figure 3.8. The images 
clearly show both the inter-slice and axial motion directions. The purpose of this investigation was 
to determine if the see-saw phantom can be used with different hardware and an optical based 
respiratory signal acquisition system and demonstrate the two motions (axial and inter-slice). The 
phantom was found to be compatible with other 4D acquisition hardware and acquisition protocols 
and therefore inter-vendor comparisons can be made, making the see-saw phantom a useful tool 
for large clinics with multiple CT scanners from different vendors. 
 
 
Figure 3.8. Sagittal reconstructions of (a) stationary see-saw phantom. (b) 3D Helical acquisition with 
moving phantom, amplitude 2.0 cm period 4 s, (c) AIP from a 4D-CT (cine mode) reconstructed into ten 
distinct phase-bins and (d) MIP from a 4D-CT (cine mode) acquisition. In the AIP and the MIP, the motion 
amplitude was 2 cm in the AP direction with a period of 4 s. The amplitude of the platform in the SI 
direction was 2.5 cm.  
(a) (b) (c) (d) 
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3.2.4. Discussion – The see-saw motion phantom 
The see-saw motion phantom was envisaged to fulfill the role of a QA phantom for 4D-CT. The 
phantom was specifically designed to be highly portable and used to directly compare both moving 
and stationary objects within the same field-of-view. The see-saw phantom can be used to test 4D-
CT acquisition protocols by comparing moving and stationary objects, both in terms of HU and 
geometric properties. The see-saw motion phantom is presented in Section 3.2, where the design 
and construction is outlined, and Section 3.2.3, where the accuracy of a motion model (Equations. 
3.1 and 3.2) characterising the phantom’s motion is assessed.  
 
Figure 3.6 shows a comparison between the AP motion recorded with the RPM system and the 
mathematical model describing the AP motion (Equation 3.1). Discrepancies between the model 
and the recorded RPM data arise from the fact that the drive-wheel contact does not contact at a 
single point, but sweeps a small area due to the cam motion and the changing angle of the 
cantilever. Equations 3.1 and 3.2 do not take this into account and use a single value d as the drive-
wheel to pivot distance. As such, Equations 3.1 and 3.2 represent a (good) approximation to the 
true motion profile. It can be seen in Figure 3.6 that as the area swept by the drive-wheel contact 
with the platform becomes smaller (decreasing amplitude), so too does the discrepancy between 
the model and the measured RPM data. The amplitudes match to within the resolution of the 
system. 
 
Figure 3.7 shows a comparison between the SI profile of the see-saw phantom and the motion as 
described by Equation 3.2. The SI profile was recorded by holding the phantom on its side. 
Although this is not ideal, the equation governing the SI motion was able to tested Again, 
discrepancies can be seen between the mathematical model and the recorded phantom profile. 
These discrepancies are due to the way the SI profile was recorded as well as approximations made 
in the mathematical equation governing the motion. Figure 3.8 (a) demonstrates that the phantom 
is compatible with X-ray CT. A saggittal view of a stationary phantom can be seen in this figure. A 
small metal artifact associated with the metal fulcrum pin can be seen. All relevant objects 
however appear artifact free. Figure 3.8 (b) shows the phantom moving during a conventional CT 
scan. The interplay between the motion and imaging period can clearly be seen This figure 
provides an excellent example of the effect motion can have on conventional CT. Figure 3.8 (c) 
and (d) demonstrate average and maximum intensity projections and highlight the motion profile 
of the phantom. 
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The phantom design, battery operation and small size facilitate inter-centre portability with one 
phantom able to be used to perform QA in multiple facilities. The DC motor speed controller is 
easy to use, whilst the thumb screw and variable amplitude settings means there is no need for 
additional tools. Of particular interest is the ability to achieve large motion amplitudes in both SI 
and AP directions. This allows the user to identify problems easily with minimal time added at the 
scanner. Multiple objects could also be placed at different positions on the platform so that 
different motion amplitudes can be captured in the same scan. 
 
The see-saw phantom presented in this work provides a valuable tool to effectively assess the 
accuracy and limitations of 4D technology. Although a number of commercial motion phantoms 
exist, ease of use and numerous coupled inter-slice / axial motion profiles make the see-saw 
phantom a useful and easy-to-use tool for commissioning and quality assurance of 4D-CT. The 
phantom as a package can be built for under $250 (USD), making it an affordable option that can 
be shared between centers (or fit in the traveling kit of a physicist servicing several diagnostic 
facilities) for routine quality assurance and commissioning of new hardware. The see-saw motion 
phantom can also be used with different motion signal acquisition systems making it inter-vendor 
friendly.  
3.3. DEVELOPMENT OF MOTION PHANTOMS: THE QUASAR RESPIRATORY MOTION 
PHANTOM UPGRADE 
3.3.1. Materials 
3.3.1.1 The QUASAR Respiratory motion phantom from Modus Medical 
The standard QUASAR respiratory motion phantom is a thoracic phantom featuring an (SI) 
oscillating insert and an AP reciprocating platform for driving surrogate monitoring systems such 
as the RPM. It is capable of coupled target and surrogate motion and is shown in Figure 3.9. The 
motion of the insert is controlled by a rotating cam and variable frequency DC motor. The insert 
motion is sinusoidal in nature and coupled to the surrogate motion so that the two motions are in 
phase. Although this platform is suitable for routine QA of motion management, in order to be able 
to perform patient-specific quality assurance, the phantom needed to be upgraded to produce 
irregular motion, as well as replicate realistic, decoupled, patient respiratory / chest-wall motion. 
Decoupling of the surrogate and insert motions was achieved by designing and constructing a 
separate lift platform controlled by a separate stepper motor. In order to achieve irregular and 
patient-specific motion, the standard DC motor was replaced with a computer controlled stepper 
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motor for finite position control. Unlike regular DC or AC motors which have commutator brushes 
to switch the coils in the motor on and off automatically, stepper motors require individual 
activation of coils by the use of a stepper motor driver circuit, and have no brushes. The major 
advantage of stepper motors over regular motors is their finite position control, which is virtually 
impossible with a regular motor. The use of stepper motors and control software allows patient 
respiratory motion data recorded via a respiratory monitoring system to be downloaded to the 
phantom controller. Detailed below are the hardware upgrades added to the QUASAR motion 
phantom to allow irregular motion to be achieved.  
 
 
Figure 3.9. (a) The standard QUASAR respiratory motion phantom shell without any inserts or motion 
control systems (b) The QUASAR™ respiratory motion phantom from Modus Medical shown with moving 
insert and standard motion control system. 
 
 
3.3.1.2 Upgrade components: Mot-102 stepper motor 
There are two main types of stepper motor, unipolar and bipolar. The Mot – 102 bipolar stepper 
motor from Ocean Controls (Ocean Controls, Seaford, Vic, Australia) runs on a current of 0.71 A 
and has a microstep capability of 1600 steps / rev. Speed tests conducted show that the motor has a 
top speed of 6000 Hz (steps / sec) as per the manufacturer’s specifications, reducing to 5000 Hz 
when a tight grip is applied to the motor shaft. The motor’s capabilities are summarised in Table 
3.3. 
 
 
 
(b) (a) 
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  Table 3.3. The physical specifications of the Mot-102 stepper motor 
Physical Specification Value 
Steps / Rev 1600 
Step angle 0.45◦ 
Resolution (variable)  0.001 – 0.1 mm/step 
Maximum Speed (ms / Step) 0.159 
Maximum Frequency (Hz) 6300 
 
 
 
3.3.1.3 Upgrade components: M325 micro-stepping driver 
The M325 (Leadshire Technology Co. Ltd., Nanshan Dist. Shenzhen, China) is a high-
performance micro stepping driver used to send pulses to the stepper motors for movement. The 
M325 uses a constant current chopping technique that allows greater speed and power to be 
extracted from the stepper motor. The M325 also allows precise current control, which is 
important since it determines the accuracy of the stepper motor being driven. The M325 runs off 
the 24 V power supply as the motor controller (see Section. 3.3.1.4) and has an output current up 
to 2.5 A with a pulse frequency of up to 100 kHz. The M325 has a variable stepping resolution that 
can be activated by selecting the number of steps per revolution of the stepper motor. The three 
main hardware components of the upgrade are shown below in Figure 3.11 and are wired 
according to Figure 3.12. 
3.3.1.4 Upgrade components: Stepper Motor Controller Model kta-190 
To control the stepper motor and provide an interface to the computer software a stepper motor 
controller was purchased. The Ocean Controls (Ocean Controls, Seaford, Vic, Australia) kta-190 
Serial Stepper Motor Controller is controlled via the serial port of a personal computer. It has a 
baud rate of 9600, 8 data bits, 1 start bit, 1 stop bit and no parity (9600,8,N,1). The kta-190 allows 
control of up to four stepper motors simultaneously and is powered by either a 12 or 24 V power 
supply. The commands for the controller are in the form: 
 
@AA CMND XXXXCR 
 
Where AA is the two digit number of the motor being addressed, between 01 and 16, CMND is a 
four letter command (Table 3.4), XXXX is a numeric value associated with the command, and CR 
is the carriage return byte (0x0D). 
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Table 3.4. kta-190 motor commands to be sent from the PC to the kta-190 controller. Taken form the 
manufacturer’s operators manual. 
Command Description 
POSN Set the position that motor AA is currently at to be XXXX where 
XXXX is between -99,999,999 and 99,999,999 
PSTT Returns the position of motor AA 
AMOV Move motor AA to the absolute position XXXX where XXXX is 
between -99,999,999 and 99,999,999 
RMOV Move motor AA relatively from the current position by XXXX 
where XXXX is between -99,999,999 and 99,999,999 
STOP Stop motor AA immediately 
STAT Get the status of the motors 
ACCN Set the maximum stepping rate of motor AA to XXXX where 
XXXX is between 0 and 9999 
ACCI Set the Acceleration interval of motor AA to XXXX where 
XXXX is between 1 and 9999 
RATE Set the minimum stepping rate of motor AA to XXXX where 
XXXX is between 1 and 9999 
 
 
3.3.1.5 Upgrade components: Separate chest-wall motion platform 
To simulate different levels of correlation between the patient’s chest-wall and their internal 
anatomy (Gierga, Brewer et al., 2005, Hoisak, Sixel et al., 2004, Hunjan, Starkschall et al., 2010, 
Ionascu, Jiang et al., 2007), a separate lift platform was designed to allow decoupling of the 
standard QUASAR insert and chest-wall platform. The platform, shown in Figure 3.10, consists of 
two identical pieces of steel joined by two brass guide rails that house Teflon bushes to decrease 
friction. As the stepper motor rotates clockwise or anti-clockwise, the platform is raised or lowered 
via a screw. The thread of the screw was custom made so that a larger than normal pitch of 3 mm 
could be obtained for faster translation. The platform has a maximum translation of 60 mm and a 
maximum speed of 11.25 mm.s-1. Using the kta-190 controller, two commands can be sent 
simultaneously to two M325 drivers. Software was developed that can initiate phase-shifts 
between the chest-wall platform and the insert motion. This feature is particularly useful for 
investigating dosimetric consequences of gating radiation delivery based on an assumed 1:1 
correlation between the external surrogate and internal anatomy, where, in reality, the correlation 
may be dynamically changing. 
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Figure 3.10. Custom built separate chest-wall motion platform. Showing the stepper motor, Teflon guide 
bushes and custom made 3 mm pitch raising / lowering screw. 
 
3.3.2. Methods 
3.3.2.1 Control system and hardware upgrade.  
Figure 3.11 shows the control architecture upgrade to achieve arbitrary programmable motion. 
Figure 3.12 shows a wiring diagram for a two motor system using these components. Irregular 
motion is achieved with the use of custom software and serial communication protocols. 
 
Figure 3.11. The control architecture for the upgraded QUASAR phantom. A PC with custom software is 
used to communicate with a serial stepper motor controller. The serial stepper motor controller then sends 
pulse signals to the M325 stepper motor driver which in turn sends step signals to the motor. 
 
Kta-190 Controller
M325 Stepper motor driver
Mot-102 stepper motor
PC with Control Software
Stepper Motor
Custom 3mm thread.
Teflon guide bushes
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Figure 3.12. Wiring diagram for the components that make up the control system. 
 
 
3.3.2.2 Software development for motion control 
A complete graphical user interface (GUI) written in MATLAB (3.1.2) was developed to control 
the upgraded QUASAR phantom. Each command consisting of the number of steps to be moved 
and the rate at which to move is sent to the kta-190 via the serial port. Following each command, 
the system needs to wait for the motion to be completed before sending the next command. 
Determining the time to wait for the motion to be completed is a simple calculation. In addition to 
this; another factor must be subtracted to ensure that the time for replication is accurate. This 
factor accounts for signal transmission time between the PC and the control system, drivers, and 
ultimately, the motor. It can be calculated by noting that the speed of serial transmission is 9800 
baud, or, 9800 symbols per second, therefore, to determine the time it takes to send a signal across 
serial transmission, one needs only the length of the communication.  
 
The GUI for control software version 1.1 is shown in Figure 3.13. The upgrade allows for not only 
patient specific replication of motion patterns, but also a number of test and sinusoid patterns. The 
GUI also provides a link to the user defined profiles, as well as the ability to simulate breath-holds 
(see Section 2.5.3), “Lujan” patterns (Lujan, Balter et al., 2003, Lujan, Larsen et al., 1999) and 
simple sinusoidal patterns with a range of amplitudes and frequencies.  
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Figure 3.13. Version 1.1 of the Graphical User Interface of the motor control software. Key features are 
highlighted with details of the various functions outlined in Section 3.3.2.2. 
 
To replicate realistic patient-like motion, an algorithm was developed which imports patient data-
sets exported from the Varian RPM system. High-frequency noise exists in the RPM recorded data 
(see Figure 3.14). Therefore, before the algorithm can work, the data from the RPM needs to be 
smoothed using a moving average filter. Following this the maxima and minima in the trace must 
be found. A peak detection algorithm takes respiratory motion data recorded with the RPM system 
and determines the locations of all the peaks and troughs in the data (Figure 3.15). Following the 
application of the moving average filter, for each minimum to minimum (complete breath cycle), 
the length of the data is divided into a user specified number of blocks. This procedure is shown in 
Figure 3.16. Finally, the distance in time and space between these points is then calculated and 
converted into a number of stepper motor steps at a specific rate. 
Replicated data 
Patient data
File input control
Mode selection 
Breath-hold functions
Sinusoidal mode “Lujan” model
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Figure 3.14. Demonstration of the need for a moving average filter to smooth RPM prior to peak detection 
for respiratory cycle analysis to be effective. 
 
Figure 3.15. Peak detection: The location of the maxima and minima detected by the code is shown overlaid 
on a patient’s respiratory trace. The green line shows a line connecting all locations of the maxima and the 
red line shows a line connecting all locations of the minima. 
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Figure 3.16. (a) A single breath recorded with the RPM system. (b) The trace in (a) broken down into 10 
points (blue crosses) between successive minima. The x-axes show the arbitrary time base and the y-axes 
shows arbitrary amplitude. 
 
An idealised sinusoidal motion profile is an unrealistic representation of actual tumour motion 
(Chen, Weinhous et al., 2001, Fitzpatrick, Starkschall et al., 2005, Kissick, Flynn et al., 2008, Sato 
and Robbins, 2001, Thorndyke, Xing et al., 2005). Lung tumours often experience irregular 
trajectories which are difficult to model explicitly with periodic functions. To replicate this 
irregular behavior, a software GUI was also developed to allow the user to draw any desired 
trajectory they wish.  
 
The GUI shown in Figure 3.17 is a simple graph in which the user defines a profile to be replicated 
with the mouse. The user can select the number of points by which they want to define their profile 
as well as the time base. The maximum amplitude of the motion is limited to 4 cm, which is the 
mechanical limit of the QUASAR phantom’s insert motion. The user can then set the number of 
times they want this particular profile to be cycled. Software that can analyse patient’s respiratory 
motion profile and provide useful statistics was also developed. 
 
(a) (b) 
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Figure 3.17. Examples of motion patterns that can be designed by the user. (a) A continuous prostate target 
drift as described by (Kupelian, Willoughby et al., 2007). (b) A commonly seen respiratory pattern where 
the duration of inhale is less than the duration of exhale. (c) The inverse of (b), where the inhale period is 
longer than the exhale period. (d) A breath-hold scenario where a single breath is replicated before a 10-
second breath-hold.  
 
 
3.3.2.3 Respiratory pattern analysis software 
A software GUI (shown in Figure 3.18 - Figure 3.20) that can import and analyse patient 
respiratory motion data from the RPM was developed in MATLAB as part of the upgrade. This 
software was designed to enable clinicians to interpret a patient’s respiratory characteristics and 
provide valuable information about the patient’s respiratory characteristics. The following 
parameters are reported by the GUI: 
 
 
 
 
 
(a) (b) 
(c) (d) 
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 Total No. of data points 
 Total length of recorded trace in seconds 
 No. Of maxima 
 No. Of minima 
 No. of complete respiratory cycles 
 Maximum base-line drift 
 Maximum variation in peak inhale position 
 Maximum variation in peak exhale position 
 Average peak inhale chest position 
 Average peak exhale chest position 
 Average respiratory cycle length 
 Maximum respiratory cycle length 
 Minimum respiratory cycle length 
 Maximum displacement of the chest-wall 
 Average time spent in inhale phases for all cycles 
 Average time spent in exhale phases for all cycles 
 Maximum time spent in inhale phase over all cycles 
 Minimum time spent in inhale phase over all cycles 
 Maximum time spent in exhale phase over all cycles 
 Minimum time spent in exhale phase over all cycles 
 
The respiratory analysis software provides a valuable tool for assessing the benefits of 
biofeedback. A patient’s respiratory regularity can be assessed following biofeedback training. 
Furthermore, the statistics provided by the software can be used to determine the best gating 
parameters on a patient by patient basis.  
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Figure 3.18. GUI of respiratory analysis software, showing the imported trace from the Varian RPM system,  
the baseline drift of the trace, as selected by the drop-down menu, amplitude and phase histograms showing 
the distribution of chest-wall positions and phase distributions. Statistics for the trace are shown on the right 
hand panel. 
 
 
 
 
BASELINE DRIFT FROM TRACE 
ORIGINAL TRACE AND TRACE WITH MOVING AV. FILTER 
HISTOGRAMS FOR AMPLITUDE 
POINTS AND PHASE  
STATISTICS  
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Figure 3.19. GUI of respiratory analysis software, showing the imported trace from the Varian RPM system, 
a stem plot of the time spent in exhale and the time spent in inhale phases per full respiratory cycle and 
phase and amplitude distributions Statistics for the trace are shown on the right hand panel. 
 
 
TIME SPENT IN INHALE PER RESPIRATORY CYCLE
TIME SPENT IN EXHALE PER RESPIRATORY CYCLE
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Figure 3.20. GUI of respiratory analysis software, showing the imported trace from the Varian RPM system 
and a stem plot of the ratio of time spent in inhale per cycle compared to time spent in exhale along with the 
usual statistics and amplitude and phase distributions. 
 
The complete hardware upgraded QUASAR system is shown in Figure 3.21. The upgraded 
phantom provides a complete motion management QA system due to the interchangeable inserts. 
The upgraded QUASAR phantom and software presented in this chapter provide the means to 
investigate and optimise motion management protocols. This feature, along with the ability to 
generate a large number of motion patterns, makes the upgraded phantom described in this chapter 
an invaluable tool for routine QA and research into motion management. Imaging quality 
assurance, prostate motion studies, the development of 4D Cone Beam CT (Clements, Kron et al., 
2013) algorithms and credentialing of clinical trials have all used the upgraded QUASAR motion 
phantom presented in this work. Furthermore, patient specific QA for stereotactic lung patients at 
Peter MacCallum Cancer Centre (PMCC) is now carried out using the upgraded phantom (Kron, 
Clements et al., 2011).  
 
RATIO OF TIME SPENT IN INHALE PHASES COMPARED TO EXHALE 
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Figure 3.21. The complete QUASAR motion phantom with additional accessories. (1) Laptop showing 
control software. (2) Custom built lift platform on separate stepper motor. (3) Upgraded QUASAR motion 
phantom with upgraded motor attached. (4) Bladder insert. (5) Film insert. (6) Ion chamber insert. (7) Ion 
Chamber. (8) Exposed film showing moving insert dose distributions. 
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3.3.3. Results – The QUASAR respiratory motion phantom upgrade 
An existing QUASAR respiratory motion phantom (3.3.1.1) was upgraded to allow for patient 
respiratory motion replication. In this section, the phantom’s accuracy in patient motion 
replication, as well as a number of test patterns for quality assurance are evaluated. The upgrade 
procedure and software development is outlined in Section 3.3.2. 
3.3.3.1 Patient replication 
Patient AP respiratory motion data recorded with the Varian RPM system (3.1.1.1) was replicated 
through the upgraded phantom. Replicated motion was also recorded with the RPM system and 
compared to the original data. Results for two patient data-set replications are shown in Figure 
3.22 and Figure 3.23. Replication of six data-sets showed a maximum p-value of 0.014, indicating 
a statistically significant degree of correlation with the original patient data. The p-value was 
obtained by comparing all data spatial data-points in the patient data-set (RPM recorded) and 
replicated data-set (RPM recorded). Differences between maxima and minima locations in space 
were found to have mean differences of 0.034 cm for maxima and 0.0102 cm for minima.  
 
Table 3.5 shows the correlation p-value for six patient traces. All replicated data showed good 
correlation to the actual patient data.  
 
Figure 3.22. Patient AP motion recorded with the RPM system (solid blue line) compared to AP motion 
replicated with the upgraded phantom system (dashed red line).  
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Figure 3.23. Replication of an irregular patient trace with base-line drift and irregularities in amplitude. 
 
 
Table 3.5. Six patient respiratory traces recorded with the RPM system and their correlation to data 
replicated with the upgraded QUASAR phantom. 
Patient No. Respiratory Profile Correlation p 
1 0.0045 
2 << 0.05 
3 << 0.05 
4 0.0136 
5 << 0.05 
6 << 0.05 
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3.3.3.2 Test patterns 
Test patterns and breath-hold scenarios are shown in Figure 3.24. The sudden change in motion 
shown in Figure 3.24 (a) tests that the RPM system’s predictive filter correctly initiates a beam-off 
signal instantly when the motion deviates significantly from the prediction. The motion platform 
allowed large, extreme breath-hold scenarios to be tested, allowing the RPM’s predictive and 
gating limitations to be ascertained. The RPM’s predictive system was found to be able to handle 
large 20 s breath-holds as long as there is at least five full respiratory cycles before the initiation of 
a hold so that the predictive filter can learn the cycle. 
 - - 121 - - 
 
 
(a)  (b) 
 
 
(c)  (d) 
 
 
 
 
Figure 3.24. Test patterns designed to commission and test the RPM system. In these diagrams, the red line 
indicates that the RPM considers the motion unpredictable. The figures also indicate where the RPM has 
initiated a ‘beam OFF’ signal, this can be seen where the square wave gate signal pulse representing the ‘beam 
ON’ time drops to zero. (a) Respiratory pattern that tests the termination of gating where patient respiratory 
motion differs from prediction. This can be seen by the red line in (a). (b) Sinusoidal trace with small amplitude 
to test predictability / gateability and resolution of the RPM system in dealing with small amplitude motions. (c) 
Example of a large amplitude / period (~15s) to test the RPM’s ability to accurately predict large motions. (d) 
Example of a ten second breath-hold simulation.  
Breathing track
Gate signal
Vertical dashed lines indicate phase based gating. 
Horizontal lines are used to set amplitude baed gating 
windows. 
Square logic pulses indicate 
corresponding beam-on times 
Red line indicates the RPM no longer considers the motion 
periodic and has terminated the beam. 
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3.3.4. Discussion – The QUASAR respiratory motion phantom 
The QUASAR respiratory motion phantom is presented in Section 3.3. The aim of this work was 
to upgrade the system to allow for the replication of actual patient respiratory motion. Patient 
respiratory motion is often treated as a sinusoidal motion, and though this is a reasonable first 
order approximation, it is simply not realistic and sometimes insufficient for QA purposes. 
Numerous authors have noted the variability in respiratory motion (Nehmeh, Erdi et al., 2004b, 
Ren, Nishioka et al., 2007, Sato and Robbins, 2001, Thorndyke, Xing et al., 2005, Chen, 
Weinhous et al., 2001, Kissick, Flynn et al., 2008, Verschakelen and Demedts, 1995). This can 
also be seen in Figure 2.3 where six patients’ respiratory profiles were recorded with the Varian 
RPM system (Figure 3.1). The data shows that not only does a patient’s breathing pattern change 
from cycle to cycle, but hysteresis, and baseline drift can all result in a deviation from a regular 
periodic function.  
 
Test patterns were also programmed to test the limitations of respiratory motion management 
systems like the Varian RPM system. These patterns, some of which are shown in Figure 3.24, 
include breath-hold patterns, simulated sudden deviation motions, for example, a simulated cough 
as well large and small magnitude movements which test the resolution of the system.  
 
A commercially available phantom was upgraded to allow for irregular motion typically seen in 
patients. By upgrading the standard QUASAR respiratory motion phantom, accessories in the form 
of inserts can also be constructed. Aside from the commercially available inserts from Modus 
Medical, custom made inserts have been constructed to house film, ion chambers, radio-sensitive 
gels, Thermoluminescence dosimeters, optically stimulated luminescence dosimeters and 
implanted seeds for analysis of prostate motion using CBCT. Clinically, the upgraded QUASAR 
phantom presented in this work is currently used in the QA of radiotherapy treatment plans for 
patients undergoing stereotactic radiotherapy (Kron, Clements et al., 2011). 
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Chapter 4. The impact of motion: CT imaging 
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- Eadweard Muybridge: 'The Horse in Motion' 
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4.1. INTRODUCTION 
During conventional three-dimensional Computed Tomography (3D-CT) imaging procedures of 
the thorax and abdomen regions, anatomical motion can lead to considerable artifacts in the 
acquired data set due to respiratory, cardiac and gastro-intestinal (GI) movements (Balter, Ten 
Haken et al., 1996a, Allen, Siracuse et al., 2004, Vedam, Keall et al., 2003b). Such artifacts can 
manifest themselves as inconsistent boundaries of anatomical structures (Keall, Kini et al., 2002) 
and in some cases, even mimic disease (Tarver, Conces et al., 1988). Errors at the CT simulation 
stage can lead to the implementation of inappropriate margins during radiotherapy planning, which 
could result in unnecessary irradiation of healthy tissue (ICRU, 1993, ICRU, 1999).  
 
Four-dimensional Computed Tomography (4D-CT) (Low, Nystrom et al., 2003, Vedam, Keall et 
al., 2003b, Keall, Starkschall et al., 2004, Pan, Lee et al., 2004) provides means of reducing the 
breathing related artifacts associated with free-breathing 3D-CT via correlation of the data-
acquisition to a respiratory signal. By binning the data as a function of the breathing-phase 
acquired from an external respiratory monitor, the target (tumor) can be imaged over a complete 
respiratory cycle, thus effectively providing the extent of the tumor motion trajectory over a single 
breath-period. Data from 4D-CT can be used to create an internal target volume (ITV), a ‘snap-
shot’ of the tumor at each designated respiratory phase and a mean tumor position (Mageras, 
Pevsner et al., 2004b, Ford, Mageras et al., 2003a, Rietzel, Liu et al., 2006a, Underberg, 
Lagerwaard et al., 2005, Underberg, Lagerwaard et al., 2004, Keall, 2004a).  
 
In many radiotherapy departments, 4D-CT has become standard for the treatment planning of lung 
cancer lesions. Since 4D-CT data can be used as the basis for dose calculation, spatial and 
temporal accuracy is important. To ensure such accuracy and quantify the potential errors of such 
technologies, it is important that phantoms are available that enable quality assurance (QA) to be 
performed on the motion management protocol being implemented (Keall, Mageras et al., 2006b, 
Jiang, Wolfgang et al., 2008, Mutic, Palta et al., 2003). Motion phantoms have previously been 
used in conjunction with 4D and 3D-CT to assess the impact of motion velocity that may cause 
motion artifacts within the target volume (Nakamura, Narita et al., 2009b), evaluate the interplay 
between parameters affecting temporal resolution and the accuracy of the resulting images (Mutaf 
and Brinkmann, 2008), as well as aid in determining the optimal respiration phase assignment 
(Mutaf, Antolak et al., 2007).  
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The objective of the 4D-CT component of this work was to use the see-saw phantom (see Section 
3.2) to determine the effect of motion on binning and motion artifacts in data sets acquired with 
4D-CT. Since these projections are commonly used for planning purposes, particular interest was 
given to MIP and AIP artifacts (Objective 2). Objective 2: “Quantify the influence of lesion size 
and motion amplitude on data acquired from 4D-CT” The methods and materials of this 
investigation are outlined in Section 4.2 and 4.3. This chapter’s results are in part taken from a 
paper published in Medical Physics in 2012 entitled “A Phantom for Testing of  4D-CT for 
radiotherapy of small lesions” (Dunn, Kron et al., 2012). 
4.2. MATERIALS 
Two CT scanners (Phillips Big Bore Brilliance CT scanner and the GE Discovery STE PET/CT) 
were chosen to demonstrate the utility of the see-saw phantom using both helical and axial 4D-CT 
acquisition protocols, as well as transducer belt and infrared optical respiratory signal acquisition 
systems. Five materials (Table 4.1) (Cork, Water, Teflon, Perspex and Nylon) were chosen to 
cover the relevant spectrum of HUs though other materials could easily be used due to the design 
of the phantom. The phantom was oriented so that the motor and drive wheel were inferior to the 
field-of-view (FOV), with the object and phantom movement occurring in the AP direction (axial 
motion). The motion signal was acquired using the Phillips Bellows belt system, as well as the 
Varian RPM system for the GE Discovery STE scans. 
Table 4.1. Overview of relevant materials and their approximate tissue equivalence. The static HU were 
measured with a consistent region of interest for all materials from scans using the Phillips Big Bore 
Brilliance CT. 
 
Measured Static HU 
Material 
Dimensions 
(l x w x h) [mm] 
Density (g/cm3) Approximate Equivalence 
Min Max Mean ± SD 
Cork 30 x 20 x 50 ~ 0.25 Lung -838 -703 -784  ±  20.9 
Water 38 x 52 x 100  1.0 Tissue -14 14 -1.09 ± 4.8 
Polytetrafluoroethylene  
     ‘PTFE’(e.g.Teflon) 
50 x 20 x 50 ~ 2.2 Bone 314 359 340 ± 7.5 
Polymethylmethacrylate 
     ‘PMMA’ 
(e.g. Perspex) 
70 x 50 x 10 ~ 1.18 N/A 63 99 84.8 ± 5.8 
Polyamide ‘PA’ 
  (e.g. Nylon) 
50 x 20 x 50 ~ 1.15 Cartilage -91 -62 -74.5 ± 5.0 
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4.3. METHODS 
4.3.1. Phillips Big Bore Brilliance CT setup 
4D-CT scans were carried on the Philips Big Bore Brilliance CT scanner (Philips Medical 
Systems, Cleveland, OH, USA). The 4D-CT data was acquired helically with a pitch factor of 
0.059, gantry rotation period of 0.44 s, 3 mm slice thickness, 0.931 pixels per mm resolution, FOV 
550 x 550 x 153 mm3 (512 x 512 x 51 pixels), 30 mA X-ray tube current, exposure of 233 mAs 
and 140 kVp. The Philips Bellows system (Philips Medical Systems, Cleveland, OH) was used to 
acquire the external respiratory signal needed for 4D-CT. This system is described in Section 
3.1.1.2. 
 
Tumor Localisation On Console (L.O.C.) software version 2.3.0 was used to retrospectively create 
Maximum Intensity Projections (MIP), as well as Average Intensity Projection (AIP) 3D data sets. 
MIP 3D data sets contain voxels whose values are derived from the maximum voxel intensity 
throughout the 4D-CT data set. A MIP image thus provides a ‘highlighted’ tumor volume over all 
phases of the respiratory cycle and can be used for ITV construction. Correspondingly, an AIP 3D 
dataset contains voxels whose values are derived from the arithmetic mean of the corresponding 
voxels of the 4D CT dataset. AIP data provides a ‘blurred’ image of the moving tumor trajectory 
over all phases and is used for dose calculation. Figure 3.4 shows the experimental setup using the 
see-saw phantom and the materials described in Table 4.1. Figure 4.1 shows the method for 
measuring CT numbers and amplitudes on MIP images. The following investigations were 
undertaken with the Phillips Big Bore Brilliance CT scanner: 
 
 HU consistency between moving and stationary objects. 
 Inter-phase variability of HUs (2.5 cm amplitude, period of 4 s). 
 MIP and AIP artifacts as a function of the number of phase-bins (5, 10, and 20 phase-bins) for 
an amplitude of 6.0 cm and a period of 4 s.  
 Verification of motion amplitude using MIP (amplitudes of 6.0, 3.0, 2.5, 2.0 and 1.5 cm, period 
= 4s). 
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4.3.2. HU consistency of moving and stationary objects 
Dose calculation in radiotherapy is fundamentally reliant upon HU data from CT. 4D-CT allows 
the incorporation of motion specific phase-bin data into the treatment plan. The see-saw motion 
phantom allows comparison between phase-bin HU to a single HU measurement in the AIP, as 
used in the single plan approach. To assess the effect of motion velocity on HU consistency, the 
period was fixed at 4 s (15 rpm) and 4D-CTs of amplitudes 6.0, 3.0, 2.5, 2.0, and 1.5 cm were 
acquired using the Phillips Big Bore Brilliance CT scanner. Data was then retrospectively binned 
into ten phases, with each phase-bin corresponding to a particular subset of the complete motion 
cycle. HUs of static and moving objects within the same FOV were then compared for each phase-
bin as well as the AIP projection. The region of interest (ROI) was selected to be consistent in size 
and position within each phase-bin as well as ensuring that it is never overlapping the boundary of 
the object. To establish the effect of motion frequency on HU variability between moving and 
static objects, the amplitude was fixed at 6.0 cm and the period of oscillation was varied from two 
to eight seconds (2 second intervals). 4D CT scans were acquired for each of the four periods and 
HUs for static and moving objects compared in the 50% phase-bin of each data set. 
  
Figure 4.1. MIP images (Cropped to 365 x 365 mm): Amplitude analysis, (a) axial and (b) sagittal 
mid plane, upper-surface to upper-surface point at minimum and maximum arm elevation used to 
measure amplitude. (Note: sagittal image has had window and leveling modified for better 
visualisation.) The red rectangle in (a) shows an example of the ROI used for HU determination. 
The dashed white line in (b) shows the extent of motion excursion from a sagittal perspective.   
(b) (a) 
Cork 
Teflon Nylon 
ROI 
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4.3.3. MIP and AIP artifacts as a function of the number of phase-bins 
The minimum number of phase-bins required to ensure a complete MIP data set was evaluated by 
visual investigation of MIP data for two motion amplitudes (6.0 and 2.5 cm, period = 4 s). The 
amplitude was set to 6.0 cm and five (0, 20, 40,…, 80%), and ten (0, 10, 20,…, 90%) phase-bins 
were used. MIP images were analysed visually to ascertain completeness of the data set. The 
Philips Brilliance scanner allows a maximum of ten phase-bins to be used. However, since the 
motion of the phantom is symmetrical, ten phase-bins over the half the motion is equivalent to 20 
over the whole range of motion. As such, ten bins over half the motion cycle were investigated (0, 
5, 10, 15,…,45%) and images were assessed for artifacts. 
4.3.4. Geometric consistency between MIP images and reality 
The geometric consistency tests were performed retrospectively using ImageJ image analysis 
software (National Institute of Health, USA). Apparent motion amplitudes were measured using 
MIP projection data (Figure 3). This was done for amplitudes 1.5, 2.0, 2.5, 3.0 and 6.0 cm. The 
MIP derived amplitudes were then compared to calculated amplitudes (Equations 3.1 and 3.2).  
4.4. RESULTS 
The results presented in this section pertain to a number of studies as listed below. All 
investigations used the see-saw motion phantom in conjunction with a number of objects of 
varying densities to cover the relevant spectrum of CT numbers (see Table 4.1). 
 
1. Evaluate the HU consistency, and possible inter-phase variability, between moving and 
stationary objects within the same field of view in 4D-CT data-sets. 
2. Determine the quality of projections (MIP and AIP) with respect to the number of phase-bins. 
3. Verify the geometrical consistency of MIP images (i.e. do the amplitudes measured on an MIP 
represent the calculated amplitudes?) 
4.4.1. HU consistency between moving and stationary objects 
Figure 4.2 shows the inter-phase variability in HU for water. In this figure, the displacement of 
maximum corresponds to the 30 and 70 % phase-bins and the minimum displacement corresponds 
to the 0 and 50% phase-bins. These data, plotted as a function of phase percentage, initially appear 
to show a phase dependent effect on the measurement of HU. Close scrutiny of individual data 
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sets, together with that of stationary objects, reveals that the variation is not systematic. It appears 
that the spread of measurements is greater in the inter maxima / minima phases, where the residual 
motion within the phase window is greatest, however it is not inconsistent with the usual expected 
HU uncertainty (shown in Table 4.1). No systematic phase dependent variation was evident for 
Nylon, Water, Cork and Teflon.  
 
To determine the effect of motion frequency on HU evaluation, the period was varied from two to 
eight seconds at a constant large amplitude of 6.0 cm. Figure 4.2 (b) shows the effect of motion 
period on HU determination. Again, the data appears to exhibit a period-dependent variation, but 
the relationship is not systematic. The largest discrepancy for a moving object occurs for the 
slower motion (8 s period) and is no worse than the HU for the stationary sample in the shorter (2 
s) period case indicating that there is no period dependence in this case. 
 
 
Figure 4.2. (a) Inter-phase variation in the HU of water. Random variations about the ‘true’ HU for water 
show no systematic dependence on phase-bin over all amplitudes of motion. A standard ROI shown in 
Figure 3.4 (area = 377 pixels) was used for all measurements. (b) The effect of motion frequency on HU 
variation. For a large motion amplitude of 6.0 cm a comparison was made between the HU of water for a 
moving and stationary object in the 50% phase-bin. Error bars represent the standard uncertainty in the 
measured HU values. 
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Table 4.2 shows a comparison between the mean HU for water evaluated on each individual 
phase-bin and averaged, compared to the HU for water from a single measurement on an AIP from 
the ten phases. For the largest amplitude (6.0 cm), if the ROI is retained in the same position for all 
phases, then errors will be seen associated with partial volume effects. This is because the edge of 
the objects will move into even a small ROI. Thus, the ROI must be moved for large amplitude 
phase images to ensure it lies completely within the object of interest. An example of the failure to 
do this is shown in the bottom row of Table 4.2 where the HU for water is erroneously measured to 
be -184 HU when averaged from the ten phases. A motion related artifact can also be seen in the 
AIP value for the 6.0 cm amplitude. The HU for water is underestimated as -18 HU primarily due 
to streaking and undersampling artifacts, as can be seen in Figure 4.3 (b). This discrepancy is not 
mirrored by the average HU from the ten phases due to the cancelling of contributions from the 
two phases that yielded the maximum and minimum HU which are of similar magnitude (see 
Moving range Table 4.2). For a large amplitude (6.0 cm), the individual phase images themselves 
feature artifacts which can contribute to this average. 
 
Table 4.2. Comparison of the mean HU for water measured on all ten phase-bins to the HU of water as 
measured on the AIP. Comparisons were performed for both the stationary and moving objects within the 
same FOV. The global mean and standard deviation for all stationary measurements is 0.07 ± 1.5 (-31 – 34). 
Amplitude Mean CT# (H2O) 10 Phases ± SD (range) Mean CT# (H20) AIP ± SD (range) 
[cm] Stationary Moving Stationary Moving 
1.5  -0.93 ± 0.86 (-17 – 16) -1.45 ± 0.99 (-13 – 17) - 1.16  ± 1.63 (-6 – 5) -1.84 ± 2.14 (-2 – 6) 
2.0  -2.90 ± 0.40 (-16 – 8) -0.21 ± 0.53 (-10 – 11) -2.71 ± 1.45 (-11 – 4) 0.24 ± 2.88 (-5 – 3) 
2.5  -0.10 ± 0.73 (-14 – 14) 2.55 ± 0.75 (-12 – 15) -0.01 ± 1.801 (-5– 6) 1.39 ± 2.41 (-2 – 8) 
3.0  0.24 ± 1.20 (-19 – 20) 1.96 ± 0.91 (-15 – 21) -0.20 ± 4.89 (-6 – 5) 3.22 ± 2.42 (-15 – 10) 
6.0  2.42 ± 1.09 (-31 – 34) 0.36 ± 7.84 (-51 – 57) -0.20 ± 4.37 (-12 – 6) -18 ± 10.48 (-52 – 11) 
6.0* - -183.9 ± 82.5 (-1024 – 160) - - 
*erroneous value which occurs if ROI is not moved to coincide with phase position of object. 
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4.4.2. The quality of MIP and AIP with respect to the number of phase-bins 
MIP and AIP data for 6.0 and 2.5 cm motion amplitudes are shown in Figure 4.3 (a-d). The MIP 
reconstruction over ten phase-bins for the 6.0 cm amplitude, Figure 4.3 (a), suffers from 
considerable artifacts for the moving objects when compared with static objects within the same 
FOV. Furthermore, missing reconstruction data due to the use of only ten phase-bins over a large 
excursion can also be seen. The AIP projection shown in Figure 4.3 (b) is similarly undersampled 
due to the extreme amplitude of motion.  
 
For the 2.5 cm amplitude MIP and AIP images (Figure 4.3 (c) and (d) respectively), the artifacts 
associated with large amplitude motions are considerably reduced. In this scenario, a ten phase-bin 
reconstruction is adequate to provide a ‘complete’ data set. As can be seen, the MIP appears as a 
complete data set over the range of motion and could be used to delineate the ITV for the object’s 
trajectory. The AIP image, Figure 4.3 (d), also shows better agreement with the 'expected' average 
density profile. 
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Figure 4.3. (a) MIP using ten phases 0 – 90% with an amplitude of 6.0 cm. (b) Average reconstruction for an 
amplitude of 6.0 cm. (c) MIP of 2.5 cm amplitude motion using ten phases. (d) Average reconstruction (2.5 
cm amplitude). 
 
The optimal number of phase-bins for accurate representation of the motion was found to depend 
on the amplitude of motion, object size, period and acquisition time per slice (typically 180 degree 
scanner rotation time). Figure 4.4 shows sagittal MIPs for the see-saw phantom undergoing a 6.0 
cm amplitude motion with 4 s period. Five phase-bins (Figure 4.4 (a)) are insufficient to establish 
the true motion amplitude, as projection data is missing and thus sub-optimal trajectory 
information is obtained. Figure 4.4 (b) shows the same amplitude with ten phase-bins. A more 
complete data set is evident, resembling the true ITV motion envelope, although the data set is still 
incomplete. Lastly, Figure 4.4 (c) uses ten phase-bins over half the motion cycle (equivalent to 20 
phase-bins over a complete cycle). It is important to note that the use of 20 phase-bins was only 
possible since the motion is symmetrical, where normal patient respiratory motion is of course 
variable and can be asymmetrical. Figure 4.5 shows a conceptual diagram of the interplay between 
an object’s size and its amplitude of motion. This figure shows that using ten phase bins, the 
(a) MIP, 6cm amplitude (b) AIP, 6 cm amplitude 
(c) MIP, 2.5 cm amplitude (d) AIP, 2.5 cm amplitude 
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unreconstructed data between phase-bins can result in gaps appearing in MIPs generated.  
 
   
Figure 4.4. Sagittal MIPs for reconstructions based on (a) 5 (0,20,40,…,80%), (b) 10 (0,10,20,…,90%)  
and (c) 20 (0,5,10,…,45%)  phase-bins. 20 phase-bins were constructed by exploiting the symmetrical 
nature of the motion and using ten phase-bins over half the motion cycle. 
 
 
 
(a) (b) (c) 
 - - 135 - - 
Figure 4.5. The interplay between motion amplitude and object size. Ten phase-bins used over three 
different amplitudes 4.0, 2.0 and 1.0 cm demonstrating the object amplitude / size interplay and the concept 
of a discontinuous data set for a MIP. The data-points represented by solid grey circles represent a small 
object moving with an amplitude of 1.0 cm, for this motion, the MIP constructed from the ten phase-bins 
would appear as a solid object. For the same size object with an amplitude of 2.0 (red circle) or 4.0 cm 
(green circle), gaps would appear in the MIP since only ten phase-bins are used. 
 
 
The effect of undersampling of small objects undergoing large excursions can be summarised 
mathematically for a sinusoidal motion by noting that gaps in the MIP will appear when: 
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MIP if S is small compared to its bin-to-bin displacement. The risk of apparent gaps in the MIP 
depends on the object’s speed and the number and temporal width of phase-bins. This effect is 
likely to be pronounced for small lesions typically seen in lung cancer patients receiving 
stereotactic treatment. Figure 4.6 demonstrates the interplay between the number of phase-bins, 
amplitude of motion and lesion size. For a small lesion with a diameter of 1.0 cm and amplitude of 
2.0 cm, Figure 4.6 indicates that for five phase-bins, the maximum bin-to-bin displacement is 
approximately 1.1 cm. This is greater than the diameter of the lesion, therefore a MIP of the 4D-
CT data set will be incomplete and gaps will be present. If missing data occurs at the extreme of 
motion, then an ITV delineated on this data set may be underestimated. Conversely, if ten phase-
bins are used, we see that the bin-to-bin displacement is less than the lesion diameter and, as such, 
a MIP based on this 4D-CT data would be a ‘complete’ data set with no gaps. One may consider 
the possible clinical utility of this information. The phase binning required for a patient case is 
somewhat dependent upon the a priori knowledge of the lesion size. In some cases this might be 
known from earlier diagnostic imaging. In cases where it is not known until 4D-CT imaging is 
undertaken for planning purposes, Equation 4.1 can be used to inform the decision whether to 
proceed with planning or to make a clinical decision to compensate for information deficiencies 
that may be present, or to justify additional imaging. It is interesting to note that for tumour 
diameters equal to or above 2.0 cm, the most common phase-binning protocol, ten phase-bins, will 
result in a complete MIP data set for all amplitudes of motion. 
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Figure 4.6. The maximum bin-to-bin displacement as a function of the number of phase-bins for a tumor 
moving with a sinusoidal profile. If the diameter of the tumor is smaller than its bin-to-bin displacement, an 
insufficient number of phase-bins will result in gaps appearing in the MIP. Data for sinusoidal peak-to-peak 
amplitudes of 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 cm are shown. 
 
 
4.4.3. XCAT simulations of the undersampling effect as a function of lesion size. 
Figure 4.7 and Figure 4.8 illustrate a simulation of the undersampling effect outlined in 4.4.2. The 
interplay of lesion size, amplitude of motion and an insufficient number of phase-bins results in 
gaps appearing in projections obtained from an insufficient number of phase-bins. Simulations 
with a 10, 15 and 20 mm diameter tumour in the left lung, and five ten or 20 bins are shown. To 
generate these images, the XCAT’s respiratory period was set to 4 s with 5, 10 or 20 time frames 
generated. The time frames in this case are representative of the phase-bin data obtained from 4D-
CT. Figure 4.7 shows MIP data generated with the XCAT phantom. In this scenario, the XCAT’s 
maximum diaphragm extension was set to 4.0 cm. The figure illustrates that a 10 mm diameter 
tumour moving with amplitude of 4.0 cm requires a larger number of phase-bins to provide a 
complete data-set on a MIP. Figure 4.8 represents the same data, however, the maximum 
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diaphragm amplitude has been reduced to 2.0 cm. With this reduced amplitude, the 10mm 
diameter lesion requires only five phase-bins to appear as a complete data-set. The simulation data 
presented in Figure 4.7 and Figure 4.8 further illustrate the experimental work with the see-saw 
motion phantom, particularly the results presented in Section 4.4.2. 
 
Figure 4.7. Simulations with the XCAT phantom and a maximum diaphragm extension of 4.0 cm. Gaps can 
be seen to appear in these MIP images for small lesions (10, 15 mm) if an insufficient number of phase-bins 
are implemented.  
 
15 mm
5 phase bins
10 mm 20 mm
10 phase bins
Tumour diameter
20 phase bins
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Figure 4.8. Simulations with the XCAT phantom and a maximum diaphragm extension of 2.0 cm. The 
reduced diaphragmatic motion and therefore reduced lesion migration results in a reduction in the gaps 
appearing in MIP images as a result of insufficient phase-bin assignment. 
 
 
4.4.4. The geometrical consistency of MIP images 
Measurement of distance is important in the quality assurance of 4D-CT. Specifically, if an ITV is 
delineated from a MIP data set, the CT data shows a motion envelope. The size of the envelope 
should be measured against a known motion to assess the accuracy of the reconstruction. Ideally, 
this should be done for a wide range of motion amplitudes and frequencies. Figure 4.9 shows MIPs 
of five different motion amplitudes ranging from 1.5 – 6.0 cm. The amplitude of motion was 
derived from these images via the method shown in Figure 4.1. Calculated AP motion amplitudes 
(Equation 3.1) were compared to the MIP derived amplitude. Table 4.3shows the results for the 
five tests. MIP derived amplitudes for 3.0, 2.5 and 1.5 cm showed sub-millimeter agreement with 
the true amplitude, whilst amplitudes of 6.0 and 2.0 cm demonstrated an underestimation of 2 mm 
and an overestimation of 1.5 mm respectively when comparing the calculated phantom motion to 
the motion as measured on a MIP. 
15 mm
5 phase bins
10 mm 20 mm
10 phase bins
Tumour diameter
20 phase bins
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Figure 4.9. MIP’s for five different amplitudes. (a) 1.5 cm, (b) 2.0 cm, (c) 2.5 cm, (d) 3.0 cm and (e) 6.0 cm. 
Each of these amplitudes was measured using the method shown in Figure 4.1 and data was binned using a 
ten phase-bin protocol. The MIP delineated amplitude was compared with the known amplitude. 
 
 
Table 4.3. Comparison between MIP derived amplitudes and physical amplitudes. The amplitude of the 
objects was calculated for five AP amplitude settings using Equation 3.1. For the MIP derived amplitudes, 
the ruler function from ImageJ was used. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Calculated amplitude (mm) MIP derived amplitude (mm) Difference (mm) Absolute difference (mm) 
60 58.008 -1.992 1.992 
30 29.650 -0.35 0.35 
25 24.984 0.625 0.625 
20 21.484 1.484 1.484 
15 15.297 0.297 0.297 
 Mean ± SD 0.0128 ± 1.30 0.95 ± 0.75 
(d) 3.0 cm (e) 6.0 cm 
(a) 1.5 cm (b) 2.0 cm (c) 2.5 cm 
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4.5. DISCUSSION 
The goal of imaging in SBRT is to provide a highly detailed visualisation of patient anatomy as it 
would appear during patient setup and throughout the treatment. The most appropriate imaging 
modality for SBRT depends on the tissue being imaged. Generally, CT makes up the primary 
imaging modality and forms the basis for SBRT treatment plans. This thesis explored how motion 
affects common practice methods like contouring on a maximum intensity projection and 
performing dose calculation on an average intensity projection.  
4.5.1. Inter-phase variation in HU 
This study evaluated the phase-variation of HU and compared each phase to the AIP. No 
systematic dependence was found in this study within the uncertainty of ±10 HU. However, this 
was only evaluated for a sinusoidal motion. Irregular motion, as stated previously, can cause errors 
in phase-bin assignment. Furthermore, if the respiratory motion is fast compared to the acquisition 
time for all projections required for reconstruction of a phase then problems should arise. The see-
saw phantom provides the means to evaluate the consistency as can be seen in Figure 4.2.  
4.5.2. The accuracy of projections from 4D-CT 
Implementing MIP and AIP information into treatment planning is only beneficial if the data 
provided by the MIP and AIP is accurate and complete. The accuracy of projections from 4D-CT 
has previously been investigated by Park et al (2009b). Park et al found that MIPs systematically 
underestimated the range of target motion and urged caution in using MIP when breathing is 
irregular. Zamora et al (2010a) identified cases in which a MIP generated from a 4D-CT under-
represented the ITV by more than 10%. This error was largely due to auto-contouring of the data 
set. In this study, examples of incomplete data sets formed by objects undergoing large excursions 
during image acquisition have been presented. If auto-contouring was used as in the case put 
forward by Zamora et al (2010a), then underestimation or overestimation of the ITV could occur. 
In this work, MIP data based on 4D-CT accurately represented the true motion of the phantom to 
within 2 mm for amplitudes below 6.0 cm. These results are consistent with Ezhil et al (2009), 
who found that a MIP from 4D-CT represented the true ITV well when compared to other methods 
of ITV delineation (e.g. 2-phase addition, ten phase addition etc.). 
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For a small object, this can result in gaps appearing in the MIP, since no data is reconstructed 
between phase-bins. The object would appear to be in a different position altogether. For the 
smaller amplitudes, although the objects have moved, their traversed bin-to-bin distance is smaller 
than the object’s diameter and therefore an object of sufficient size would create a complete MIP 
data set with no apparent missing information.  
 
The accuracy of the AIP is important for dose calculation purposes as will be discussed in Chapter 
6. The consistency of HU in AIP is particularly important since it is generally used for dose 
calculation in a treatment plan based on 4D-CT (Guckenberger, Wilbert et al., 2007, Rietzel, Chen 
et al., 2005b, Rietzel, Liu et al., 2004, Cai, Read et al., 2008, Tian, Wang et al., 2012). 
Inconsistencies in CT number to electron density calculations that are based on misrepresented CT 
data could contribute to dose calculation errors. In this work, the quality of AIPs for a sinusoidal 
motion was evaluated. Irregular motion could cause incorrect HU to electron density conversions 
due to the AIP formation being incomplete or containing artifacts from incorrect phase-bin 
assignment from 4D-CT. 4D-CT has been previously shown to produce errors if the patient’s 
breathing is irregular, particularly for a helical acquisition (Pan, 2005, Park, Huang et al., 2009a). 
 
The present study has shown that ten phase-bins are adequate to provide a complete MIP dataset 
for amplitudes ≤ 3.0 cm and object sizes of > 1.0 cm. Amplitudes larger than this resulted in 
incomplete data sets when ten phase-bins or less were used. This effect has been quantified in what 
is termed “the Completeness Criterion” (Equation 4.1). Equation 4.1 demonstrates that if the 4D-
CT scanner is capable of reconstruction into greater than ten phase-bins, then this should be 
pursued for small lesions undergoing large excursions, if only to compare to the ten phase-bin 
standard. The large amplitudes shown in our study (6.0 cm) represent extreme cases 
(Seppenwoolde, Shirato et al., 2002b, Sixel, Ruschin et al., 2003), though they have been observed 
clinically by the authors and lung tumour excursions up to 5.0 cm have been reported by Chen et 
al (2001). It also appears appropriate that for commissioning and QA, extreme cases should be 
considered to highlight possible problems.  
 
The clinical utility of such a criterion would be to establish the need for more phase-bins or the use 
of abdominal compression (Heinzerling, Anderson et al., 2008, Han, Cheung et al., 2010) based on 
a scout 4D scan. If the target was identified a priori as being highly mobile, the clinician could 
then use Equation 4.1 to determine if the criterion required more phase-bins than the default (10) 
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to ensure an artifact free MIP. A re-scan of the patient would then be completed with a higher 
number of phase-bins selected. The clinician could also implement a motion reduction strategy to 
minimise respiratory induced motion of the target.  
 
The computational XCAT phantom was used to further explore the experimental results obtained 
with the see-saw phantom and the Completeness Criterion presented in Sections 3.2 and 4.4.2 
respectively. The results are shown in Figure 4.7 for a 4.0 cm diaphragm extension and Figure 4.8 
for a 2.0 cm diaphragm extension with multiple tumour diameters (10 mm, 15mm and 20mm) and 
phase-bin arrangements (5, 10, 20 bins). These simulations highlight the object size / amplitude 
relationship between the number of phases used for reconstruction, and the completeness of the 
MIP. The XCAT results show that a small lesion of the order of 1.0 to 2.0 cm undergoing a 2.5 – 
4.0 cm excursion is incorrectly represented on a MIP with ‘missing’ data causing banding artifacts 
if less than 10 phase-bins are used.  
4.6. CONCLUDING REMARKS ON THE EFFECT OF MOTION ON IMAGES OBTAINED FROM 
4D-CT 
Using a moving phantom it is possible to measure the HU consistency of moving and stationary 
objects of the same dimensions and material. The properties (HU values / dimensions) of moving 
objects can then be compared the stationary objects’ properties to determine the quality of images 
and projections from 4D-CT. In the present work, the effects of motion on images and projections 
obtained from 4D-CT using a custom built see-saw phantom have been presented. Further to this, a 
derivation of a mathematical quantification of the conditions needed for a ‘continuous’ MIP for 
sinusoidal motion (Equation 4.1) has also been presented. Sinusoidal profiles were used to 
quantify the object size / amplitude ratio that would lead to undersampling when using ten phase-
bins. Figure 4.5 demonstrates that for a moving object with a period of 4 s and acquisition time per 
slice (temporal phase-bin width) of 0.22 s, an object smaller than 0.5 cm with an amplitude of 4.0 
cm will appear discontinuous on the MIP if ten phase-bins are used. For amplitudes below 3.0 cm 
(object size > 1.0 cm), ten phase-bins are sufficient to delineate an ITV and obtain an AIP 
representative of the true motion and density profile, provided the breathing pattern is regular. 
Clinically, the amplitude and size of the object being imaged are of importance. Amplitudes of 6.0 
cm are rare, but have been observed by the authors. A small lesion undergoing such a large 
amplitude excursion should be considered an extreme case. Regardless, small objects traversing 
large distances, along with the interplay of helical acquisition with object motion, can create 
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undersampling errors in the acquired MIP and AIP data sets. These errors manifest as artifacts or 
‘missing data’. Figure 4.5 demonstrates this effect for amplitudes of 1.0, 2.0 and 4.0 cm, whereby 
the magnitude of the object’s displacement between successive phase-bins is greatest for larger 
amplitudes. 4D-CT has been shown to significantly reduce the artifacts associated with respiratory 
motion in conventional CT. By binning oversampled CT data into divisions of the respiratory 
cycle observed via an external surrogate, the tumour’s excursion over a complete respiratory cycle 
can be evaluated. Projections from 4D-CT have been used for planning in SBRT with the MIP 
being used to delineate an ITV and the AIP used for dose calculation. This work has highlighted 
that the quality of these projections is based on a tumour size / amplitude relationship. The 
accuracy of these projections is critical in delivering an accurate dose to the treatment region in 
SBRT.  
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Chapter 5. The impact of motion: PET imaging 
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“Machines take me by surprise with great frequency.” 
- Alan Turing 
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5.1. INTRODUCTION 
PET is becoming increasingly used for treatment planning in SBRT in conjunction with 4D-CT. 
The impact of motion on PET imaging has been reported extensively in the literature and is 
outlined in this work in Section 2.3.3. However, less well documented is the impact the size of 
lesions will have on the known impact of motion in conventional PET. The objective of the PET 
component of this work was to assess the impact of lesion motion and size on images acquired 
with PET (Objective 3). Specifically: 
 
1.  With the limited resolution of modern PET systems, how does the lesion’s size and amplitude 
of motion affect the system’s ability to resolve the uptake hotspot?  
2. What is the reduction in apparent activity that occurs as the motion amplitude increases and 
how does this depend on the lesion’s size?  
3.  Can the volume overestimation and apparent activity reduction be recovered using 4D-PET? 
 
An experimental investigation was conducted using the phantom described in Section 3.3 with a 
customised insert containing reservoirs of various sizes filled with 18F-FDG. The objectives of this 
experimental study were: 
 
1. Observe the effect that various magnitudes of lesion displacement have on 3D PET images on 
various size lesions. 
2. Quantify the ability of the PET system to recover signal loss when using 4D PET scanning.  
 
The above measurements have only been applied to the phantom study, observation of the 
analogous effects in an anthropomorphic geometry have been derived using Monte Carlo 
techniques. Monte Carlo allows a systematic study of these effects for lesions of different sizes 
undergoing different motion amplitudes that would otherwise be impossible on real patients. 
 
The Monte Carlo portion of this study was conducted using the GATE platform (Section 2.10.3.2) 
in conjunction with the XCAT anthropomorphic phantom (Section 2.10.3.3). XCAT phantoms 
were generated with lesions in the mid to lower right lung. The lesion’s size ranged from 10 – 30 
mm with activity ratios of 10:1, 5:1 and 2:1 (lesion:background). These phantoms were then used 
as the geometry for Monte Carlo simulations. A complete Phillips allegro PET scanner was 
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modeled in GATE and used to detect annihilation quanta emanating from the XCAT phantom.  
 
Experimental results, as well as results from Monte Carlo GATE and XCAT phantom simulations 
are presented. The experimental portion of this work was the subject of a paper published in the 
Australian Physical Scientists and Engineers in Medicine (APSEM) journal. The manuscript was 
entitled Motion effects on SUV and lesion volume in 3D and 4D PET scanning by Callahan, J., 
Binns, D., Dunn, L. and Kron, T.  2011. Australas Phys Eng Sci Med, 34, 489-95. The Monte 
Carlo and XCAT studies are in preparation for publication. 
5.2. BACKGROUND  
Over the past decade, PET and CT have become invaluable tools in the evaluation of oncologic 
processes. Both imaging modalities are affected by respiratory motion. The areas most affected by 
this are the lower lungs, liver and upper abdomen. Artifacts present in these images have the 
potential to affect the correct diagnosis of diseases, delineation of target volumes for radiotherapy, 
impair staging of disease before surgery and lead to incorrect quantitation in therapeutic 
monitoring.  
 
The most common parameter used to characterise a lesion using PET is the Standardised Uptake 
Value SUV. The SUV is defined as the ratio of the tissue radioactivity concentration at time t and 
the injected activity at the time of injection (t=0) divided by the body weight. SUV indicates the 
degree of peripheral uptake by the tumour relative to the whole body background, and is therefore 
related to metabolism. Clinically, the SUVmax is an important factor (Larson, Nehmeh et al., 2005). 
The SUVmax is defined as the maximum pixel SUV within a region of interest drawn around a 
lesion. Some studies have advocated the use of SUVmax as a threshold for differentiation of benign 
and malignant lung nodules (Hubner, Buonocore et al., 1996, Garcia Vicente, Soriano Castrejon et 
al., 2010). Thus the ability to measure voxel by voxel activity is important, and motion induced 
apparent changes need to be properly accounted for.  
 
The use of PET in radiotherapy planning is a well established practice (MacManus, Nestle et al., 
2009). 18F- fluorodeoxyglucose (18FDG) PET greatly enhances the sensitivity and specificity in 
staging and diagnosis compared to CT (Benedict, Yenice et al., 2010, Lardinois, Weder et al., 
2003, Günther, Schenk et al., 2004). In the context of radiotherapy treatment planning, dual 
imaging PET/CT using FDG is being increasingly used for delineation of target volumes (Mac 
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Manus and Hicks, 2012, Mac Manus, Hicks et al., 2006, Zhang, Tachiya et al., 2010). A limitation 
of PET scanning is the whole body scan time takes roughly 20 – 30 minutes (Callahan, Binns et 
al., 2011, Callahan, Kron et al., 2011), it is necessary therefore for the patient to breath freely 
during the acquisition. Free breathing acquisition can lead to blurring artifacts and mis-registration 
between the PET and CT scans makes accurate delineation difficult (Aristophanous, Berbeco et 
al., 2012a).  
 
It is well known that patient respiratory motion causes blurring of the activity distribution of a PET 
avid lesion (Xu, Yuan et al., 2011, Xu, Xie et al., 2012, Reyes, Malandain et al., 2005, Park, 
Ionascu et al., 2008, Osman, Cohade et al., 2003, Nehmeh, Erdi et al., 2003, Nehmeh, Erdi et al., 
2004b, Nehmeh, Erdi et al., 2004a, Nehmeh, Erdi et al., 2002b, Nehmeh, Erdi et al., 2002a). The 
blurring of the activity distribution causes a decrease in the apparent activity of a lesion and an 
increase in the apparent volume. In the context of SBRT, accurate delineation of targets is 
essential. If respiratory motion is not managed in PET and PET/CT of the thorax, then the added 
functional information afforded by PET may actually be detrimental to treatment planning, 
diagnosis and assessment of tumour response following treatment. Recently, 4D PET/CT has been 
examined as a possible solution to the volume overestimation and intensity reduction associated 
with respiratory motion.  
 
A number of phantom studies have been completed to determine the benefits and pitfalls of 4D 
PET/CT acquisition. Nehmeh et al (2002b) investigated the reduction in activity smearing with 
phantom studies and found that the reduction in activity smearing afforded by 4D-PET is 
dependent on lesion size, the number of bins used for data acquisition and the lesion amplitude. 
4D-PET also improved the lesion / background ratio and consistency in the measurement of SUV. 
These studies however, evaluated these effects for target sizes larger than those typically seen in 
SBRT.  
 
A more recent study published in Radiotherapy and Oncology (Mac Manus, Everitt et al., 2013) 
demonstrated the benefits of PET/CT in planning for lung cancer radiotherapy. The study 
investigated the impact of radiotherapy planning FDG-PET/CT on management of non-small cell 
lung cancer and found that planning PET/CT frequently changed management and was associated 
with improved survival. PET/CT changed the way patients were selected for either curative or 
palliative treatments therefore allowing resources to be managed more effectively. Overall survival 
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for patients given chemotherapy in conjunction with radiation therapy (chemoRT) following 
PET/CT based planning was 77.5% and 35.6% at 1 and 4 years, respectively and was 32% for 
stage IIIA patients at 4 years compared to the 1-year and 4-year overall survival estimate of 56.8% 
and 24.9% respectively. Their study also showed that without PET, FDG-avid tumour would 
reside outside the planning target volume (PTV) in 36% of radical cases and in 25% of cases, less 
than 90% of the PTV would have received greater than 95% prescribed dose.  
 
As the use of PET/CT becomes more prevalent, it is hoped that similar increases in overall 
survival such as those reported by Mac Manus et al can be achieved for patients undergoing 
SBRT. However, an understanding of the impact of motion on the use of PET and PET/CT for 
SBRT needs to be understood. This chapter aims to identify some of these issues and present tools 
to study these effects. 
5.3. MATERIALS 
5.3.1. Experimental materials 
The upgraded QUASAR respiratory motion phantom outlined in Section 3.3 was used in 
conjunction with customised cylindrical inserts. The insert carriage contains four milled cylindrical 
reservoirs with varying diameters of 5, 10, 15 and 20 mm diameter reservoirs, each 15 mm in 
height. This phantom and custom made insert is shown in Figure 5.1. 
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Figure 5.1. Upgraded QUASAR motion phantom left with moving insert right. The insert contains 5, 10,15 
and 20 mm diameter reservoirs each 15 mm in height. An ‘L’ shaped reservoir can also be seen. 
5.3.2. Monte Carlo materials 
A full Monte Carlo computational study was conducted using both the GATE platform (Section 
2.10.3.2) and the XCAT phantom (Section 2.10.3.3). Simulations were run on the tango cluster at 
the Victorian Partnership for Advanced Computing (VPAC). The tango cluster is a large AMD 
Opteron system and consists of 111 compute nodes, each with two AMD Shanghai 2.5 GHz quad-
core processors for a total of 888 CPUs. This permitted up to 20 simulations to be run 
simultaneously, each using one quad-core processor. 
5.4. METHODS 
5.4.1. Experimental methods 
5.4.1.1 Phantom 
Each of the four cylindrical reservoirs was filled with the same concentration of 18F-FDG. No 
background activity can be used with the insert. Motion patterns of up to 4 cm peak-to-peak were 
generated with frequencies between 7.5 and 30 rpm. The full range of amplitudes and motions is 
listed below: 
 
 15 RPM / 1cm 
Reservoirs 
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 15RPM / 2 cm 
 15 RPM / 4cm 
 30 RPM / 2cm  
 7.5 RPM / 2 cm 
 
The range of 7.5 – 30 cycles per minute was chosen to represent the breathing rate most patients 
would fall into. The range of lesion displacements was also chosen to reflect a realistic range of 
tumour induced motion due to respiration. These ranges were selected based on literature 
(Seppenwoolde, Shirato et al., 2002b) and clinical experience. Each scan was re-binned into ten 
phase-bins using the respiratory trigger and reconstructed using the same parameters with 
attenuation correction applied using the co-acquired CT. 
 
 
5.4.1.2 Data acquisition 
The phantom was scanned on the GE Discovery STE 8 PET/CT using the Varian RPM system for 
gating. Un-gated 3 minute 3D PET scans were acquired of the static phantom for baseline 
measurements. A stationary helical CT scan was also acquired for attenuation correction. A 10 
minute 3D list mode PET scan with a respiratory trigger (Varian RPM) was then acquired of the 
phantom at five different sinusoidal respiratory motions (Frequency / Amplitude). 
5.4.1.3 Data analysis 
The Siemens TrueD image analysis software was used to analyse the maximum and mean activity 
Amax, Amean and volume of each lesion using a 40% Amax threshold on the un-gated (3D) scan. The 
Amax is defined as the maximum pixel activity within a region of interest drawn around a lesion. 
Correspondingly, the Amean is the average pixel activity within a region of interest. To determine 
the activities the SUVmax and SUVmean functions of the software were used, however, in the 
phantom studies, the body-mass and activity concentration normalisations are arbitrary, so the 
relative activities are the quantities of interest. In this work, the volume of interest was selected 
using a semi-automated threshold method to outline the lesion. The 40% threshold method was 
chosen to reduce operator bias and has previously been shown as a reproducible method of 
contouring tumour volumes (Bradley, Thorstad et al., 2004). The same parameters were measured 
in all ten bins of the 4D-PET scan. The average Amax, Amean and lesion volume were compared to 
the values obtained from the 3D-PET scan. All values were then compared to the baseline data 
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corresponding to the maximum and mean activity recorded for a static phantom. 
5.4.2. Monte Carlo simulations 
As no patients are experimentally possible for a systematic investigation to assess the impact of 
lesion size and motion on images acquired with PET, Monte Carlo methodologies using the GATE 
platform were pursued. 
5.4.2.1 XCAT phantoms 
Firstly, XCAT anthropomorphic male torso phantom datasets were created with simulated 
respiratory and cardiac motion. Each phantom was created with a pixel size of 5 x 5 mm2 with a 
slice thickness of 5 mm resulting in a phantom with dimensions of 200 x 128 x 128 pixels. The 
respiratory period was kept constant at 4 s with a total of 40 output frames (0.1 s in length each). 
Both CT attenuation and activity phantoms were generated. The CT attenuation phantoms were 
used to define the material properties for the geometry in a GATE simulation. The activity 
phantoms were used to translate the voxel values for specific organs / lesions into activities in the 
GATE simulations.  
 
Five diaphragm displacements that control the deformation and translation of the organs / lesions 
affected by respiratory motion were simulated. Phantoms with diaphragm displacements of 0 (no 
motion activated), 0.5, 1.0, 2.0 and 3.0 cm were then created. Amplitudes of greater than 3 cm 
were not simulated as the XCAT phantom has a maximum diaphragm extension of 3.0 cm. For 
each of these amplitudes, spherical lesions of 0.5, 1.0, 2.0 and 3.0 cm diameters were added to the 
mid-to-lower right lung close to the diaphragm so that the associated lesion amplitude matched 
closely to the diaphragm’s extension (see Figure 5.2). This resulted in four phantoms (with 
different lesion sizes) per diaphragm extension.   
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Figure 5.2. Location of the lesion within the right lung for GATE simulations. 
 
5.4.2.2 Construction of the Phillips Allegro PET scanner 
A Phillips Allegro scanner was modelled with GATE. The parameters for the input file are based 
on manufacturer’s specifications and reported values from (Lamare, Turzo et al., 2006). This 
scanner model was chosen as Lamare et al have previously extensively benchmarked this scanner 
in GATE against measured data. The Phillips Allegro scanner's technical features and physical 
performance are outlined in Table 5.1 and Table 5.2 respectively. The scanner consists of 28 flat 
blocks arranged in a ring, with each block made of 22 x 29 Gadolinium orthosilicate (GSO) 
crystals. Each crystal element has a surface area of 4 x 6 mm2 and is 20 mm thick. A schematic of 
this scanner, created in GATE is shown in Figure 5.3. To create the scanner in GATE, an input file 
was generated outlining the scanner’s geometrical properties, detection systems and signal 
processing specifications. These values were taken from Table 5.1with the signal processing 
variables defined by (Lamare, Turzo et al., 2006). The Phillips Allegro / GEMINI PET scanner 
was simulated in GATE and used in conjunction with the XCAT phantom. Lamare et al have 
previously evaluated the accuracy of the detection system through a comparison of simulated and 
measured results obtained with the Allegro / GEMINI systems for a number of NEMA NU2-2001 
performance protocols. These included, spatial resolution tests, sensitivity and scatter fraction 
comparisons. In addition, an approximate model of the system's dead time at the level of detected 
single events and coincidences was developed in an attempt to simulate the count rate related 
LESION  
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performance characteristics of the scanner. The group also developed a reconstructed image 
quality protocol which was used to assess the overall performance. Their results indicated an 
agreement of less than 3 % in scatter fraction, with a difference between 4 % and 10 % in the true 
and random coincidence count rates respectively, over a range of activity concentrations and under 
various imaging conditions. Simulated and measured count rates demonstrated less than 8% 
difference (noise equivalent count rates). The image quality validation study revealed a good 
agreement in signal-to-noise ratio and contrast recovery coefficients for a number of different 
volume spheres and two different (clinical level based) tumour-to-background ratios.  
 
 - - 156 - - 
Table 5.1. Technical features of the Phillips Allegro PET scanner (Tarantola, Zito et al., 2003). 
 
Feature Allegro Factory Specifications 
Number of rings 28 
Ring diameter (mm) 860 
Patient port (mm) 565 
Crystals number 17,864 
Crystals material Gadolinium orthosilicate (GSO)  
Crystal size (mm) 4 x 6 x 20 
PMT number 420 
Crystals/block No blocks 
Energy window width (keV) 435-590 
Coincidence window (ns) 8 
Acquisition mode Full 3D 
Transaxial FOV (mm) 576 
Axial FOX (mm) 180 
Number of image planes 90 
Slice Thickness (mm) 2 
Septa material N/A 
Septa dimensions N/A 
 
 
Table 5.2. Physical performance and other features of the Philips Allegro PET scanner (adapted from 
(Tarantola, Zito et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Performance Allegro Factory Specifications 
Transaxial resolution   
FWHM (mm) at 1 cm 4.8 
FWHM (mm) at 10 cm 5.9 
Axial resolution  
FWHM (mm) at 0 cm 5.4 
FWHM (mm) at 10 cm 6.5 
Scatter fraction (%)  25 
System sensitivity (net trues) (cps/Bq/mL) 19.0 
Energy resolution (FWHM)  15% 
Filtered  
Backprojection YES (3D) 
Iterative algorithms FORE / OESM, 3D-RAMLA 
Transmission source 137Cs 
Source activity (MBq) 740 
Source geometry Point 
Transmissive energy window (keV) 600 -720 
Whole body scan length (cm) 198 
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Figure 5.3. (a) Schematic of the Phillips Allegro scanner detection geometry in GATE. (b) The same scanner 
with the voxelised XCAT phantom shown. 
 
5.4.2.3 Incorporating the XCAT phantom into GATE 
Incorporating the XCAT as the phantom geometry in GATE involved converting all XCAT 
datasets to 16-bit integers and using a range translator to convert pixel values to materials used by 
gate (i.e. organ compositions). Following this, activity distributions were assigned to the tumour 
and lungs for each phantom dataset. The phantom was then imported using an ‘InterFile’ format 
where the number of frames, dimensions of the phantom, attenuation and activity translators are 
defined. The centre of the XCAT phantom was placed at the origin (0,0,0) of the ‘world’ volume. 
The C++ class described by Descourt et al (2006) was then implemented to read successive XCAT 
datasets during the Monte Carlo simulation. This process is shown in Figure 5.4. This process was 
then repeated for each phantom set, consisting of a particular amplitude and lesion size depending 
on the simulation. The activity of the tumour was set to 10 kBq with the lung background activity 
(a) (b) 
Cylindrical ring detector bank
Voxelised XCAT phantom inside cylindrical bore.
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set to 1, 2 or 5 kBq to define different activity ratios. The rest of the voxel activities were set to 
zero, equivalent to no background outside the lung to decrease the simulation times which take 
approximately 2-3 days using 20 processors per simulation. Figure 5.5 and Figure 5.6 show a 
selection of XCAT phantoms that were generated and used as the phantom geometry in the Monte 
Carlo GATE simulations.  
 
 
 
Figure 5.4. A diagram illustrating the way XCAT phantoms are incorporated into the GATE Monte Carlo 
framework.  
 
5.4.2.4 PET Acquisition settings 
For every diaphragm amplitude and tumour size (Table 5.3) PET data was acquired for 600 
seconds with the phantom’s geometry being updated every 0.1 s. This resulted in 150 (600/4) full 
4 s respiratory cycles being simulated during the course of a simulation.  
5.4.2.5 4D- PET simulations 
4D-PET simulations are presently unavailable with the GATE software. To simulate a 4D 
Load next phantom series 
corresponding to time-slice 0.1 to 
0.2 s and repeat until total 
simulation time is reached. 
1 3D phantom dataset 
(200x128x128) (0 - 0.1 s) 
MC simulation for 0.1 s
Pause simulation 
PET Detector ring 
XCAT phantom 
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acquisition, a novel methodology was developed. To begin, each simulation was made to run for 
no longer than the XCAT’s respiratory period (4 s) so that the inbuilt job splitter could be used to 
split the single respiratory period into distinct phases. To achieve an equivalent level of counts as 
the previous 3D studies, which are acquired over 600 s, the activity of the target and background 
was increased by the ratio of scan lengths i.e. a factor of 150 (600/4). Using the GATE job splitter, 
a single simulation covering 4 s of acquisition was split into separate simulations of 5, 10 or 20 
individual files. Each macro file then corresponds to the total scan time, divided by the number of 
splits. Therefore, each data set produced corresponds to the data akin to that found in a particular 
phase of the respiratory cycle of a 4D-PET acquisition. 
 
 
Table 5.3. Complete list of simulations with the XCAT phantom and GATE Monte Carlo platform.  
 
Phantom No. Max. Diaphragm 
Amplitude (cm) 
Lesion diameter (mm) Activity Ratios  
(lesion / background) 
Simulation type 
0 0 10, 20, 30 10:1, 5:1, 2:1 3D and 4D (5, 10 and 20 bins) 
1 0.5 10, 20, 30 10:1, 5:1, 2:1 3D and 4D  (5, 10 and 20 bins) 
2 1.0 10, 20, 30 10:1, 5:1, 2:1 3D and 4D  (5, 10 and 20 bins) 
3 2.0 10, 20, 30 10:1, 5:1, 2:1 3D and 4D  (5, 10 and 20 bins) 
4 3.0 10, 20, 30 10:1, 5:1, 2:1 3D and 4D  (5, 10 and 20 bins) 
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Figure 5.5. XCAT phantoms generated for use in the GATE Monte Carlo simulations, showing a (a) 10 mm, (b) 20 mm and (c) 30 mm diameter lesion residing in the 
lower right lung with a 10:1 activity ratio. The phantom’s diaphragmatic amplitude was varied from 0 to 3.0 cm. Note: the motion in GATE occurs in real-time, and 
depictions of the motion shown in these images are used to indicate the magnitudes of lesion motion that were set using the XCAT phantom and therefore, the motion that 
occurred during the Monte Carlo PET simulations.  
(a) 
(b) 
(c) 
3.0 cm amp. 30 mm 2.0 cm amp. 30 mm 1.0 cm amp. 30 mm 0.5 cm amp. 30 mm 0.0 cm amp. 30 mm 
0.0 cm amp. 20 mm 0.5 cm amp. 20 mm 1.0 cm amp. 20 mm 2.0 cm amp. 20 mm 
. 
3.0 cm amp. 20 mm 
3.0 cm amp. 10 mm 2.0 cm amp. 10 mm 1.0 cm amp. 10 mm  0.5 cm amp. 10 mm   0.0 cm amp. 10 mm  
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Figure 5.6. XCAT generated phantoms used in Monte Carlo GATE simulations. Activity ratios of 5:1 and 
2:1 (lesion:background) respectively are shown. Here phantoms with the diaphragm amplitude set to 3.0 cm 
are shown, as stated previously, the motion is in real-time during the Monte Carlo simulation and these 
average intensity phantoms are shown for display purposes only to highlight the degree of motion that was 
assigned to the phantoms. The complete list of XCAT phantoms created for use with GATE is shown in 
Table 5.3. 
 
5.4.2.6 Data output 
Each PET simulation in GATE results in a ‘.root’ file. ROOT is an object oriented framework 
written in C++ which provides all the functionality needed to handle and analyse large amounts of 
data in an efficient manner. ROOT allows histogramming, curve fitting, graphics and visualisation 
classes and function evaluation to be performed in batch mode or parallel processing 
environments. The ROOT files output from GATE contain the complete history of every particle 
(primary and secondary) generated during the course of a simulation. The GATE system creates 
the complete list of singles (annihilation photon hits), false positive coincidences and true 
coincidences.  
10 mm lesion 
3.0 cm amp. 5:1 act. rat. 
10 mm lesion 
3.0 cm amp. 2:1 act. rat. 
20 mm lesion 
3.0 cm amp. 5:1 act. rat. 
20 mm lesion 
3.0 cm amp. 2:1 act. rat. 
30 mm lesion 
3.0 cm amp. 5:1 act. rat. 
30 mm lesion 
3.0 cm amp. 2:1 act. rat. 
(a) 
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5.5. RESULTS  
5.5.1. Experimental results 
Figure 5.7 shows the apparent activity for the reservoirs displayed in Figure 5.1 scanned in both 
3D (top row) and 4D modes. In 3D mode, the blurring of the apparent activity of each reservoir is 
evident as the amplitude of motion increases. For the largest amplitude, Figure 5.7 (c), the impact 
of the motion profile can also be seen, with the ‘dumbbell’ shape occurring as the phantom spends 
more time at peak exhale and inhale (sinusoidal motion).  
 
Figure 5.7 (bottom row) demonstrates the reduction in motion blurring that can be achieved using 
4D scanning techniques. A single phase-bin of data allows a closer approximation of the true 
lesion size to be ascertained even for large amplitude motions and smaller lesions. Figure 5.8 
shows a 4 cm displacement split into ten phases. At the inter-maxima / minima phases, the blurring 
of the 5 and 10 mm diameter lesions can be seen to increase due to residual motion associated with 
an increased target velocity coupled with partial volume effects.  
 
Figure 5.9 (a) shows the effect of lesion motion and size on the reduction in Amax recorded. The 
apparent Amax can be seen to decrease with increasing amplitude irrespective of the lesion size. The 
differences in Amax for different lesion sizes with no motion is attributed to the partial volume 
effect, which is known to be more severe for smaller lesions (Soret, Bacharach et al., 2007). Figure 
5.9 (b) shows the Amax recorded using 4D-PET. Figure 5.9 (c) shows the increase in the apparent 
volume of a lesion if 3D scanning is used. Figure 5.9 (d) shows the degree of true lesion volume 
recovered when 4D scanning is used. Figure 5.10 shows the impact of various respiration rates on 
the Amax reported. Changing the respiration rate can be seen to have little effect with the 
determination of the Amax for each respiration rate showing little variation.  
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Figure 5.7. 3D (top row) and 4D (bottom row) PET images of (a) a 15 RPM 1cm motion, (b) a 15 RPM 2 cm 
motion and (c) a 15 RPM 4.0 cm motion. Data from the 1st phase bin was taken for the 4D data. 
 
 
Figure 5.8. 4 cm of displacement split into ten phase-bins. 
(a) (b) (c) 
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Figure 5.9. (a) Apparent lesion maximum activity normalised to the injected activity concentration as a 
function of motion displacement and lesion size for a 3D scan. (b) The activity recorded through a 4D 
acquisition. (c) Volume overestimation as a function of lesion size and amplitude for a 3D scan. (d) Volume 
recovery with a 4D scan. 
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Figure 5.10. The impact of the motion frequency rate on activity, Amax, normalised to the injected activity 
concentration, for three motion frequencies (2 cm motion amplitude).  
 
5.5.2. Monte Carlo and XCAT simulations 
The impact of motion in PET images incorporating anthropomorphic geometry, and the inclusion 
of lung background activity, was systematically investigated using both the XCAT phantom and 
the GATE Monte Carlo package for Geant4. The method of this investigation is outlined in 
Section 5.4.2. Table 5.3 outlines the complete list of simulations that were carried out. Data 
presented in this section is in the form of activity distribution images and line profiles through the 
centre of the lesion in the direction of motion (SI). Figure 5.11 shows activity distribution images 
for a 30 mm tumour located in the lower right lung influenced by respiratory motion. The first 
image in this series, Figure 5.11 (a) shows the activity distribution of a static 30 mm diameter 
tumour. The tumour’s activity was set to 10 kBq with the lung background activity set to 1 kBq. 
Figure 5.11 (f) indicates the reduction in maximum activity over a line profile through the centre 
of the lesion along the dashed line shown in the panels (a) – (e). The width of these profiles 
indicates the increase in apparent lesion size. Figure 5.11 (g) shows 3D isosurface representations 
with isosurfaces at 0.1 %, 20% and 60 % of the maximum activity. Figure 5.13 shows similar data 
for a 10 mm diameter lesion. Here, a static lesion and a lesion undergoing a 3.0 cm motion 
amplitude are shown. The differences between the experimental and Monte Carlo aspects of this 
work can be attributed to the anthropomorphic geometry, used in the Monte Carlo study as 
opposed to the phantom based experimental work.  
GE STE8 – Maximum Activity
 
 
 
 
 
Amax 
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5.5.2.1 3D-PET GATE activity distributions for a 10:1 (tumour:background) activity ratio 
Figure 5.11 shows a typical set of data output from a GATE simulation using the XCAT phantom. 
In this saggittal slice taken through the centre of the lesion, the uptake hotspot of the 30 mm 
diameter lesion can be seen against the background of the lung. As the amplitude of motion 
increases, the reduction in the apparent activity can be seen in the line profiles (Figure 5.11 (f)). 
Each of these images has its colour scale maximum set to the maximum activity recorded in the 
stationary case. The colour bar for each image demonstrates the maximum reduction in apparent 
activity normalised to the stationary case for the 3.0 cm motion. This can also be seen in the line 
profiles, Figure 5.11 (f). Figure 5.12 shows 3D isosurface representations of a static 30 mm 
diameter lesion and a lesion moving with 3.0 cm motion amplitude.  
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Figure 5.11. Sagittal activity distributions for a 30 mm diameter tumour moving in the SI direction with a 
sinusoidal motion profile. The tumour’s activity was set to 10 kBq, with the background of the lungs set to 1 
kBq. (a) Static 30 mm diameter tumour, (b) 0.5 cm amplitude, (c) 1.0 cm amplitude, (d) 2.0 cm amplitude 
and (e) a 3.0 cm amplitude. (f) Line profiles through the centre of the lesion as indicated by the vertical 
dashed line in (a) – (e). The colourbars show the normalised activity with respect to the stationary case. The 
coarseness of the resolution in these images arises from the 5 mm3 voxel size of the XCAT phantom. 
 
(a) (b)
(d)(c) 
(e) (f) 
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Figure 5.12. 3D isosurfaces of constant activity levels of 0.1 (green), 20 (red) and 60 % (blue) of the 
maximum activity demonstrating the increase in apparent lesion size. (a) Static 30 mm lesion and (b) the 
same lesion with a 3.0 cm amplitude. 
                
                       
Figure 5.13. Sagittal activity distributions for a slice through the centre of a 10 mm diameter tumour moving 
in the SI direction with a sinusoidal motion profile. The tumour’s activity was set to 10 kBq, with the 
background of the lungs set to 1 kBq. (a) Static 10 mm diameter tumour, (b) 3.0 cm amplitude, (c) line 
profiles showing overestimation of lesion size and reduction in apparent activity. Note the colour bar scale in 
image (b) is normalised to the maximum activity found in the static case. The background activity of the 
lung can also be seen. Compared to the 30 mm lesion, the reduction in apparent activity is grater for a 
moving lesion of smaller dimensions. 
(a) (b)
(c) 
(a) (b)
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Figure 5.14 shows line profiles for the Monte Carlo simulations. All cases with the lesion in 
motion show a reduction in activity for all lesion sizes and activity ratios simulated. The largest 
recorded reduction in apparent activity was found to by 42 % for a 10 mm lesion moving with an 
amplitude of 3.0 cm. In comparison to the experimental results presented in Figure 5.9 (a), the 
degree of apparent activity reduction is, on average, lower. However, both methods showed a 
strongly correlated reduction in activity associated with increasing lesion motion. For activity 
ratios of 10:1 and 5:1, the 10 mm lesion suffered a greater reduction in activity compared to the 20 
and 30 mm lesion, respectively.  
 
Interestingly, for a 2:1 activity ratio, the increased lung activity results in increased activity ‘spill-
over’ into the tumour from partial volume effects which negates some of the reduction in apparent 
activity as a result of motion. This is evident in the fact that for a 2:1 activity ratio, the 10 mm 
lesion is affected the least, compared to the 20 and 30 mm lesions respectively. The ‘spilling-in’ of 
activity from lung regions surrounding the lesion makes the smaller lesions appear more 
aggressive then they are (Soret, Bacharach et al., 2007) which in turn will cause one to think that 
there may be more viable tumor tissue within the tumor center than there really is and appears to 
offset the reduction in apparent activity due to motion. This effect is illustrated below in Figure 
5.15 taken from (Soret, Bacharach et al., 2007).  
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Figure 5.14. PET scans simulated with the GATE system using the XCAT phantom as the source. A 
consistent reduction in the apparent activity can be seen for all activity ratios as the amplitude increased 
beyond 1 cm. (a) Reduction in maximum activity across a line-profile through the centre of the lesion for a 
10:1 activity ratio, (b) 5:1 activity ratio and (c) 2:1 activity ratio.  
 
 
 
Figure 5.15. Illustration of ‘spill-in’, ‘spill-out’ effects taken from (Soret, Bacharach et al., 2007). The 
measured image (D) of the true activity distribution (A) is the result of the sum of the spill-out (B) and spill-
in (C).  
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5.5.2.2 4D simulations for a 10:1 activity ratio and 10 mm lesion size. 
Phase-bin line-profiles through the centre of lesion for 4D simulations are shown in Figure 5.16 - 
Figure 5.18. The reduction in counts increases the noise of a real 4D simulation, and as such the 
4D data is often acquired over an extended period of time. Figure 5.16 shows five phase-bin data 
sets of a 10 mm diameter lesion with an activity 10 kBq (10:1, lesion:background). The diaphragm 
extension in the XCAT phantom input data was set to 3.0 cm with a 4 s respiratory period. With 
five phase-bins a representation of the tumour’s excursion over a complete respiratory cycle can be 
acquired. Figure 5.17 shows the same data using ten phase-bins. With ten phase-bins, there is 
increased information about the position of the lesion over a respiratory cycle with some residual 
blurring occurring at phases where the velocity of the lesion is at a maximum. The residual 
blurring results in a 7 % (approximate) reduction in apparent activity compared to the maximum 
inhale / exhale phases. Figure 5.18 shows the same data with 20 phase-bins. Using greater than ten 
phase-bins is not recommended as there is an increase in noise in the phase-bin data due to the 
reduction in counts per phase-bin. This is illustrated in Figure 5.18. If the volume of the lesion was 
to be delineated on the 0% phase-bin, the lesion would appear larger than in the 3D case.  
 
It must be noted that the partial volume effect associated with the small lesion size (10 mm) causes 
the lesion to appear larger than in reality due to increased activity spill-over into the surrounding 
These effects have previously been characterised by (Soret, Bacharach et al., 2007).  
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Figure 5.16. Line profiles through the centre of a 10 mm diameter lesion over 5 phase-bins from a 4D PET 
simulation. The 3D line profile is shown with a blue dashed line and circle markers. The displacement of the 
diaphragm was set to 3.0 cm with a 4 s respiratory period and the lesion’s activity set to 10 kBq with the 
lung background at 1 kBq. (a) All phase-bin and 3D simulation line profiles superimposed, (b) the 0% 
phase-bin from 4D-PET compared with the 3D simulation. 
 
 
(a) – 10 mm lesion, 3.0 cm 
amplitude, 5 phase-bins per 
complete respiratory cycle 
(b) – 10 mm lesion, 3.0 cm 
amplitude, 0% phase-bin 
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Figure 5.17. Line profiles through the centre of a 10 mm diameter lesion over 10 phase-bins from a 4D PET 
simulation. The 3D line profile is shown with a blue dashed line and circle markers. The displacement of the 
diaphragm was set to 3.0 cm with a 4 s respiratory period and 10:1 activity ratio. (a) All phase-bin line 
profiles superimposed, (b) the 0% phase-bin from 4D-PET compared with the 3D simulation. 
 
(a) – 10 mm lesion, 3.0 cm 
amplitude, 10 phase-bins per 
complete respiratory cycle 
(b) – 10 mm lesion, 3.0 cm 
amplitude, 0% phase-bin 
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Figure 5.18. Line profiles through the centre of a 10 mm diameter lesion over 20 phase-bins from a 4D PET 
simulation. The 3D line profile is shown with a blue dashed line and circle markers. The displacement of the 
diaphragm was set to 3.0 cm with a 4 s respiratory period and 10:1 activity ratio. (a) All phase-bin line 
profiles superimposed, (b) the 0% phase-bin from 4D-PET compared with the 3D simulation. With 20 phase 
bins, there is a considerable increase in noise due to the reduction in counts per phase-bin.  
 
(a) – 10 mm lesion, 3.0 cm 
amplitude, 20 phase-bins per 
complete respiratory cycle 
(b) – 10 mm lesion, 3.0 cm 
amplitude, 0% phase-bin 
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5.6. DISCUSSION 
5.6.1. Experimental phantom study 
In the experimental work presented in this chapter, the upgraded QUASAR phantom (Section 3.3) 
was utilised to observe a relationship between the degree of lesion displacement and Standardised 
Uptake Value (SUV). 4D PET was then implemented to determine the degree of SUV restoration 
and true lesion volume recovery. The results, shown in Figure 5.9 demonstrated that with 
increasing lesion excursion the SUVmax and SUVmean decreased and the volume increased. Using 
un-gated 3D scanning there was a clear correlation between a lesion’s apparent size and the 
magnitude of motion. For a 4 cm amplitude motion there was up to a seven-fold increase in the 
measured volumes of lesions compared to the baseline. Across all lesion sizes and displacements, 
gated scans completely restored the volume overestimation as compared to the static case.  
 
There was also a clear correlation between increased lesion motion and a loss of SUV on the un-
gated scans when compared to the baseline static case. The smaller lesions (5 and 10 mm) showed 
a greater drop in SUVmax at the highest displacement when compared to larger lesions, 15 and 20 
mm diameters, respectively. 
 
The study showed that by using 4D imaging, the SUVmax, SUVmean and volume were mostly 
recovered regardless of the amount of lesion displacement. In the experimental portion of this 
work, it has been shown that given the significant loss in SUV signal observed in moving lesions it 
will be difficult to use absolute SUV as a determinant of malignancy in lung cancer. This would be 
seen to complicate attempts to auto contour lesions based on a percentage of SUVmax or a fixed 
SUV threshold. Respiratory Gated PET scanning was shown to improve the recovery of the 
SUVmax and reduce the distortion in lesion volume associated with motion. Furthermore, changes 
in SUV between two scans are used to indicate changes in tumour metabolism. A difference in 
motion amplitude due to a change in breathing pattern / depth could mimic changes in metabolism. 
4D-PET is therefore recommended where lesion motion is in excess of 1 cm. 
5.6.2. Computational simulations to determine the effect of motion on images acquired with PET 
In this work, Monte Carlo simulations were utilised to systematically evaluate the effect of motion 
on images acquired with PET. The results are shown in Section 5.5.2.   
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5.6.3. Simulation results: GATE 3D PET Simulations 
Over all amplitudes and tumour sizes simulated, there was a decrease in the maximum activity 
found over a line profile of the tumour that increased with amplitude. Examples of saggittal 
activity distribution images for a 30 mm diameter lesion undergoing respiration induced motion 
are shown in Figure 5.11. The activity distribution correspond to a 600 s PET acquisition of 
moving XCAT 3D phantoms with lesions of varying diameter in the lower right lung. In this 
scenario the tumour’s activity was set to 10 kBq with the background lung activity set to 1 kBq. 
The lesion is visible over all amplitudes with distinct blurring for diaphragm displacements greater 
than 2.0 cm. Figure 5.14 shows a measurable motion related reduction in apparent activity can be 
seen for diaphragm amplitudes greater than 1.0 cm. A summary of the results obtained is presented 
in Table 5.4. From Table 5.4 it can be seen that there is a consistent reduction in activity as the 
lesion’s motion amplitude is increased. The largest reduction of which occurred of this reduction 
was on, average largest for the 10 mm lesion 16.6 % over all amplitudes and activities (lesion and 
background) simulated. On average, the 20 and 30 mm lesions suffered a 14.4 % and 10.7 % 
reduction respectively, over all amplitudes and activity ratios simulated. 
 
Table 5.4. Summary of the 3D PET MC results as a function of lesion size, amplitude, and activity ratio with 
respect to the background. 
Lesion Diameter (cm) Amplitude (cm) Reduction in activity relative to static 
case (%) 10:1, 5:1, 2:1 
1.0 0.5 16 12 3 
- 1.0 20 14 9 
- 2.0 43 32 8 
- 3.0 42 36 16 
     
-2.0 0.5 2 10 2 
- 1.0 15 11 10 
- 2.0 23 27 5 
- 3.0 41 45 25 
     
3.0 0.5 5 3 11 
- 1.0 6 4 14 
- 2.0 11 9 18 
- 3.0 29 24 27 
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For smaller lesions, the partial volume effect is exacerbated where even for a static case, the lesion 
will appear larger and of lower activity than it really is. The partial volume effect strongly depends 
on the size of the tumor. The smaller the lesion, the greater the underestimation of the uptake. As a 
result of this, different size tumors with the same uptake value yield tumor images with different 
degrees of brightness and hence different estimated uptake values. This effect is compounded even 
further when a small lesion is undergoing a large displacement and suffers motion related activity 
smearing along with increased partial volume effects.  
 
‘Spill-out’ effects, where activity spills out from the lesion to the surrounding tissue and ‘spill-in’ 
effects, where activity spills in from surrounding tissues could be seen as both the size of the lesion 
and activity of the lung were varied. Spilling in of the activity increased as the background activity 
of the lung increased falsely negating some of the activity lost through motion related smearing.  
5.6.4. Simulation Results: GATE 4D-PET simulations 
At present, the GATE platform does not allow for 4D simulations to be performed. However, one 
can simulate a 4D acquisition in the following manner. If the respiratory period of the XCAT 
phantom is 4 s then one can simply set the total simulation time to 4 s. The jobsplitter in GATE 
can then be used to set the number of phase-bins, each corresponding to a particular portion of the 
phantom’s anatomical state over a complete respiratory cycle. This obviously requires the lesion 
and background activities to be increased. The factor to be applied is dependent on the total time 
difference between a full and ‘gated’ simulation (Tf and TG respectively). For example, the original 
simulations here had a total scan time of 600 s with the lesion’s activity set to 10 kBq and the 
background activity set to 1 kBq. To ensure the same number of counts in the gated simulation, the 
lesion and background activities must be increased by a factor of Tf / TG = 600/4 = 150. The 
jobsplitter can then for example set 5 jobs to be assigned, this means that the first job covers the 
respiratory cycle time 0 – 0.8 s, the second job 0.8 – 1.6 and so forth. This is the method by which 
gating was simulated in these experiments and to the author’s knowledge has not been described 
before. 
 
4D simulations for a 20 mm lesion (3.0 cm diaphragm displacement), with an activity ratio of 10:1 
(lesion:background) are shown in Figure 5.16 - Figure 5.18. With a high activity ratio between the 
lesion and the background it is possible to increase the number of phase-bins, however, lower 
activity ratios require an increased scan time or smaller number of bins. For 5, 10 and 20 phase-
bins, this work demonstrates that motion related artifacts can be mitigated with the use of gating. 
For most clinical applications, 5 – 10 phase bins are sufficient to capture the spatio-temporal data 
needed to inform decisions without overly increasing the scan time.  
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5.6.5. Limitations and future direction for the use of Monte Carlo and computational phantoms 
A limitation of the work pertaining to the use of the XCAT phantom in conjunction with the 
GATE platform is the large computational resources required. A voxel size of 5 mm3 for the 
XCAT phantoms was chosen to provide a balance between computational resources and the 
current capabilities of the GATE platform. Further work would make use of the data already 
obtained here and repeat the simulations with reduced voxel dimensions. This work would 
determine what effect, if any, this has on the impact of motion on images acquired with PET. 
5.6.6. Comparisons between results obtained via experimental and Monte Carlo methodologies 
In the two methodologies (phantom study, Monte Carlo) used to assess the impact of motion on 
images obtained with PET there was a decrease of apparent activity associated with lesion motion 
and the smearing of the apparent activity distribution. An overall increase in apparent lesion size 
was also found that was strongly correlated to the lesion’s amplitude of motion when using 3D 
scanning. Figure 5.19 shows a comparison in the reduction in activity as a function of lesion 
motion amplitude for the two methodologies with a 10 and 20 mm diameter lesion used for 
comparison. Differences between the data arise due to the varying investigation methodologies. 
The phantom experiment was conducted with no background activity and in a phantom geometry 
and the Monte Carlo simulation provided an accurate anatomical geometry with a lung background 
activity present. Overall, both methods show an associated decrease in apparent activity that is 
strongly correlated with increasing lesion motion amplitude though the magnitude is varied.  
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Figure 5.19. Comparison of the reduction in maximum activity measured as a function of lesion amplitude 
for the two methods. Lesions with diameters of 10 and 20 mm are shown with the lesion activity set to 10 
kBq in the Monte Carlo simulations. Experimental, in phantom results showed the highest decrease in 
activity compared to Monte Carlo. Note that a 4 cm motion amplitude was not possible in the Monte Carlo 
simulation due to limitations in the XCAT phantom’s motion simulation. 
 
5.6.7. Comparisons to published data 
It is understood that the apparent SUV of PET avid lesions residing in the lungs is reduced due to 
respiratory induced motion in a conventional PET scan (Nehmeh, Erdi et al., 2002a, Nehmeh, Erdi 
et al., 2004a, Nehmeh, Erdi et al., 2003). In this study it has been shown via Monte Carlo methods, 
in conjunction with computational phantoms that the effect of motion on images acquired with 
both conventional and 4D PET is significant for small lesions typical of SBRT. Furthermore, the 
ability to accurately measure a small lesion’s SUV is hampered by partial volume effects, which 
serve to make even a static lesion appear larger and cooler than it is in reality.  
 
PET/CT is now emerging as a way to provide functional, as well as anatomical, localisation of 
lung lesions. In a large patient study (n = 26), Lupi et al (2009) investigated gated PET/CT and 
found that regardless of the gating method chosen, SUV showed a marked increase from a mean of 
9.2 ± 6.9 in conventional PET to an average of 13.4 ± 11.7 over the gated studies. Their study 
concluded that in lung cancer, triggering procedures increase the signal to noise ratio, and that the 
increase in SUV determined by 4D-PET is very variable.  
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5.6.8. Clinical consequences 
In this work it has been demonstrated that the effect of motion on PET images is to make a PET-
avid lesion appear fainter and larger against the background. Respiratory motion tends to reduce 
the SUV and therefore has the potential to cause radiotherapy planning errors, affect the correct 
diagnoses of disease and impair staging of disease. Incorrect clinical analysis of malignancies and 
false lesion sizes also has an impact on therapeutic monitoring.  
 
A number of studies have advocated SUVmax thresholds as a differentiator for benign and 
malignant lesions. Examples of this method have been reported in the literature where an SUVmax 
of less than 2.5 is used to differentiate between benign and malignant lesions in the lung (Garcia 
Vicente, Soriano Castrejon et al., 2010, Hubner, Buonocore et al., 1996). This work has shown 
that the SUV metric can break down due to motion related effects for small lesions undergoing 
large displacements. Therefore, an accurate measurement of SUVmax is often not possible. With 
4D-PET and PET/CT however, consistently higher SUVs have been found upon the use of motion 
correction (Lupi, Zaroccolo et al., 2009).  
 
The results presented in this work demonstrate that when the effect of motion is combined with a 
small-sized lesion, which is also subject to a partial volume effect, then a lesion with uptake of a 
metabolic tracer can become falsely negative or falsely positive if the lesion includes a necrotic 
region, and activity ‘spill-in’ is prevalent. As PET is often used to assess tumour response to 
radiation therapy, SUVs based on pre and post treatment may be unreliable as a result of motion 
blurring. In the case of radiation therapy treatment planning, the contours of a lesion as seen on a 
PET image may encompass more than the real metabolically active part of the tumor due to the 
limited spatial resolution in PET images (~5 mm). In PET/CT, the fusion of the PET and CT 
images usually clearly shows this discrepancy between the tumor contours as displayed on the CT 
image and those on the PET image. However, the contours seen on the CT image may not 
delineate the metabolically active part of the lesion as CT does not show metabolically active 
tissue. Only high-resolution PET imaging provides an accurate delineation of the metabolically 
active part of the tumor. The results presented here also establish that the GATE platform can be 
used to simulate a 4D PET acquisition using the XCAT phantom and the jobsplitter. To the 
author’s knowledge, this has not been achieved prior to this work.  
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Chapter 6. The impact of motion:  
Treatment planning and dose calculation 
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“The first principle is that you must not fool yourself  
and you are the easiest person to fool.”  
― Richard Phillips Feynman 
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6.1. INTRODUCTION 
SBRT of the lung is not only complicated by motion, but also a direct calculation of dose is 
difficult due to the lack of electronic equilibrium (Section 2.9.1). In the context of radiotherapy of 
lung tumors, this may affect the minimum dose received by lesions and is particularly important 
when prescribing to covering isodoses. Furthermore, dose calculation in areas of heterogeneous 
density is a complicated process. In the context of lung cancer, the lack of electronic equilibrium at 
interfaces between the low density lung and tumour is known to cause an underdosage at the 
periphery of the lesion (Metcalfe, Kron et al., 2007).  
 
Part 1 of this work evaluated the extent of underdosage to lung lesions using Monte Carlo 
radiation transport methods for a range of tumour sizes, field sizes and positions relative to the 
chest-wall. The degree of peripheral underdosage is shown to vary with positional parameters such 
as depth behind the chest-wall (due to secondary build-up effects). Therefore, the 2nd part of this 
study explicitly models the cumulative effect where motion changes this parameter. This method is 
akin to incorporating data from 4D-CT into dose calculation.  
 
Poor image quality and mismanagement of motion can have detrimental consequences for 
treatment planning and delivery. At present, the incorporation of 4D information from 4D-CT into 
dose calculation is not facilitated in most treatment planning systems. As such, alternate methods 
such as a single dose calculation on an average intensity projection from 4D-CT (3D) are often 
pursued for dose calculation. 
 
It is for this reason that the hypothesis of Part 2 of this work, was that performing dose calculation 
on an average intensity projection in multi-field SBRT does not result in clinically significant 
differences in dose, compared to accumulating dose on each individual phase data-set from 4D-
CT.  
 
Part 1 of this work is published in the manuscript entitled “Determination of peripheral 
underdosage at the lung-tumor interface using Monte Carlo radiation transport calculations.” in 
Medical Dosimetry (Taylor, Dunn et al., 2011). The study was carried out using two Monte Carlo 
codes (EGSnrc & Geant4) to facilitate a more rigorous approach while at the same time comparing 
the two codes. The second part of this study addresses Objective 5: “To evaluate dose calculation 
on lung tumours, in particular quantifying the differences between 4D calculations, which 
explicitly account for dynamic geometry, and conventional 3D calculation, based on AIP.” This 
work is in preparation to be submitted for publication in Physics in Medicine and Biology. 
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6.2. BACKGROUND: INCORPORATION OF 4D INFORMATION INTO DOSE CALCULATION 
This explicit incorporation of temporal information into treatment planning is termed 4D treatment 
planning (Keall, Siebers et al., 2004, Keall, Joshi et al., 2005, Keall, Joshi et al., 2003, Keall, 
2004b). The traditional method of dose calculation relies on the AIP from 4D-CT to determine the 
dose distribution to the ITV. This method is much less laborious planning wise as it involves a 
single dose calculation, whereas the 4D method involves contouring the lesion (GTV) and organs-
at-risk in all phases from 4D-CT, performing dose calculation on each GTV, then registering and 
summing the respective dose distributions. Section 6.5.2 is dedicated to determining the 
equivalency of these two methods since they are both used in clinics today in multi-field SBRT 
treatments. In this Monte Carlo study, only dose calculation on the treatment volumes is 
performed. The influence of target motion direction, amplitude and motion profile (breathing 
pattern) on the equivalency between the two methods are each investigated as well as a 
confirmation of the expected breakdown in equivalency when contributions from a single beam 
only are examined.  
 
Temporal variation in anatomy and tumour motion can introduce significant errors in imaging 
(Shepp, Hilal et al., 1979, Tarver, Conces et al., 1988, Shimizu, Shirato et al., 2000), treatment 
planning (ICRU, 1999) and radiation delivery (Jiang, Pope et al., 2003, Bortfeld, Jiang et al., 
2004). Carcinomas residing in the lung are particularly subject to movement due to respiration 
(Shirato, Seppenwoolde et al., 2004, Keall, Mageras et al., 2006b). Generally, without the use of 
motion management, uncertainties in target location and temporal motion can necessitate larger 
field margins and may result in target under-dosage or greater irradiation of healthy tissue.  
 
Recent developments in imaging technology, such as Four-Dimensional Computed Tomography, 
(4D-CT) (Ford, Mageras et al., 2003a, Vedam, Keall et al., 2003b, Keall, Starkschall et al., 2004) 
are becoming widely used in the treatment planning of radiotherapy for lung carcinoma. 4D-CT 
provides the means to reduce the breathing related artifacts associated with 3D-CT via correlation 
of the data-acquisition to a respiratory signal, as well as allowing the clinician to explicitly 
incorporate patient-specific respiratory motion into the treatment plan (Rietzel, Liu et al., 2008b).  
 
A particularly useful feature of 4D-CT is that it can be used to improve upon 3D images of tumour 
excursion used to delineate an ITV, by using projection data such as MIPs. By using the MIP from 
a 4D-CT data-set, a more accurate representation of the complete motion trajectory over a 
respiratory cycle can be achieved. The AIP is however still used for dose calculation since it more 
 - - 185 - - 
accurately represents the probability density function of the tissue densities within the ITV. 
 
With the advent of 4D-CT, the clinician now has the ability to create a ‘four-dimensional’ 
treatment plan (Antony, Carlson et al., 2007, Esthappan, Santanam et al., 2008, Guckenberger, 
Wilbert et al., 2007, Rietzel, Chen et al., 2005a). An example of a ‘four dimensional’ treatment 
plan would be to perform separate dose calculations on each individual phase data set obtained 
from a 4D-CT. In this work, combining the doses from individual phase data-sets is termed 
‘U10V’ or Union of 10 Volumes. The U10V is formed by registering and adding the dose 
distributions on each respiratory phase data-set obtained by 4D-CT to form a composite, or ‘union’ 
of ten dose distributions but has the complication that the same tissue occupies different spatial 
voxels in different phases. The common less laborious approximation to the aforementioned 
method is a single dose calculation on an AIP, with the contouring derived from a MIP. In this 
work, this is termed ‘AVG’ and is equivalent to a 3D dose calculation. 
 
Since 4D-CT is now the standard of care in treatment planning for SBRT of lung cancer (Benedict, 
Yenice et al., 2010) and conventional radiotherapy (Senan, De Ruysscher et al., 2004), clinicians 
can now explicitly incorporate 4D-CT data into the treatment plan by performing dose calculation 
on multiple breathing phase data sets, or calculating on a single data set, representing the average 
density, the AIP. The question naturally arises as to the equivalency of these approaches and the 
benefits of incorporating the additional information afforded by 4D-CT into the treatment plan, 
which is generally more time consuming. In this work, the aim was to determine whether dose 
calculation on an AIP is equivalent to accumulating and registering dose calculations on each 
individual phase of the breathing cycle when considering dose to the treatment volume. Monte 
Carlo simulation is used to systematically determine the degree of equivalency of these two 
methods with respect to motion amplitude, motion profile, single field versus multiple fields and 
the direction of tumour motion relative to the beam direction. 
6.3. MATERIALS 
Both Geant4 (Section 2.10.3.1) and EGSnrc (Section 2.10.3.5) were used to perform Monte Carlo 
simulation. Simulations were performed on the Victorian Partnership for Advanced Computing 
(VPAC) tango server with each simulation typically using four to ten processors (AMD, Barcelona 
2.3 GHz quad core).  
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6.4. METHODS 
6.4.1. METHOD I: Determination of peripheral underdosage at the lung-tumor interface using Monte 
Carlo radiation transport calculations. 
In this work, Monte Carlo calculations using Geant4 (Section 2.10.3.1) are used to develop a set of 
data which could be routinely used by clinicians as a reference to determine errors in dose 
prediction that could occur due to limitations of treatment planning systems. Monte Carlo 
simulation facilitates greater accuracy in areas of heterogeneous density typically seen in lung 
cancer SBRT treatment planning. The aim of this work was to determine the extent of underdosage 
that exists at the periphery of a tumour relative to the centre, and to evaluate the dependence on a 
number of parameters. These parameters are outlined in Table 6.1. 
 
Table 6.1. Systematic simulation parameters.  
Variable  
Photon beam energy, E (MVp) 6 and 15  
Field size, FS (mm2) 30 x 30, 35 x 35, 40 x 40, 50 x 50 and 70 x 70  
Tumour diameter, Ø (mm) 10, 16, 20, 30 and 50 
Distance from chest-wall to tumour boundary d (mm) 5, 10, 20 and 40 
 
 
The lung is lower in density than both the chest-wall and the tumour itself. To model this geometry 
in Geant4, a three-stage geometry was developed. This geometry is shown in Figure 6.1. The 
geometry consists of a polyenergetic photon beam incident on a region with the density of soft 
tissue (ρ = 1.06 g/cm3) representative of the chest-wall. A spherical tumour (ρ = 1.00 g/cm3) is 
located within a region of lung equivalent density (ρ = 0.26 g/cm3) directly adjacent to the 
preceding chest-wall region. The composition of these tissues is outlined in Table 6.2 
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Figure 6.1. Monte Carlo geometry. A photon beam of energy E and field size FS is incident upon a region of 
tissue equivalent density representative of the chest-wall (20 x 80 x 80 mm3). The chest-wall is then 
followed by a region of lung equivalent density with dimensions (110 x 80 x 80 mm3). Inside the lung tissue 
region, a spherical lesion of diameter Ø is placed at a distance d from the chest-wall. The distances (d) and 
tumour size (Ø) are variable. The tumour’s size determines the field size. 
 
 
The scoring region of interest was the tumour itself. To facilitate the determination of the degree of 
underdosage of the shell relative to the centre, key spherical scoring voxels were implemented 
within the spherical tumour. A schematic of the key dose points is shown in Figure 6.2. The 
entrance, exit and lateral dose points were chosen as they experience different effects with respect 
to forward, backward and lateral scattering and electronic disequilibrium. The central dose was 
chosen as the underdosage of the periphery must be described relative to the centre. Although the 
central dose will also be affected by these effects to a lesser extent. ‘Entrance’ and ‘exit’ refer to 
the closest and furthest points on the tumour with respect to the source of the beam. ‘Lateral’ refers 
to the four lateral sides of the lesion, i.e. top, bottom, left and right of centre. 
 
A parallel beam was chosen to remove inverse square effects related to isocentric configurations. 
Field sizes were chosen based on the tumour diameter and extend to 10 mm beyond the tumour 
boundary. Photon spectra for both 6 and 15 MV were simulated with data obtained from (Mohan, 
Chui et al., 1985). These spectra are shown in Figure 6.3.  
 
20 mm 110 mm 
80 mm 
80 mm 
Lung tissue Lesion Chest-wall (soft tissue) 
d 
ØT 
Polyenergetic 
photon beam, 
E with varying 
field size FS 
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Figure 6.2. (a) The scoring geometry simulated with Geant4. The 1 mm diameter voxels; entrance (Ent), exit 
(Ext), Reference (Ref) and lateral dose points both vertical and horizontal (Lat) are shown. (b) A schematic 
of the key dose points indicating the regions of interest for scoring dose. The points are marked with a black 
X and the field in both views is indicated by a shaded region.  
 
Figure 6.3. (a) 6 MV and (b) 15 MV photon spectrum from (Mohan, Chui et al., 1985). This data was used 
as the photon spectra incident on the chest-wall as seen in Figure 6.1. 
 
 
 
Ent
Ext
Ref
Lat
Lat(a) 
(b) 
(a) (b) 
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The tissue compositions and fractional elemental compositions used in the geometry are shown in 
Table 6.2 These tissue compositions, with the exception of the lung carcinoma, were obtained 
from ICRU Report 44 (Units, Measurements et al., 1989). The density of lung carcinoma was set 
to that of water (1.00 g.cm-3) with its elemental composition obtained from combustion studies of 
excised squamous cell carcinoma reported by (Maughan, Chuba et al., 1997).  
 
 
Table 6.2. The density and elemental composition of the relevant tissues modeled in the study. Values are 
presented as percentage by weight. Lung carcinoma data was determined by combustion studies of excised 
squamous cell lung carcinoma reported by (Maughan, Chuba et al., 1997). Soft tissue and lung tissue 
definitions were taken from ICRU Report 44 (Units, Measurements et al., 1989). 
 
Density / Elemental Comp. Soft Tissue Lung Tissue Lung Carcinoma 
ρ (g.cm-3) 1.06 0.26 1.00 
H 10.2 10.3 9.9 
C 14.3 10.5 19 
N 3.4 3.1 4.5 
O 70.8 74.9 65.45 
Na 0.2 0.2 0.1265 
P 0.3 0.2 0.253 
S 0.3 0.3 0.322 
Cl 0.2 0.3 0.1955 
K 0.3 0.2 0.253 
 
 
The physics processes activated in Geant4 (version 4.9.4 beta) include Bremsstrahlung production, 
positron annihilation (both in flight and at rest), pair and triplet production, multiple scattering, 
Compton scattering, Rayleigh scattering, the photoelectric effect, Møller scattering, Bhabha 
scattering, continuous energy loss through discrete events, atomic relaxation and electron impact 
ionisation. The relevant physics models assigned above are described in Table 2.6 and Table 2.7. 
Production cut offs were set to 990 eV and 40 keV respectively for photons and electrons. These 
energy cut offs correspond to range cuts of 0.1 mm.  
6.4.2. METHOD II: The incorporation of 4D information into dose calculation. 
MATLAB (The Mathworks Inc., Natick, Massachusetts) was used to create 3D voxelised virtual 
phantoms as shown in Figure 6.4. The phantoms contain a chest-wall region (160 x 160 x 20 mm) 
of density 1.00 g/cm3 and a region of lung tissue (160 x 160 x 120 mm) with density equal to 0.25 
g/cm3. A voxelised spherical ‘tumour’ (diameter = 40 mm) was also created and added to the 
primary matrix. The density of lung is known to change from 0.25 – 0.4 g/cm3 depending on both 
the respiratory state and the health of the patient’s lungs (Keall, Mageras et al., 2006a). Normal 
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tumour density is around 1.00 g/cm3 and with a lung density in the lower range, the maximum 
effect relating to the difference in density can be examined.  
 
The entire composite geometry (lung + chest-wall + tumour) is divided into 1 mm3 voxels. The 
location of the tumour with respect to the chest-wall was determined by a motion profile vector 
containing ten locations within the lung. These ten data-sets represent the phase-bin data sets 
obtained in a 4D-CT scan. An AIP was then created using the same method as 4D-CT by taking 
the voxel-by-voxel mean across all ten phase data-sets. The AIP therefore contains a mixture of 
densities between a minimum of lung and a maximum of the tumour density. The density profiles 
throughout the virtual phantom are therefore motion profile dependent and therefore are naturally 
weighted by the time the tumour spends at particular phases.  
 
 
 
Figure 6.4. Beam, geometry and motion direction arrangements for the present study. (a) Geometry and 
beam arrangements showing a 40 mm diameter tumour in a region of lung equivalent density (160 x 160 x 
120 mm3), a 10 x 10 cm2 field of 6MV photons is incident on a tissue equivalent region (160 x 160 x 20 
mm3) with a parallel opposed beam arrangement, in this scenario, the tumour’s motion is parallel to the 
beam direction. (b) A single field scenario with the tumour’s motion again occurring parallel to the beam 
direction. (c) A parallel opposed arrangement with the tumour’s motion occurring perpendicular to the beam 
direction and (d) a single field arrangement with the tumour motion occurring perpendicular to the beam 
direction. 
 
The positions of the tumour at each phase within the virtual phantoms are assigned based on a 
position array. The position array’s elements have a specific pattern based on breathing patterns 
commonly seen in patients. The breathing profiles are described below and examples are shown in 
z
x
y
98 x 98 cm2  6MV photon beam 
From Varian 600C model 
(parallel opposed arrangement) 
40 mm diameter tumour 
with motion occurring 
Parallel to beam direction  
Chest-wall 1 (left) –  
(160 x 160 x 20 mm)  
density = 1.00 g/cm3 
Lung tissue –  
(160 x 160 x 120 mm)  
density = 0.25 g/cm3 
Single beam – 
98 x 98 mm2 6MV Varian 
600C, motion parallel 
Single beam – 
10 x 10 cm2 6MV Varian 
600C, motion 
perpendicular 
Parallel opposed – 
10 x 10 cm2 6MV Varian 
600C, motion perpendicular 
(a) 
(b) 
(c)
(d)
Chest-wall 2 (right) –  
(160 x 160 x 20 mm)  
density = 1.00 g/cm3 
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Figure 6.5. The time axes is shown, however, it is arbitrary as only one full respiratory cycle is 
used to assign the tumour’s location within the lung.  
 
1. Motion 1 (sinusoidal): Inspiration period = expiration period. 
2. Motion 2 (Asymmetric): Inspiration period < expiration period. 
3. Motion 3 (Asymmetric): Inspiration period > expiration period. 
4. Motion 4 (Asymmetric): Inspiration period = expiration period followed by a pause. 
 
 
Figure 6.5. The motion profiles that were chosen as the basis for determining the location of the tumour 
within each of the ten phase-bins. (a) Motion 1 - symmetrical (b) Motion 2 - asymmetrical: Inspiration < 
expiration, (c) Motion 3 - asymmetrical: inspiration > expiration and (d) Motion 4 - Asymmetrical with a 
pause in-between breaths. 
 
 
As is done in a 4D acquisition, one respiratory cycle from these patterns is divided into ten phase 
bins (commonly) corresponding to a particular phase percentage of the breathing cycle. Motion 
amplitudes of; 5.0, 3.5, 2.0 and 0.5 cm were assigned to each of the four motion profiles with the 
following beam arrangements: 
 
1. Two beams (parallel opposed) with target motion occurring parallel to the beam. 
2. A single beam incident on the chest-wall with the motion of the target parallel to the beam 
direction. 
3. Two beams (parallel opposed) with target motion occurring perpendicular to the beam. 
4. A single beam incident on the chest-wall with target motion occurring perpendicular to the 
beam motion.  
(a) (b) 
(c) (d) 
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The beam arrangements are shown in Figure 6.4 and were chosen to represent worst case scenarios 
(single beams) and investigate the discrepancies for multi-beam scenarios with different lesion 
motion directions relative to the beams. 
 
The Monte Carlo package EGSnrc (Kawrakow, 2000b) was used along with BEAMnrc (Rogers, 
Faddegon et al., 1995) and the user-code DOSXYZnrc for dose-calculation. For each of the four 
motion profiles and amplitudes, 11 full Monte Carlo simulations were performed corresponding to 
the ten individual phases (U10V) plus a single calculation on the AIP (AVG). With two beam 
arrangements and two tumour motion directions resulting in 352 separate Monte Carlo 
simulations. For each motion profile both in beam or parallel (anterior-posterior), motion was 
simulated as well as target motion perpendicular (superior-inferior) to the beam direction. In all 
simulations, a 6 MV, 98 x 98 mm2 field was incident upon the z- face of the phantom. The ‘phase-
space’ file used to generate the primary photons was previously generated by a BEAMnrc model 
of a Varian 600C Clinac with a mounted BrainLAB m3 mini-multileaf collimator (MMLC).  
 
The model was developed based on schematics provided by Varian Medical Systems and 
BrainLAB under non-disclosure agreements (Kairn, Aland et al., 2010, Kairn, Kenny et al., 2010). 
The model of the Varian 600C with MMLC was dosimetrically-matched to measured data using 
percent depth-dose curves, beam profiles and scatter factors. For each simulation, 4x109 photon 
histories were simulated per-phase and AIP simulation. EGSnrc parameters for electron and 
photon transport cut-offs were 0.561 MeV and 0.001 MeV respectively. The PRESTA-II electron-
step, along with the EXACT boundary crossing algorithms were used with a step size of 0.25 
(maximum fractional energy loss, ESTEPE). EGSnrc has been shown to produce step-size 
independent results at a sub 0.1 % level even at interfaces of high Z media in fine geometries 
(Kawrakow, 2000b, Verhaegen, 2002).  
 
To compare key points on both U10V and AVG, doses to the entrance (A), central (B) and exit (C) 
voxels of the tumour in each of the ten phase bins were compared to the entrance (A(AIP)), central 
(B(AIP) and exit (C(AIP)) voxels on the AIP. The accumulated dose of these voxels over the ten 
phases was compared to the AIP voxels as a ratio. This comparison highlights the potential 
differences that may arise due to the density difference at the borders of lung tissue and the tumour 
in both methods as well as being highly motion path (respiratory profile) dependent. A schematic 
of this method is shown in Figure 6.6. 
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Figure 6.6. A schematic of the comparison between the two dose calculation methodologies. At each of the 
ten phases the entrance (A), central (B) and exit (C) doses are recorded as well as the dose to GTV. The 
entrance, central and exit doses, as well as the dose to the ITV (AVG) volume are also recorded for 
comparison. The dose to the lesion volume in each phase-bin is added to form the U10V. Note the 
assignment of phases in this scenario is arbitrary. The AVG is derived from the 10 phases from 4D-CT. Its 
boundary is defined by the MIP and the distribution of densities within the ITV derived directly from the 
AIP. In this work, simulations are conducted with the lesion moving in both the SI and AP directions relative 
to the beam. The parallel opposed fields are in the AP direction. 
 
Cumulative DVHs were calculated using a MATLAB script which read in three-dimensional dose 
files (‘3ddose’) from the Monte Carlo simulations. An algorithm then extracted the target volume 
(spherical tumour) within each phase-bin and the AIP volume (defined by the ITV) for DVH 
analysis. The dose distributions from each of the ten phase-bins were then added to form the 
composite target volume dose and the DVH (U10V) calculated. The boundary of the AIP volume 
for DVH (AVG) analysis was defined from the ITV as would be delineated from a Maximum 
Intensity Projection (MIP) showing the extrema of target motion. The U10V dose bins are 1% of 
the maximum dose found within the target volume within a particular phase-bin. For AVG, the 
dose bins are 1% of the maximum dose found within the ITV. The Gross Tumour Volume (GTV) 
A CBPhase(i)
Phase(i+9)
A(AIP) B(AIP) C(AIP)
98 x 98 mm2 , 
6 MV photon beam
Sum of dose to volume 
in each phase = U10V
AVG
A CB
A CB
A CB
A CB
A CB
A CB
A CB
A CB
A CB
 - - 194 - - 
in each individual phase data-set is delineated mathematically and there is no additional margin. It 
is important to note that registering the GTVs in each individual phase-bin data set was 
accomplished via translation only. This methodology for the construction of the U10V is only 
possible since the tumour is uniform in shape (spherical) and is always within the boundary of the 
beam. A more clinically relevant case requires deformable registration to track delivered dose 
across varying anatomical states (Rietzel and Chen, 2006b).  
6.4.3. Computing hardware 
All simulations were run on the ‘Tango’ cluster at the Victorian Partnership for Advanced 
Computing (VPAC). The Tango cluster is a large AMD Opteron system and consists of 111 
compute nodes, each with two AMD Shanghai 2.5 GHz quad-core processors for a total of 888 
CPUs. This permitted up to 20 simulations to be run simultaneously, each using one quad-core 
processor. 
6.5. RESULTS 
6.5.1. RESULTS I: Determination of peripheral underdosage at the lung-tumor interface using Monte 
Carlo radiation transport calculations. 
Because of the complicated build-up then build-down and then build-up convolution arising from 
chest-wall, lung, tumour interfaces respectively, even the dose to the centre of each tumour is a 
complex function of tumour size and location within the lung. As a result of this, results presented 
below are given as the ratio of points on the boundary of the lesion to that of the central dose voxel 
for each lesion. The specific points are outlined in Figure 6.1 and Figure 6.2 respectively. The 
points represent the boundary point on the lesion facing the beam, the boundary point where the 
beam exits the lesion and the four lateral sides of the tumour intersected by Cartesian axes, with 
the origin being the centre of the lesion. This ratio can be summarised for beam and geometry 
parameters outlined in Table 6.1 as:  
 
 
ref
boundary
D
D
EFSdR ,Ø,,          (6.1) 
 
Where R is the ratio of the dose at the point on the boundary (Dboundary) to the reference dose point 
(Dref). Here, the reference point refers to the dose calculated at the centre of the lesion. R is a 
function of the distance from the chest-wall to the tumour boundary, d, the field size, FS, and the 
tumour diameter Øτ on which the field size is based. The results presented in Table 6.3 and Table 
6.4, are values of R calculated with Geant4 and refer to the entrance, exit and lateral ratios for a 6 
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and 15 MV photon beam respectively. The ratios are presented for various tumour distances d, 
field sizes FS and tumour diameters Øτ and energy E. 
 
Table 6.3. Dose ratios (Equation 6.1) for a 6MV photon spectrum from Figure 6.3 (a). The entrance-to-
central dose, exit-to-central dose and average of the lateral-to-central dose is shown. The standard 
uncertainty is shown in brackets.  
 Øτ (mm) / FS (mm2) 
ENTRANCE DOSE           
d (mm) 10 / 30 x 30 16 / 35 x 35 20 / 40 x 40 30 / 50 x 50 50 / 70 x 70 
5 1.02(±0.03) 1.04(±0.04) 1.03(±0.05) 0.99(±0.06) 1.02(±0.08) 
10 1.01(±0.03) 1.02(±0.04) 1.00(±0.05) 1.05(±0.06) 0.99(±0.08) 
20 1.01(±0.04) 1.01(±0.04) 0.99(±0.05) 0.99(±0.06) 0.98(±0.08) 
40 1.00(±0.04) 0.98(±0.04) 1.00(±0.05) 0.99(±0.06) 0.97(±0.08) 
EXIT DOSE      
d (mm) 10 / 30 x 30 16 / 35 x 35 20 / 40 x 40 30 / 50 x 50 50 / 70 x 70 
5 0.98(±0.03) 0.99(±0.04) 0.94(±0.05) 0.94(±0.06) 0.94(±0.08) 
10 0.97(±0.04) 0.98(±0.04) 0.95(±0.05) 0.96(±0.06) 0.93(±0.08) 
20 0.99(±0.04) 0.99(±0.04) 0.95(±0.05) 0.94(±0.06) 0.87(±0.08) 
40 0.99(±0.03) 0.97(±0.04) 0.95(±0.05) 0.93(±0.06) 0.91(±0.09) 
LATERAL DOSE      
d (mm) 10 / 30 x 30 16 / 35 x 35 20 / 40 x 40 30 / 50 x 50 50 / 70 x 70 
5 0.99(±0.05) 0.98(±0.06) 0.97(±0.07) 0.97=8(±0.09) 0.98(±0.11) 
10 0.98(±0.05) 0.96(±0.07) 0.95(±0.07) 1.00(±0.09) 0.96(±0.12) 
20 0.97(±0.06) 0.96(±0.07) 0.97(±0.07) 0.95(±0.09) 0.94(±0.12) 
40 0.97(±0.05) 0.95(±0.07) 0.96(±0.07) 0.97(±0.09) 0.96(±0.12) 
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Table 6.4 Dose ratios (Equation 4.2) for a 15MV photon spectrum from Figure 6.3 (b). The entrance-to-
central dose, exit-to-central dose and average of the lateral-to-central dose is shown. The standard 
uncertainty is shown in brackets. The standard uncertainty is shown in brackets. 
 Øτ  (mm)  / FS (mm2) 
ENTRANCE DOSE      
d (mm) 10 / 30 x 30 16 / 35 x 35 20 / 40 x 40 30 / 50 x 50 50 / 70 x 70 
5 1.01(±0.03) 0.98(±0.03) 0.95(±0.04) 0.89(±0.04) 0.86(±0.06) 
10 1.01(±0.03) 0.95(±0.03) 0.95(±0.04) 0.93(±0.05) 0.86(±0.06) 
20 0.99(±0.03) 0.96(±0.03) 0.96(±0.04) 0.93(±0.05) 0.86(±0.06) 
40 0.97(±0.03) 0.94(±0.03) 0.92(±0.04) 0.93(±0.05) 0.93(±0.06) 
EXIT DOSE      
d (mm) 10 / 30 x 30 16 / 35 x 35 20 / 40 x 40 30 / 50 x 50 50 / 70 x 70 
5 1.01(±0.03) 1.01(±0.03) 0.99(±0.04) 0.95(±0.05) 0.92(±0.06) 
10 1.02(±0.03) 0.99(±0.03) 0.97(±0.04) 0.98(±0.05) 0.90(±0.06) 
20 1.04(±0.03) 1.01(±0.03) 1.01(±0.04) 0.96(±0.04) 0.92(±0.06) 
40 1.02(±0.03) 1.01(±0.03) 0.98(±0.04) 0.97(±0.05) 0.97(±0.06) 
LATERAL DOSE      
d (mm) 10 / 30 x 30 16 / 35 x 35 20 / 40 x 40 30 / 50 x 50 50 / 70 x 70 
5 0.97(±0.05) 0.92(±0.05) 0.91(±0.06) 0.88(±0.07) 0.86(±0.07) 
10 0.97(±0.05) 0.91(±0.05) 0.89(±0.06) 0.91(±0.07) 0.85(±0.07) 
20 0.96(±0.05) 0.92(±0.05) 0.92(±0.06) 0.89(±0.07) 0.84(±0.07) 
40 0.95(±0.05) 0.90(±0.05) 0.89(±0.06) 0.89(±0.08) 0.89(±0.08) 
 
6.5.1.1 The dose reduction factor (DRF)  
A dose reduction factor was developed as a means to express the underdosage of the ‘shell’ of the 
lesion with respect to the central (reference) dose. The dose reduction factor is outlined in 
Equation 4.3 and is intended for clinical purposes where multiple conformal beams are incident 
upon the tumour from multiple directions. The net effect will be approximated by the average of 
each of the contributing terms. 
 


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ilateralexitentrance
ref
DDD
D
DRF        (6.2) 
 
Using this metric, the degree of shell underdosage can be calculated. The results of these 
calculations are shown in Table 6.5 and Table 6.6. 
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Table 6.5. DRFs calculated using Equation 6.2 for a 6MV photon spectrum as a function of the tumour’s 
size (Øτ) and distance from the chest-wall (d). Standard uncertainty is 0.5%. 
 
6 MV     Øτ (mm)     
d (mm) 10 16 20 30 50 
5 1.00 1.00 0.97 0.98 0.98 
10 0.98 0.97 0.96 1.00 0.96 
20 0.98 0.97 0.97 0.95 0.94 
40 0.98 0.96 0.96 0.97 0.96 
 
 
Table 6.6. DRFs calculated using Equation 6.2 for a 15MV photon spectrum as a function of the tumour’s 
size (Øτ) and distance from the chest-wall (d). Standard uncertainty is 0.5%. 
 
15 MV   Ø (mm)   
d (mm) 10 16 20 30 50 
5 0.98 0.95 0.93 0.89 0.87 
10 0.98 0.93 0.91 0.92 0.86 
20 0.98 0.94 0.93 0.91 0.86 
40 0.97 0.93 0.91 0.91 0.91 
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6.5.2. RESULTS II: The incorporation of 4D information into dose calculation 
The previous section quantified the underdosage that occurs in key regions of lung tumours. The 
development of a metric to estimate such underdosage was also presented. In this section, we look 
at how 4D-CT based dose calculation can take this into consideration. The methodology of this 
investigation is outlined in 6.4.2. 
6.5.2.1 Comparisons between U10V and AVG: Characteristic points  
The results for the comparison between the points A, B and C for both AVG and U10V dose 
calculation methods are shown in Figure 6.7 and Figure 6.8. The characteristic point locations and 
method for comparison are shown in Figure 6.6. The value R in Figure 6.7 and Figure 6.8 
corresponds to the ratio of the accumulated entrance (A), central (B) and exit (C) doses over the 
ten separate phase based dose calculations (U10V) to the single calculation on an average intensity 
projection (AVG). Negative values in Figure 6.7 and Figure 6.8 indicate that, on average, the 
specific point received a lower dose over the ten phases when compared to the dose prediction 
based on the AIP. The uncertainty in all Monte Carlo simulations within the region of interest was 
0.5-1.0% with 4x109 primary photons.  
 
For a static scenario, the lesion is centered between the walls. For the moving case, inspiration 
corresponds to the tumour moving away from the left side chest wall, chest wall (1) in Figure 6.4 
and expiration has the tumour moving towards the left side chest wall if the lesions motion is 
parallel to the beam direction. ‘Entrance’, point A, refers to the dose to the entrance of the lesion if 
only a single beam were incident upon the target from the outside the left-hand chest wall, chest 
wall (1) in Figure 6.4. 
 
The entrance and exit points on the ITV were chosen since they lie in a heterogeneous region of 
high density gradient and therefore should receive a lower dose than points in homogenous regions 
in the inner areas of the lesion due to the lack of electronic equilibrium (Taylor, Dunn et al., 2011). 
Central dose voxels were chosen for comparison since clinically, they are often chosen as a 
reference dose point. The largest discrepancy for a single field was found to be 16.73% (at the exit 
side of the tumour. This discrepancy occurred for a tumour moving with an amplitude of 5.0 cm 
and motion Type 3 (Figure 6.4 (c)). With a parallel opposed field (Figure 6.7) however, the largest 
discrepancy was reduced to 2.86 % and was found for a 5.0 cm amplitude with the target moving 
with motion Type 2 (Figure 6.4 (b)). For a parallel opposed field, all motion profiles and 
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amplitudes simulated result in differences between the two methodologies of less than 5% with no 
significant trends for the entrance, exit and central dose points. A single field on the other hand 
produces larger variation between the two methods with up to 16% variation in entrance doses for 
a 5.0 cm motion amplitude.  
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Figure 6.7. Analysis of characteristic points over all motion profiles and amplitudes simulated for a parallel 
opposed beam arrangement. Data presented here is the ratio of the accumulation of the point over the ten 
phases, to the single point on the AIP. Here, R(A) represents the ratio of the entrance voxels, R(B) the ratio 
of central dose voxels and R(C), the ratio of exit dose voxels. The method of comparison is outlined in 
Figure 6.6. The four motion types outlined in Figure 6.5 are shown. (a) Sinusoidal motion (motion Type 1) 
(b) inspiration period less than expiration (motion Type 2) (c) inspiration period greater than expiration 
(motion Type 3) and (d) inspiration and expiration period followed by a pause (motion Type 4). 
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Figure 6.8. Analysis of characteristic points over all motion profiles and amplitudes simulated for a single 
field. Data presented here is the ratio of the accumulation of the point over the ten phases, to the single point 
on the AIP. Here, R(A) represents the ratio of the entrance voxels, R(B) the ratio of central dose voxels and 
R(C), the ratio of exit dose voxels. The method of comparison is outlined in Figure 6.6. The four motion 
types outlined in Figure 6.5 are shown. (a) Sinusoidal motion (motion Type 1) (b) inspiration period less 
than expiration (motion Type 2) (c) inspiration period greater than expiration (motion Type 3) and (d) 
inspiration and expiration period followed by a pause (motion Type 4). The schematic above illustrates the 
points of interest.  
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The net results for each point over the motion cycle as shown in Figure 6.7 and Figure 6.8 arises 
due to the different contributions from the time spent at different depths. Figure 6.9 shows the per-
phase variation in dose over ten phases compared to a single calculation on the AIP. A 5.0 and 0.5 
cm amplitude motion for both parallel opposed and single fields are shown. This figure highlights 
the dependence on field arrangements and amplitudes on the agreement between the two 
methodologies when considering characteristic points. The figure demonstrates the magnitude of 
differences that can occur between the two methodologies if single fields are used and large 
amplitudes are present. For smaller amplitudes, the discrepancy between the two methods reduces. 
This can be seen in Figure 6.9 (b) and (d).  
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Figure 6.9. (a) Dose differences between the two methodologies per phase. Here, the points represent the 
dose to the entrance, central and exit voxels on the tumour in each of the ten phases. The straight lines 
represent the dose measured on the average intensity projection dataset formed by the ten phases for the 
same points (A, B, C). This method is outlined Figure 6.6. (a) 5.0 cm amplitude with motion of Type 1 
(sinusoidal), in a parallel opposed field arrangement. (b) 0.5 cm amplitude motion for a parallel opposed 
field and motion of Type 1. (c) A 5.0 cm amplitude motion of Type 1 in a single field arrangement and (d) 
0.5 cm motion of Type 1 in a single field arrangement. Note the y-axes scale differences between multiple 
and single field scenarios, respectively. 
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6.5.2.2 Comparisons between U10V and AVG: DVH analysis 
Dose volume histograms were used to analyse the entire dose distribution for both methods (U10V 
and AVG). Results presented here are for target motion both parallel and perpendicular to the 
beam direction. The focus, however, is on target motion parallel to the beam direction as the 
contributions from attenuation and inverse-square effects within the dose distributions can 
contribute and therefore the largest possible discrepancies should become evident.  
 
Figure 6.10 demonstrates the differences between the two methodologies presented in this work, 
U10V and AVG. The single dose calculation (AVG) volumes increase in size as the amplitude of 
motion increases since the ITV motion envelope increases. Whereas, in the case of the U10V 
method, the individual GTVs are delineated and registered and so the volume in this case is simply 
the original volume of the GTV. Provided of course that the GTV is delineated exactly the same in 
each phase-bin data-set. 
 
Figure 6.10. The two methods (U10V and AVG) produce different volumes for treatment. The U10V 
method involves contouring the target volume in each of the respiratory phases and then registering and 
summing the individual dose distributions. The AVG method, on the other hand performs a single dose 
calculation on the ITV (if the PTV is set to ITV). Data presented here is for a parallel opposed arrangement 
and sinusoidal motion profile. 
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6.5.2.2.1. DVH analysis: Parallel opposed arrangement 
Figure 6.11 shows DVHs for a tumour moving with a sinusoidal motion profile (Figure 6.5(a)) and 
amplitudes of 5.0, 3.5, 2.0 and 0.5 cm. A parallel opposed field is incident on the tumour. The 
figures indicate that the agreement between the U10V and AVG dose distributions is only 
significantly different for amplitudes above 2.0 cm.  
Figure 6.11. (a) DVHs for a 5.0 cm amplitude sinusoidal motion with parallel opposed fields, showing 
U10V (red line) and AVG (blue line). (b) 3.5 cm amplitude (c) 2.0 cm amplitude and (d) 0.5 cm amplitude.  
 
6.5.2.2.2. DVH analysis: Single field arrangement 
Figure 6.12 shows DVHs for a tumour moving with a sinusoidal motion profile (Figure 6.5 (a)) 
and amplitudes of 5.0, 3.5, 2.0 and 0.5 cm. In this simulation, a single field is incident on the 
tumour. The figures indicate that the discrepancy between the U10V and AVG dose distributions 
is significant for amplitudes above 0.5 cm. 
(a) (b) 
(c) (d) 
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Figure 6.12. (a) DVHs for a 5.0 cm amplitude sinusoidal motion with a single field, showing U10V (red 
line) and AVG (blue line). (b) 3.5 cm amplitude (c) 2.0 cm amplitude and (d) 0.5 cm amplitude. 
 
6.5.2.2.3. DVH analysis: Target motion perpendicular to the beam 
DVH analyses for tumour motion perpendicular to the beam are shown in Figure 6.13. In 
comparison to the data presented in Figure 6.12 (single field, motion parallel), the discrepancy 
between the DVH for U10V and AVG for motion perpendicular to the beam direction is reduced. 
This scenario, where tumour motion occurs perpendicular to the beam direction is more likely to 
reflect the clinical scenario, where tumour motion would be occurring predominately in the SI 
direction (Seppenwoolde, Shirato et al., 2002b). The data presented in Figure 6.13 indicates that 
even for a single field, the discrepancy between the two methods is minimal below amplitudes of 
3.5 cm. This is predominately due to the removal of contributions from the inverse square law and 
attenuation within the ITV. Since the tumour’s in-beam motion is zero and for a sufficiently large 
(a) (b) 
(c) (d) 
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field size the tumour is always in a region of consistent dose gradient. Irrespective of the beam 
arrangement, the differences in density between AVG and U10V have little effect. 
 
Figure 6.13. Motion of the lesion perpendicular to the beam. Comparison of the two methods for a 3.5 and 
0.5 cm amplitude of motion respectively. The target’s motion relative to the beam results in greater 
agreement in single fields for motion perpendicular to the beam direction compared to the parallel motion 
scenario.  
 
 
6.5.2.2.4. DVH analysis: Dependence on motion profile 
The dose distributions within the U10V and AVG volumes demonstrate a slight dependence on 
motion profile. This is demonstrated in Figure 6.14 where DVHs for a tumour moving parallel to 
the beam direction with motion amplitude of 5.0 cm are shown. Dose-volume histograms for each 
of the four motion profiles outlined in Figure 6.5 are shown. The large amplitude motion of 5.0 cm 
was chosen to highlight potential variation in the dose distribution as a consequence of different 
motion profiles.  
(c) (d) 
(a) (b) 
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Figure 6.14. (a) The effect of motion profile on the cumulative dose-volume histograms (U10V) and (b) the 
effect of differing motion profiles on dose-volume histograms calculated from AVG. 
 
 
6.6. DISCUSSION 
The accurate calculation of dose distributions at interfaces of differing tissue densities is non 
trivial. In the context of radiotherapy of lung lesions, the differences in density between lung (0.25 
– 0.4 g/cm3) and the lesion (~ 1.0 g/cm3) can result in underdosage of the periphery of the lesion 
due to electronic disequilibrium. With the advent of 4D-CT, new dose calculation options 
including dose calculation on individual phase data-sets is now possible. The objectives of this 
work were as follows: 
 
 Quantify the extent of underdosage in key regions of the tumour boundary with respect to the 
central region and develop a factor for clinical estimation of this for a range of tumour sizes, 
field sizes and distances from buildup regions. 
 
 Determine the equivalency of two methods of dose calculation based on data from 4D-CT. (1) 
Calculation on an average intensity projection and (2) cumulative dose calculation on individual 
phase-bin data-set from 4D-CT. 
 
(a) (b) 
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6.6.1. Determination of peripheral underdosage at the lung-tumor interface using Monte Carlo radiation 
transport calculations – Discussion of results 
In this work, Monte Carlo simulations using Geant4 were used to determine a set of clinically 
relevant dose reduction factors that could be used to gauge the degree of peripheral underdosage of 
a lesion in the lung. Underdosage of the shell of a lesion residing in the lung derives from a 
number of processes. At the proximal region of the lesion, there is electronic disequilibrium due to 
the reduction of forward scattered electrons from the lung tissue. Lateral points on the periphery of 
the lesion are under-dosed due to a lack of lateral equilibrium. There is also reduced forward and 
backscatter that result in longitudinal disequilibrium. Doses to the distal regions of the lesion are 
consistently lower than central doses due to attenuation within the lesion itself and the loss of 
backscatter at the exit. 
 
Considering the dose reduction of the shell is particularly important when considering dose 
prescription to covering isodoses. The dose to the centre of the tumour may also be affected by 
electronic disequilibrium. In the case of SBRT, the lesion is often less than 5 cm in diameter 
(Beitler, Badine et al., 2006). A small lesion can provide insufficient build-up within the lesion 
itself, thereby resulting in disequilibrium.  
 
Underdosage was found to be dependent on the tumour’s size, position from the chest-wall and the 
beam energy used. On average, over all tumour diameters and distances from the chest-wall, a 6 
MV beam results in an underdosage of 3%  (± 2%, 1σ) to the periphery of the lesion with respect 
to the centre. On the other hand a 15 MV beam results in an average of 8% (± 4%, 1σ) reduction to 
periphery regions (Table 6.5 and Table 6.6). Underdosage was found to be more prevalent for the 
higher energy beam, larger tumour sizes and lesions situated at a larger distance from the chest-
wall.  
 
This data also provides validation for the choice of 6MV beams over higher energy beams (15 -18 
MV) for treatment of lung lesions. This result is supported by Wang et al (2002), who showed that 
Monte Carlo dose calculation predicted increased penumbra width with increased photon energy 
resulting in decreased lateral dose homogeneity for 15 MV plans. Their study also showed that 
while the 15 MV dose distributions and DVHs generated by the clinical treatment planning 
calculations were as good as, or slightly better than, those generated for 6 MV, all target coverage 
indicators were significantly worse for 15 MV than for 6 MV. Particularly, the portion of the 
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planning target volume (PTV) receiving at least 95% of the prescription dose dropped dramatically 
for the 15 MV in comparison to the 6 MV. Their study concluded that lower energy photon beams 
(6 MV) are preferable over higher energies (15 - 18 MV) because of the significant loss of lateral 
dose equilibrium for high-energy beams in the low-density medium. Although their study was 
based on conformal plans and not SBRT plans, it is important to note, that although higher energy 
beams provide greater uniformity in radial dose across steep density gradients (which is preferable 
in SBRT) their use must be weighed carefully against the lateral beam degradation due to 
penumbra widening. Doses to the lateral regions in the Monte Carlo study here were, on average, 
over all conditions simulated, found to be underdosed by 11% and 8% for 15 MV and 6 MV 
respectively.  
 
Conversely, in an IMRT planning study conducted by Weiss et al (Weiss, Siebers et al., 2007) a 
study of 13 patients revealed, on average, no clinically or statistically significant differences 
between 6- and 18-MV plans. Their study concluded that high photon energies should therefore 
not be excluded a priori when a dose-calculation algorithm is utilised that accurately accounts for 
heterogeneities. Their study, however, was based on clinical treatment planning systems with 
superposition convolution dose calculation algorithms which have been shown to only 
approximate the penumbral broadening in low-density media when using high energy beams 
(Carrasco, Jornet et al., 2004). 
6.6.2. Determination of peripheral underdosage at the lung-tumor interface using Monte Carlo radiation 
transport calculations – Clinical relevance 
Patients with early stage but medically inoperable lung cancer have a poor rate of primary tumor 
control (30% - 40%) and a high rate of mortality (3-year survival, 20% - 35%) with current 
management (Timmerman, Paulus et al., 2010). Furthermore, lung cancers now account for 15% 
and 14% of all new cancer occurrences in men and women respectively. When treating with 
external beam radiotherapy, the photon beam is incident upon the chest-wall, of tissue equivalent 
density, then lung tissue of a lower density (roughly one third of normal tissue density), then into 
the lesion itself, which has a density roughly equivalent to that of tissue. Problems in dose 
calculation can arise due to the range of secondary electrons particularly if pencil-beam algorithms 
are used to calculate the dose to the lesion.  
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A typical SBRT treatment might involve the use of either an arc or multiple field arrangement with 
up to 9 fields (Hiraoka and Nagata, 2004, Hiraoka, Matsuo et al., 2010, Hiraoka, Matsuo et al., 
2007, Hiraoka and Ishikura, 2007). For multiple fields, the contribution of the reduced entrance 
and exit doses over all beam angles incident on the lesion results in an underdosed periphery of the 
lesion with respect to the centre. Underdosage of the peripheral region may have significant 
consequences for the effectiveness of radiation therapy. The reduction of dose to this region can 
result in a reduction in the tumour control probability. Most clinically operational TPSs would not 
be able to predict the magnitude of dose reduction at the periphery of a lung lesion. This is mainly 
due to the calculation grid size, and the inability of the algorithms to calculate dose distributions in 
the presence of inhomogeneities on a millimeter scale. The DRF derived in this work presents a 
method to estimate the degree of underdosage compared to the centre of the lesion. This in turn 
could inform the prescription dose. 
6.6.3. The incorporation of 4D information into dose calculation 
In the era of 4D-CT, the clinician now has the ability to incorporate motion into the treatment plan 
and obtain useful information about tumour trajectories, as well as define treatment volumes with 
the use of MIPs. New dose calculation methodologies have also become available for SBRT based 
on data from 4D-CT. Namely, the treatment planner now has the ability to calculate dose on each 
individual phase data-set from 4D-CT and accumulate the individual distributions, or a planner can 
perform dose calculation on an average intensity projection (AIP) representative of the probability 
density function over the tumour’s excursion of the densities that can be expected and is therefore 
equivalent to a 3D dose calculation. 
 
This work aimed to determine the differences of two methods of dose calculation using a range of 
amplitudes, motion profiles, and beam arrangements in systematic full Monte Carlo simulations. 
The two generally accepted methods for dose calculation using 4D-CT data are as follows Figure 
6.6. 
 
 Performing dose calculation on each phase-bin dataset obtained from a 4D-CT and 
registering the cumulative distributions across the entire breathing cycle (U10V)  
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 Performing a single calculation on the ITV volume delineated from a MIP of all the 
tumour locations (phase bin information) whose voxel density values are derived from the 
AIP (AVG), equivalent to a 3D dose calculation. 
 
In the present work, a comprehensive Monte Carlo study on the equivalency of two dose 
calculation methodologies based on data akin to that from 4D-CT was presented. Characteristic 
points in regions of high density gradient were analysed and compared for both the AVG (3D) 
method and the U10V method. The majority of points exhibited good agreement. When multiple 
fields (parallel opposed beams) were used, the two methods yielded equivalent results for lesion 
amplitudes below 3.5 cm (within the Monte Carlo uncertainty). Single fields however, produced 
large discrepancies (up to 16.73%). Dose-volume histogram analysis also confirmed these results. 
Overall parallel opposed fields, provided better homogeneity and agreement between the U10V 
and AVG methods, however, 5.0 cm motion amplitudes showed discrepancies in both single and 
parallel opposed beam arrangements. A 5.0 cm tumour motion amplitude would be considered an 
extreme case (Seppenwoolde, Shirato et al., 2002a, Sixel, Ruschin et al., 2003), with typical 
respiratory induced tumour motion being in the range 2 – 30 mm (Keall, Mageras et al., 2006b). 
Nevertheless, it is pertinent to incorporate large amplitude motions to determine the limits of 
equivalency and to ensure the complete range of clinical amplitudes was covered. 
 
Interestingly, the target’s motion profile had little impact on the discrepancies between the two 
methodologies (U10V/AVG) for amplitudes less than 5.0 cm and multiple fields. Clinically, 
tumour motion is predominately in the superior-inferior direction (Seppenwoolde, Shirato et al., 
2002a), and as such, is generally perpendicular to the treatment beam. Simulations performed in 
this study, used a tumour motion parallel as well as perpendicular to the beam to highlight 
potential discrepancies between the two calculation methods. For a single field, simulations with 
the tumour motion perpendicular to the beam showed better agreement for the two dose calculation 
methods than the parallel case. This is due to the reduction in contributions from inverse square as 
well as attenuation effects. For a parallel opposed field, the dependency on tumour direction 
relative to the beam was also worse for target motion parallel to the beam direction (‘in-beam’) 
though the discrepancy was reduced compared to a single beam scenario  
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Previous planning based studies have also concluded that performing dose calculation on an 
average intensity projection is equivalent to performing dose calculation on each individual phase 
from 4D-CT and combining the resulting distributions. However, these studies only assessed the 
equivalency for relatively small target motion excursions and were calculated with treatment 
planning systems and not full Monte Carlo simulation. Admiraal et al (2008a) concluded that when 
dose calculations were performed on the AIP, the dose distribution compared well to the 
cumulative dose-per-phase. The authors found that for nine out of ten patients undergoing 
stereotactic lung radiotherapy, the dose criterion (at least 54 Gy should be received by 99% of the 
PTV) was met when planning on the average intensity projection. The mean range of amplitudes 
for their study, however, was 0.2 – 0.3 cm and their work was based on treatment planning system 
(TPS) dose calculation algorithms. Ehler et al (2008) compared cumulative (ten phase) dose 
distributions for IMRT treatment planning in three data sets: a single 4D-CT phase, a 4D-CT phase 
with a density override to the tumour motion envelope and a plan on the average. The authors 
found that all three planning methods yielded acceptable treatment plans. However, planning on an 
average intensity projection qualitatively resulted in a more uniform dose to the tumour, especially 
for carcinomas residing in the periphery of the lung. Again, their study was based on TPS 
calculations. Starkschall et al (2009) retrospectively performed 4D dose calculations on CT data-
sets for patients with stage II non-small-cell lung cancer. Target volume coverage and doses were 
compared to conventional 3D dose-calculation methodology. Their results showed that for 11 out 
of 15 patients, clinical target volume coverage was comparable in both 3D and 4D calculations and 
in 7 of the 15 patients, planning target volume coverage was comparable. For the other patients, the 
4D calculation indicated a difference in target volume dose sufficiently large enough to warrant 
replanning. Vinogradskiy et al (2009a) quantified the increase in accuracy of using phase-bin data 
from 4D-CT for dose calculations versus 3D dose calculation. Their study employed motion 
phantoms along with deformable lung inserts. Their study also found no significant differences in 
the accuracy between the two dose calculation methods inside the GTV. Film measurements, on 
the other hand demonstrated that cumulative dose calculation (on each phase from 4D-CT) 
provided better accuracy than AIP dose calculations in heterogeneous dose regions. Wang et al 
(2009) investigated the dosimetric impact of using 4D-CT and multiphase (helical) CT images for 
treatment planning target definition in SBRT of lung cancer. Their study found that compared to 
the conventional approach using helical images for target definition, 4D CT and multiphase 3D CT 
treatment planning further reduces the amount of normal lung being irradiated while still providing 
good target coverage when image guidance was used. 
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6.6.4. Clinical application 
There are several factors that need to be taken into account in a clinical situation. The results 
presented here are for idealised geometries. In reality, the lung represents a complex geometry 
whose density changes during delivery with the volume of air present and this may alter the 
density composition of the tissue surrounding the AVG. Furthermore, the GTV (U10V) and ITV 
(AVG) in this study are extracted perfectly, i.e. the target voxel dose values are mathematically 
extracted in the same way they were mathematically created. In a clinical situation, inter-observer 
variations in GTV delineation (Van de Steene, Linthout et al., 2002, Giraud, Elles et al., 2002) 
could contribute to the overall geometric error and also introduce differences in the DVHs. The 
study presented here seeks to quantify the discrepancy attributable to large amplitude motions and 
variable breathing patterns in a systematic fashion. 
6.6.5. Chapter summary 
6.6.5.1 The Dose Reduction Factor (DRF) 
The aim of this work was to develop a dose-reduction metric, termed the Dose Reduction Factor 
(DRF) for use by clinicians and treatment planners to estimate the magnitude of underdosage of 
lung lesions due to electronic disequilibrium. The level of accuracy afforded by full Monte Carlo 
simulations performed here provides insights into underdosage at the periphery of lung lesions that 
may not be evident when using commercial treatment planning systems. Monte Carlo simulations 
performed with the Geant4 toolkit demonstrate that doses to the peripheral region of a lung lesion 
may be up to 14 % lower than the dose to the centre of the lesion. This work also demonstrated 
that the peripheral underdosage is generally more severe for higher energy beams compared to 6 
MV. The underdosage was also shown to be partially mitigated by the cumulative effect of 
multiple beams from different directions. 
6.6.5.2 Dose calculation on U10V versus AVG 
Clinically, 4D dose calculation involves registering and combining separate dose calculations on 
phase-data from 4D-CT. The hypothesis of this work was that performing dose calculation on an 
average intensity projection in multi-field radiotherapy does not result in clinically significant 
differences in dose, compared to accumulating dose on each individual phase data-set from 4D-
CT. Large amplitude motions (5.0 cm), were purposely simulated to exacerbate potential 
differences between the two dose calculation methodologies and therefore err on the side of 
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conservativeness.   
 
With 4D-CT becoming the standard of care for treatment planning of lung cancer, the additional 
information obtained allows the clinician to evaluate the impact respiratory induced target motion 
may have on the treatment plan. Planning on an AIP was found to be sufficient for dose calculation 
purposes when compared to the more laborious method of contouring and calculating dose on each 
individual phase data-set, and registering / combining the resulting distributions in a union of 
GTVs.  
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Chapter 7. Conclusions & Outlook 
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“He knew that all the hazards and perils were now drawing together to a point: 
the next day would be a day of doom, the day of final effort or disaster, the last 
gasp.” 
― J.R.R. Tolkien 
 
 
 
 
“With all due respect, sir, I believe this is going to be our finest hour.” 
― R. D. Franich, rejoinder (channeling Gene Kranz, Apollo 13 Mission Control)  
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7.1. INTRODUCTION 
In this work the impact of motion on aspects of treatment planning for SBRT of lung cancer was 
assessed. SBRT differs from conventional radiotherapy lung treatments in that generally it is 
delivered to smaller lesions, with a reduced fractionation scheme characterised by higher doses per 
fraction. Of particular interest for the present work is also that margins around target volumes are 
typically substantially reduced with the need to account for any targeting uncertainties. The 
potential benefits of SBRT can only be fully realised if the inherent uncertainty in the target’s 
position is minimsed.  
 
This work has presented a number of studies whereby some of the issues surrounding motion 
management in SBRT have been investigated by pursuing the following objectives: 
Objective 1: Assess the effect of motion on the identification and delineation of small, moving tumours. 
Objective 2: Quantify the influence of lesion size and motion amplitude on data acquired from 4D-CT 
Objective 3: Determine the degree to which the same relationships affect PET data if and when this 
imaging modality if incorporated into the treatment planning process. 
Objective 4: To assess the mitigation of motion effects in PET that can be achieved by implementing 4D 
phase-binned PET.  
Objective 5: To evaluate dose calculation on lung tumours, in particular quantifying the differences 
between 4D calculations, which explicitly account for dynamic geometry and conventional 3D calculation, 
based on average intensity projection data from 4D-CT. 
7.2. DEVELOPMENT OF MOTION PHANTOMS 
To experimentally study the effects of motion on both imaging and delivery of radiation in SBRT, 
phantoms that are able to move with patient-like patterns are necessary. This work detailed the 
development of an upgrade to an existing commercially available respiratory motion phantom. 
Upon the creation of a new control system and software, the phantom can now import actual 
patient traces recorded with the Varian RPM system, as well as simulate custom profiles (see 
Figure 3.16 and Figure 3.17) accurately. The upgraded QUASAR phantom was found to be useful 
in testing the Varian RPM system as was published in the article (Dunn, Kron et al., 2011a).  
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A second phantom, the see-saw motion phantom, was designed with quality assurance of 4D-CT 
in mind. The phantom’s unique design enables motion in two directions (axial and inter-slice) with 
a large range of amplitudes and frequencies of motion. The see-saw phantom allowed for the 
investigation of the impact of motion on images and projections from 4D-CT. The see-saw 
phantom presents a unique 4D-CT QA phantom capable of a large range of coupled SI and AP 
motion profiles. The derivation of a motion model for the phantom matched the physical profiles 
well in both AP and SI direction and the motion model can be used to accurately calculate the 
amplitude of the phantom in any number of configurations which is useful for assessment of 4D 
measured data. 
 
The two QA phantoms that have been presented in Chapter 3 can be used to assess the impact of 
motion on treatment planning for SBRT of lung cancer. These phantoms allow patient specific QA 
to be performed for SABR/SBRT patients and as SABR / SBRT techniques become more 
widespread, these phantoms provide an invaluable tool for QA. The AAPM Task Group Report 
101 on “Stereotactic Body Radiation Therapy” recommends that treatment-specific and patient-
specific QA protocols be established to govern both the treatment planning and delivery process 
(Benedict, Yenice et al., 2010). The phantoms described in this work allow such protocols to be 
developed, and indeed, the modified QUASAR respiratory motion phantom presented here is 
currently used for patient-specific SBRT QA at the Peter MacCallum Cancer Centre. Furthermore, 
the TG-101 report recommended that for all SBRT patients with targets in the thorax or abdomen, 
a patient specific motion assessment be conducted.  
 
The respiratory analysis software developed and presented as part of this thesis enables the 
statistics of respiratory traces recorded from a surrogate to be compared with lesion motion data 
collected with 4D-CT or fluoroscopy. This enables the correlation between the external and 
internal anatomy to be assessed and can inform the clinician whether a certain motion management 
technique is feasible. The software provides a number of metrics for analysing the patient’s 
respiratory function and comparing respiratory traces recorded at different times throughout a 
treatment schedule or following bio-feedback respiratory coaching. The respiratory analysis 
software can also be used to determine if a patient’s treatment would likely benefit from gating, 
another recommendation of the TG-101 report. 
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7.3. THE IMPACT OF MOTION ON IMAGES ACQUIRED WITH CT AND 4D-CT 
The impact of motion on 4D-CT image quality for SBRT treatment planning was assessed in this 
thesis. Results obtained using the see-saw motion phantom indicate that if 4D-CT is to be used to 
assess the magnitude of motion and provide valuable spatio-temporal information to the treatment 
planning process, care needs to be taken to ensure that an adequate number of phase-bins is chosen 
to provide complete MIP and AIP data-sets. This is particularly relevant for patients with long 
breathing periods where consideration needs to be given to increasing the rotation period of the 
gantry. 
 
A criterion which quantifies these effects has been presented, which indicates the number of 
phase-bins required to provide a complete data-set. This criterion was used to demonstrate that for 
lesions with diameters greater than 2.0 cm and displacements up to 4.0 cm, ten phase-bins are 
adequate to provide complete MIP and AIP data-sets. For smaller lesion sizes however, the 
interplay of large amplitude motions and small targets could have considerable consequences. 
Binning artifacts in 4D-CT and residual motion effects that have been described and evaluated as 
part of this thesis may result in an incorrect delineation of both the ITV and CTV if used for SBRT 
planning. This in turn can lead to dose delivery errors and a potential increase in normal-tissue 
dose or poor target coverage.  
 
In SBRT, typical margins for defining the minimal distance separating the CTV and PTV surfaces 
are 0.5 cm in the axial planes and 1.0 cm in the superior/inferior directions (Timmerman, Papiez et 
al., 2003, Benedict, Yenice et al., 2010) indicating that the accuracy of data from CT and other 
sources is critical to the treatment efficacy. 4D-CT scanning parameters, such as scan time per 
revolution, slice thickness, inter-slice gap and the time-scale of any anatomical motion also 
directly affects the size and appearance of tumour volumes. In this work, it has been shown that 
4D-CT imaging of small targets undergoing large motion excursions requires an understanding of 
the limitations of both the scanner and the 4D protocol being used to acquire the 4D data. By 
carefully selecting both the scanning parameters and 4D protocol parameters, one can potentially 
mitigate these effects. The see-saw motion phantom allows for investigation of these effects and 
can be used for QA and optimisation of 4D-CT acquisition protocols at a drastically reduced cost 
compared to commercially available phantoms. 
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The impact of motion on images acquired with 4D-CT described in this work in Chapter 4 may 
also have implications for image guided delivery techniques. 4D-Cone Beam CT (4D-CBCT) for 
example is an emerging imaging technique that can be used to resolve tumour motion, though a 
large number of projection angles are required for each respiratory phase and as such the scan 
length is longer than a conventional CBCT (~ 4 minutes) depending on the patient’s breathing 
cycle. The projections from 4D-CBCT can be reconstructed into phase-bins and therefore a 
verification of the tumour position at each phase can be achieved. In addition, conventional CBCT 
provides an assessment of motion being a slow scanning modality, where image blurring is 
reflective of motion. As such it can be compared to the planning 4D-CT MIP and used as a 
verification of the patient setup just before treatment delivery though alignment issues have been 
reported (Clements, Kron et al., 2013). The phantoms developed as part of the present work were 
used in these investigations.  
7.4. THE IMPACT OF MOTION ON IMAGES ACQUIRED WITH PET 
The impact of motion on PET images was evaluated in this work with a focus on the effects of 
lesion size and amplitude of motion on target delineation in 3D PET and the degree of mitigation 
afforded by the use of 4D-PET. At present, a PET/CT scan is considered the standard of care for 
lung cancer patients prior to commencement of radiation therapy (Mac Manus and Hicks, 2012, 
Mac Manus, Everitt et al., 2013). In this thesis, experimental phantom studies were used to 
investigate a relationship between lesion size and amplitude and the measured activity and 
apparent lesion size. It was demonstrated that the reduction in activity associated with motion 
blurring is dependant on motion parameters, the size of the lesion and its apparent acitivty against 
the bakground. Monte Carlo GATE simulations using XCAT computational phantoms featuring 
lung lesions with diameters of 10 – 30 mm and activity ratios of 10:1, 5:1 and 2:1 were used to 
compare the anthropomorphic geometry case to the experimental phantom study results. Overall, 
Monte Carlo methods and experimental phantom studies predicted different magnitudes of activity 
underestimation, suggesting that predictions from either method may not be easily transferable 
between the two scenarios. These factors may have negative consequences on the benefits of PET 
for both target delineation and management. As a result of this, if motion of small lesions ( 2 cm) 
exceeds 1 cm then 4D-PET is recommended. 4D-PET was found to increase the recovery of 
apparent activity and decrease the blurring associated with motion over all amplitudes and lesion 
sizes measured and simulated.  
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There are a number of strategies currently available to compensate for lesion motion due to 
respiration in PET and PET/CT: non attenuation corrected PET, deep inspiration breath-hold PET, 
respiratory gated PET plus free breathing CT, respiratory gated PET plus breath-hold CT, 
respiratory gated PET plus respiratory gated CT (Callahan, Kron et al., 2011). The gold standard 
protocol for obtaining the most information about target size and motion magnitude is to use 4D-
PET and 4D-CT in a combined 4D-PET/CT where attenuation correction is performed for each 
phase of the PET scan using the corresponding 4DCT phase. The use of this hybrid imaging 
technology when available has recently been shown to have a beneficial impact on conventional 
NSCLC treatment planning to assist in the delineation of target volumes as it currently provides 
the most comprehensive planning data to assist in target delineation (Mac Manus, Everitt et al., 
2013) and it is likely to have an impact on treatment planning for SBRT. 
7.5. THE IMPACT OF MOTION ON TREATMENT PLANNING AND DOSE CALCULATION 
In SBRT of lung cancer, the primary concerns are the exposure of the target to a very high dose 
per fraction and minimisation of normal tissue receiving high doses outside of the target to limit 
treatment toxicity. As a result of this margins need to be tight and the gradient of the dose fall-off 
outside the target needs to be steep. Poor image quality and mismanagement of motion can have 
detrimental consequences for treatment planning and delivery. At present, the explicit 
incorporation of 4D information from 4D-CT into dose calculation algorithms is not facilitated in 
most treatment planning systems. As such, alternate methods such as a single dose calculation on 
an average intensity projection from 4D-CT, equivalent to a 3D calculation are often pursued for 
dose calculation. 
 
A comparison between a single dose calculation using an average intensity projection and the ‘4D’ 
method of registering and accumulating the dose distributions on phase-bin data from 4D-CT 
using the EGSnrc Monte Carlo code has been presented. To facilitate a systematic approach with 
multiple motion profiles and lesion amplitudes, geometries for Monte Carlo calculations were 
created consisting of a lesion located within a lung equivalent box with slabs representing the 
chest-wall. To test the Monte Carlo methodology and ensure that differences between the average 
intensity projection and 4D methods could be discerned, Monte Carlo simulations of the static 
scenario were performed. These simulations quantified the underdosage of the periphery of the 
lesion consistent with what is expected due to the lack of electronic equilibrium. Monte Carlo dose 
calculation methodologies enable the full effect of this to be quantified more accurately than with 
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most currently available TPS dose calculation algorithms (Taylor, Dunn et al., 2011). As a result 
of this work a Dose Reduction Factor (DRF) was developed which describes the underdosage ratio 
of the periphery with respect to the central region. The mean of this was found to be 0.97 and 0.92 
for a 6 MV and 15 MV beam respectively. The DRF metric may assist clinicians in the estimation 
of the magnitude of potential discrepancies between prescribed and delivered dose distributions as 
a function of tumour size and location.  
 
Monte Carlo simulations of the dynamic scenario revealed discrepancies between the two methods 
(AIP and 4D) for large amplitude motions (> 3.0 cm) of up to 4 % for parallel opposed fields 
which partially compensate for the 16 % discrepancy associated with each single field. As such, 
the use of the 4D method for dose calculation when considering small lesions with large motion is 
recommended. For amplitudes smaller than 3 cm however, the differences between the two 
calculation methodologies was found to be less than 2.5 %. This indicates that the use of average 
intensity projection CT image sets derived from 4D CT is adequate for dose calculation in most 
circumstances. 
7.6. OUTLOOK 
In assessing some of the effects and challenges of motion management in SBRT, tools have been 
developed and tested that can, and have been implemented clinically for patient specific QA of 
SABR / SBRT treatment plans, as well as QA devices for 4D imaging modalities used in SBRT 
planning for lung caner. These phantoms have also proven to be useful for other studies including 
studying the effect of irregular breathing patterns on internal target volumes in four-dimensional 
CT and cone-beam CT images in the context of stereotactic lung radiotherapy (Clements, Kron et 
al., 2013), exploring the use of radiochromic film for individual patient QA in extracranial 
stereotactic lung radiotherapy (Kron, Clements et al., 2011) and validation of 4D-PET Maximum 
Intensity Projections for Delineation of Internal Target Volumes (Callahan, Kron et al., 2013). The 
next step in the use of these phantoms is to develop other QA protocols based on them and extend 
their use to other fields. For example, as 4D-PET becomes more prevalent, the see-saw motion 
phantom can be adapted for 4D-PET QA and used to develop protocols for clinical use. In the 
future it is hoped, that the upgraded QUASAR phantom could also be used to develop and evaluate 
4D-CBCT in preparation for routine clinical use. 
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In modern radiotherapy many dose measurements are accompanied by Monte Carlo calculations – 
either to characterise the detector, obtain information of a radiation field that cannot be measured 
(such as spectrum) or to calculate dose in circumstances where measurements are too difficult. 
Monte Carlo calculations have been used for the latter by determining dose at interfaces. Future 
work will determine if the DRF developed here proves to be of value for clinicians, in particular 
when solid targets move in a low density environment. It is also expected that Monte Carlo 
calculations will more widely used to assess dose distributions in moving targets. In principle the 
calculation times should not be significantly different from a static case as uncertainty only 
depends on the overall number of histories. This makes the Monte Carlo approaches used here well 
suited for more future studies. 
 
Ultimately, the outcomes of this thesis should be used prospectively to inform substudies of 
clinical trials to assess 4D imaging for many real patients as a function of breathing pattern and 
tumour motion amplitude. 
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